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Introduction to multidrug transporters, cellular resistance 
and lantibiotic production in Lactococcus lactis
H. Bart van den Berg van Saparoea and Arnold J.M. Driessen
Summary
Multidrug resistance (MDR) proteins are membrane-embedded transporters 
that secrete a broad range of toxic compounds. They contribute substantially to 
the drug resistance phenotype of many (if not all) organisms. To date, a wide 
variety of MDR proteins has been identified and these are categorized in different 
protein families. Despite their apparently common function, no conserved 
amino acid sequence motifs or other characteristic element has been recognized 
among these proteins. Assignment of a transporter as a MDR protein therefore 
remains a matter of experimental determination. In the lactic acid bacterium 
Lactococcus lactis three MDR proteins have been characterized, LmrP, LmrA, and 
LmrCD. LmrP and LmrA confer drug resistance to a heterologous host such as in 
Escherichia coli, while studies using the natural host L. lactis have mainly focussed 
on the transport mechanism. Remarkably, inactivation of the lmrA gene in L. lactis 
has no effect on drug resistance, while LmrCD has been shown to be a major 
determinant in the multidrug resistance in this organism. MDR transporters are 
also involved in peptide secretion, amongst others antimicrobial peptides that 
belong to the class of lantibiotics. These peptides function in an offensive survival 
mechanism, and are posttranslational modified from a peptide precursor. The aim 
of the studies presented in this thesis was to further define the function of the 
lactococcal multidrug transporters LmrA and LmrP in cellular drug resistance, 
and of the ABC transporter NisT in the lantibiotics secretion.
8Introduction
In Gram-positive bacteria, the border between the “inside” and the “outside” 
of the cell comprises only of a single cellular membrane, a phospholipid 
bilayer with embedded membrane proteins. Gram-negative bacteria contain 
two membranes. Their inner membrane is highly similar to the cytoplasmic 
membrane of Gram-positive bacteria, while the outer membrane is an 
asymmetric membrane composed of phospholipids and membrane protein, 
lipoproteins that are peripherally associated with the membrane, and 
lipopolysaccharides. The latter are exposed on the outer surface of the outer 
membrane. The space between the inner and outer membrane is called the 
periplasm, which can be regarded as an intermediate zone between the “inside” 
and the “outside” of the cell. 
The outer membrane contains proteins (porins) that act as channels or pores 
that allow passive diffusion of small solutes, ions and most other charged 
molecules for which the membrane is otherwise highly impermeable. The 
cytoplasmic membrane is mostly impermeable for small solutes. These may 
enter the cell via specific transporters and channel proteins. Transport proteins 
that utilize the energy contained in the proton motive force (the transmembrane 
electrical potential and pH gradient across the cytoplasmic membrane) or in the 
molecule ATP can even accumulate solutes in the cell against their concentration 
gradient. However, the membrane does not provide an absolute barrier for 
molecules to enter the cell. Many hydrophobic or uncharged molecules are able 
to intercalate between the phospholipids and pass the membrane independent 
of proteins. This includes many toxic compounds that may inhibit growth and 
interfere with the viability of cells.
Drug resistance mechanisms
Any environment in which organisms thrive can contain compounds that 
are potentially harmful for these organisms. Whether these compounds are 
produced by other organisms, introduced into the environment by humans 
such as xenobiotics or antibiotics, or the product of (other) natural processes, 
in the end, through selective competition, only the cells will survive that are 
able to resist the harmful effects of such molecules. The subject of the studies 
presented in this thesis is the lactic acid bacterium Lactococcus lactis. L. lactis is 
a Gram-positive micro-organism commonly found in plant material and raw 
milk from cows (1). Although it may not be able to replicate and multiply under 
all conditions, it is able to survive and remain viable in harsh environments 
such as the human gastrointestinal tract. Environments may differ in the 
availability of nutrients, oxidation state, and other factors that are important for 
cell maintenance and survival, but also in the presence of different hazardous 
compounds. Cells may become resistant to toxic compounds in a number 
of ways. The target of the toxic compound can be altered, e.g. the affinity of 
an affected enzyme for the drug may be lowered through the selection of 
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9mutations that reduce the efficiency of binding and inhibition. Drugs may also 
be degraded or modified, e.g. hydrolysed, acetylated or phosphorylated, to 
yield a non-toxic derivative. Alternatively, specific proteins or other molecules 
can bind the toxic compound with a high affinity, thereby lowering the amount 
of free toxic compound in the cell, or the toxic compound can be secreted from 
the cell by a specific transport protein. These mechanisms all concern specific 
resistance strategies that are effective with particular drugs only or with a class of 
structurally related compounds. Another protection mechanism is the secretion 
of toxic compounds from the cell by a polyspecific transport protein, a mechanism 
that is termed multidrug resistance (MDR) as it confers a broad resistance to the 
cells. The term multidrug resistance protein is designated to (transporter) proteins 
that confer resistance to a variety of often chemically and structurally unrelated 
compounds. 
Multidrug resistance transporters
In general, substrates of MDR transporters will enter the cell by passive diffusion 
across the membrane(s) of the cell. To secrete these molecules and to effectively 
increase the barrier function of the membrane(s), energy input is required, 
i.e. active transport. According to the energy source they use to drive their 
transport cycle, transport systems (proteins) are divided into two main classes, 
i.e., primary and secondary transporters. The majority of primary transporters 
use the free energy of ATP hydrolysis for transport of their substrate(s), while 
secondary transport proteins use the electrochemical gradient of protons or 
sodium that is maintained across the cytoplasmic membrane. 
Many MDR transporters are members of the large ATP-binding cassette 
(ABC) superfamily (2). They contain several amino acid sequence motifs that 
are characteristic for this superfamily, i.e., the Walker A, Walker B, and the 
signature motif that are involved in ATP binding and hydrolysis (3). Another 
major characteristic of ABC-type transporters is their modular organisation of 
four distinct domains forming one functional unit. ABC-type MDR transporters 
typically consist of a membrane domain (MD) that is either fused at the N- or 
C-terminus to an ATP-binding domain (ABD). A functional ABC transporter 
is either comprised of two identical (homodimer) or two dissimilar units 
(heterodimer) (so-called ABC half-transporters), or exists as a single polypeptide 
in which these domains are fused (so-called ABC full-transporters). LmrC and 
LmrD of L. lactis each constitute a membrane domain coupled to an ATP-binding 
domain, i.e., N-MD-ABD-C. These proteins are organised as a heterodimer 
to form a functional transporter (4).  On the other hand, LmrA of L. lactis 
consist of two identical half-transporters that together form a homodimer (5). 
The human drug transporter ABCB1 (P-glycoprotein or MDR1) is a full-
transporter in which a single polypeptide encompasses all four domains (N-MD-
ABD-MD-ABD-C) (6). The lactococcal MDR transporter LmrP is an example of a 
secondary transporter that belongs to the Major Facilitator Superfamily (MFS). 
LmrP uses the electrochemical potential of the proton gradient to secrete drugs 
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from the cell (7;8). MFS transporters typically consist of a single polypeptide with 
12 transmembrane segments, and they are involved in a multitude of small solute 
transport reactions that are driven by the proton- or sodium ion gradient across 
the cytoplasmic membrane (9) (Figure 1.1). 
Besides the aforementioned major transporter superfamilies, MDR transporter 
proteins can be found in other protein families such as the Multidrug And Toxic 
compound Extrusion (MATE) family and the Small Multidrug Resistance (SMR) 
family. Members of the MATE family secrete drugs from the cell energized by the 
proton- or sodium motive force (10). The SMR family harbours proton gradient 
driven MDR transporters arranged as dimers of relatively short (~110 amino acid) 
polypeptides (11). Another distinct class of MDR transporter proteins is found 
within the Resistance-Nodulation-Cell Division (RND) superfamily. These are 
proton motive force driven transporters that are part of a larger protein complex 





















Figure 1.1. Schematic representation of the major protein (super)families harbouring 
prokaryotic MDR proteins. The ATP-binding cassette (ABC) superfamily of primary 
transporters that hydrolyse ATP to drive drug secretion. The major facilitator 
superfamily (MFS) of secondary transporters that contain 12 or 14 membrane spanning 
helices and are driven by the proton motive force (pmf). Transporters of the Multidrug 
And Toxic compound Extrusion (MATE) family secrete drugs from the cell energized 
by the proton- or sodium motive force. The Small Multidrug Resistance (SMR) family 
harbours pmf driven MDR transporters that are arranged as dimers of relatively 
small (~110 amino acid) polypeptides. The pmf-driven transporters of the Resistance-
Nodulation-Cell Division (RND) superfamily are part of a larger protein complex 
with additional subunits that form a pore in the outer membrane and that span the 
periplasm to connect the transporter domain in the cytoplasmic membrane with the 
outer membrane pore. d, drug; OM, outer membrane; CM, cytoplasmic membrane.
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the periplasm to connect the transporter domain in the cytoplasmic membrane 
with the outer membrane pore (12). 
A vast number of genes in the growing number of genome sequences published 
are annotated as (putative) MDR genes. For instance 37 genes in Escherichia coli, 
39 genes in L. lactis, and 14 genes in Streptococcus pneumoniae (13-15). Based on the 
presence of specific consensus motifs and general homology in their amino acid 
sequences, most proteins can be classified in one of the major transporter protein 
families. However, no specific amino acid motif(s) unique to MDR proteins has 
yet been identified. Therefore, an experimental confirmation of the presumed 
MDR function remains important for the proper annotation of these transporters. 
Nishino and Yamaguchi analysed each of the 37 putative MDR transporter genes 
in the E. coli genome by expressing them in a drug sensitive E. coli strain (13). This 
strain lacks the major multidrug efflux system AcrAB, which together with TolC 
forms an RND-type secretion complex (16). Resistance to 24 toxic compounds was 
tested, including antibiotics, chemotherapeutic drugs, cationic dyes, uncouplers 
and detergents. By functional complementation of the drug sensitive strain with 
a plasmid encoding the acrAB operon, this major multidrug efflux system was 
shown to confer resistance to 19 of the 24 compounds tested. AcrAB increased 
the minimal inhibitory concentration of 17 out of these 19 compounds by 8-fold 
or more. In addition, 19 genes conferred resistance to a subset of the compounds 
tested. The remaining 17 transporters did not complement the drug sensitive 
E. coli strain, indicating that almost half of the potential MDR transporters likely 
have a function other than drug resistance.
Typically, the overexpression of a putative MDR transporter increases the 
resistance of an organism to a range of toxic compounds. However, with some of 
these proteins, expression at wild-type levels does not reveal a function in drug 
resistance. For example, in Bacillus subtilis the overexpression of either the bmr 
or the blt gene results in an increased resistance to a panel of toxic compounds 
including ethidium bromide, rhodamine, tetraphenylphophonium, doxorubicin 
and fluoroquinolone antibiotics (17). The similarity in substrate range of these 
two homologous proteins Bmr and Blt suggests highly overlapping functions. 
However, while the inactivation of the bmr gene increases the cellular susceptibility 
of B. subtilis to various drugs, that of blt does not. It was furthermore noted that 
the transcriptional control and the expression patterns of these two genes differ 
considerably. Finally, Blt was identified as a spermidine transporter (18). Since 
spermidine secretion seems to be the physiological function of Blt, it appears that 
this transporter can opportunistically act as a MDR protein when expressed at non-
physiologically high levels. This apparent opportunistic multidrug efflux activity 
is likely not specific for Blt, but might be a more general feature of putative MDR 
transporters when highly overexpressed under nonphysiological conditions. 
Presumably, cells contain only a limited number of hydrophobic molecules that 
need to be retained in the cytoplasm (19). These molecules often tightly associate 
with cellular constituents such as proteins and are therefore not easily secreted 
from the cell. As a result, the transporter proteins dedicated to the secretion of 
specific hydrophobic molecules from the cytoplasm do not require very specific 
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substrate binding sites to exclude other molecules. Such weakly specific binding 
sites can likely accommodate a range of hydrophobic compounds allowing the 
transporter to opportunistically efflux multiple drugs.
Multidrug resistance and drug export in Lactococcus lactis
The discovery of multidrug resistance transporters in L. lactis has been an 
accidental event. During measurements of the internal pH of L. lactis, it was 
observed that cells actively extruded the synthetic pH indicator BCECF (20;21). 
This extrusion appeared energy-dependent, and mutants could be identified that 
were defective in BCECF extrusion. This phenomenon hinted at the presence of 
a (multi-)drug transporter in L. lactis. When L. lactis is grown in the presence of 
an increasing concentration of toxic compounds (specifically ethidium bromide, 
rhodamine 6G, or daunomycin), mutants can be obtained that resist high levels of 
these compounds (22). Remarkably, the obtained mutants were not only resistant 
against the compound selected for, but also had acquired an elevated resistance 
to a number of unrelated toxic compounds, which is the hallmark of multidrug 
resistance. In these mutants however the BCECF extrusion remained unaltered. 
The notion that indeed an active extrusion mechanism is responsible for the MDR 
phenotype of the mutant strains was supported by the observation that these 
strains showed an elevated rate of ethidium extrusion as compared to the parental 
strain. From the sensitivity to uncouplers and ATPase inhibitors, it appeared that 
in these MDR strains at least two different extrusion mechanism prevail, i.e., a 
proton motive force- and an ATP-dependent mechanism. 
The proton motive force-driven MDR protein LmrP
In search of the genetic elements that encode the ethidium extrusion activity, a 
library of chromosomal DNA of L. lactis was screened for the ability to confer 
ethidium resistance to an E. coli host (7). In this screen, a proton motive force-
driven antiporter belonging to the MFS was identified. This gene was termed 
lmrP from lactococcal multidrug resistance with P designating the proton motive 
force-dependence. Overexpression of LmrP in L. lactis results in a highly elevated 
ethidium extrusion activity that is completely abolished when the proton motive 
force is dissipated. On the other hand, deletion of the lmrP gene resulted in only 
a slight increase in susceptibility to ethidium bromide and has only a marginal 
effect on the ethidium extrusion activity. In the MDR strains the expression of the 
lmrP gene is unaltered and also no specific mutations could be identified in the 
structural gene or putative regulatory elements. Transcriptome analysis conducted 
a decade later confirmed that there is no significant difference in the expression 
level of lmrP between the parental strain and the various MDR strains (14), which 
suggests that LmrP is not responsible for the acquired MDR phenotype.
Although LmrP is apparently not essential for the ethidium resistance of its host 
or involved in the acquired resistance of the MDR strains, drug transport by 
this protein (at high overexpression levels) has been extensively characterized. 
For instance the presence of multiple drug binding sites within the transporter 
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was revealed by characterizing the inhibition of LmrP-mediated Hoechst 33342 
transport by several inhibitory compounds (26). Both Hoechst 33342-transport 
in membrane vesicles and ethidium extrusion from intact cells were studied to 
elucidate the role of acidic residues in the transporter. Four acidic residues, one 
of which is located in a membrane-embedded domain and may be part of the 
drug binding pocket of LmrP, were shown to be critical for transport of these 
cationic drugs (24). Mutation of these four acidic residues results in facilitated 
influx of ethidium into cells mediated by LmrP, demonstrating that these residues 
are involved in the energy coupling of the transport cycle (25). 
In this latter study expression of the energy-uncoupled LmrP mutants was 
shown to increase the susceptibility of L. lactis to ethidium, most likely due to the 
facilitated influx of the compound into the cells. This is however one of the few 
studies in which LmrP-mediated drug resistance as well as LmrP-mediated efflux 
(or influx) of the same drug are demonstrated. For instance, Hoechst 33342 has 
been used extensively as a substrate to characterize LmrP in membrane vesicles 
(8;23-26). Remarkably, no LmrP-mediated efflux of Hoechst 33342 from cells can 
be detected, nor does the overexpression of LmrP in L. lactis confer resistance to 
this compound. On the other hand, LmrP confers resistance to E. coli to a range of 
antibiotics from different classes, including tetracyclines and macrolides (27). In 
L. lactis, overexpression of LmrP increases the cellular resistance to the macrolide 
erythromycin, indicating that this MDR protein may be involved in antibiotic 
resistance of its host.
The ATP-dependent Lactococcus MDR protein LmrA
Another system that has been implicated in MDR in L. lactis is the ABC-type 
MDR transporter LmrA. The lmrA gene was discovered on a chromosomal DNA 
fragment adjacent to the apl gene that specifies an alkaline phosphatase-like 
enzyme (5). The function of the gene product LmrA was deduced from its high 
sequence similarity to the human multidrug resistance protein ABCB1 (MDR1, 
P-glycoprotein). LmrA harbours amino acid sequence motifs that are typical for 
the ATP Binding Cassette (ABC) type transporters and when aligned with both 
the N- and C-terminal halves of the human ABCB1, approximately one in every 
three amino acids is identical. The ability of the lmrA gene to confer multidrug 
resistance has primarily been shown through heterologous expression in a drug-
sensitive mutant of the Gram-negative bacterium E. coli (5;28;29). In this strain, 
LmrA confers resistance to ethidium bromide, daunomycin, rhodamine 6G, 
tetraphenyl phosphonium (TPP+), a wide range of antibiotics, and salt, wine and 
ethanol stress. In addition, LmrA can partially substitute for the lipid A transporter 
MsbA in E. coli (30).  Remarkably, the bacterial transporter could be functionally 
expressed in human lung fibroblast cells (31). LmrA confers multidrug resistance 
to these cells similar to the human MDR protein ABCB1. 
Studies on the activity of LmrA in the natural host L. lactis have been limited 
mainly to uptake and secretion experiments using the dye ethidium bromide. In 
one of the first reports, cells overexpressing LmrA were shown to accumulate 
less ethidium than control cells (32). In later studies most often LmrA-
mediated ethidium extrusion from preloaded cells is analysed (33-35). Cells are 
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ATP-depleted, loaded with ethidium and subsequently energized to observe 
efflux of the compound from the cells. This is a down-hill process, and does not 
signify active transport per se. Interestingly, under ATP-depleted condition LmrA 
facilitates both influx and efflux of ethidium into and from cells (34). The influx of 
ethidium under these conditions is even associated with ATP synthesis indicating 
that the ethidium gradient can force the LmrA catalytic cycle to run in the reverse 
direction.
While the function of LmrA as an MDR protein in L. lactis remains to be shown, 
transport and substrate binding mechanisms have been characterized in 
detail. The transporter functions as a homodimer (32;36). Vinblastine binding 
experiments revealed two allosterically linked drug binding sites on the LmrA 
homodimer (36). A model for the transport cycle of LmrA was proposed that 
involves two alternating drug-binding sites. Analogous to a two-cylinder engine, 
the allosterically linked binding sites have been proposed to cycle through three 
distinct states during a turnover of the transporter. In the ATP-bound state the 
transporter is thought to expose a high-affinity drug-binding site on the cytoplasmic 
side of the membrane and a low-affinity drug-binding site on the other side. Drug 
binding to the high-affinity site would then trigger the hydrolysis of ATP. This 
would result in an intermediate, ADP-Pi-bound state, in which the high-affinity 
drug-binding site becomes occluded (inaccessible). While binding of ATP to the 
second NBD changes the low-affinity binding site into a high-affinity binding site 
exposed to the cytoplasmic side of the membrane, release of phosphate from the 
first NBD was proposed to change the occluded drug-binding site into a low-
affinity binding site exposed to outside of the cell releasing the drug.
Using a cysteine scanning accessibility approach one face of the sixth membrane 
spanning helix (MSH6) of LmrA was shown to be accessible from the aqueous 
environment on the cytoplasmic side of the membrane (37). In each of the other 
five helices membrane embedded residues were shown to be similarly accessible, 
indicating the presence of an aqueous chamber within the LmrA membrane 
domain. In the same study, several residues in MSH6 were shown to be involved 
in Hoechst 33342 transport and/or binding of the antagonist verapamil. By 
photolabeling using drug analogs, MSH3, MSH5, and MSH6 of LmrA were 
implicated to form a substrate-binding domain (38). From comparison of the 
labelling frequency distribution in different nucleotide binding states it was 
deduced that upon binding of ATP the substrate accessibility of MSH5 increases 
while that of MSH6 decreases. When the nucleotide is hydrolysed the substrate 
accessibility of MSH5 decreases again while that of MSH6 increases. These 
observations indicate a repositioning of MSH5 and MSH6 during the catalytic 
cycle.
Structural studies indeed indicate that the various states of the catalytic cycle of 
LmrA differ in conformation. The membrane-embedded region of the transporter 
was shown to be highly dynamic, exhibiting large translational and rotational 
movements (39). The NBD domains are highly mobile in the nucleotide-free 
state (40). Their mobility is reduced in the ATP-bound state, likely due to tight 
interactions between the two NBDs, but increases again in the post hydrolysis 
state. The structural changes induced by the nucleotide occupancy of the NBDs 
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are transmitted to other regions in the protein, and vice versa. When a drug 
binds to the membrane-embedded region structural changes are detected in 
regions located in the cytoplasm while the ATPase activity is altered (41). Also the 
membrane spanning helices change in conformation upon binding and hydrolysis 
of ATP. 
The ATP-dependent Lactococcus MDR protein LmrCD
Transcriptome analysis of four independently isolated MDR strains of L. lactis 
showed a remarkable and common feature (14). The genome of L. lactis contains 
39 genes that may specify putative MDR transporter proteins. In the MDR 
strains selected for growth in the presence of ethidium bromide, rhodamine 6G, 
daunomycin, or cholate, only the lmrCD genes were significantly up-regulated. 
The lmrCD operon encodes two ABC-type half-transporters that together form a 
functional MDR transporter (4). Except for yxbD, encoding a putative MFS MDR 
transporter, in the rhodamine 6G- and cholate-resistant strain, the expression of 
none of the other putative MDR genes was changed significantly. Direct evidence 
for an important role of LmrCD in multidrug resistance of L. lactis followed from 
the disruption of the lmrCD operon which led to a hypersensitivity of the cells 
to Hoechst 33342, daunomycin, cholate, rhodamine 6G, and ethidium bromide. 
Transcriptome analysis further revealed changes in the 351 base pair long gene 
upstream of the lmrCD genes. This region specifies for a gene, termed lmrR, which 
encodes a transcriptional regulator that was shown to bind the promoter region 
of the lmrCD genes and to interact with Hoechst 33342 and daunomycin (42;43). 
In three of the MDR strains, the lmrR gene contained mutations preventing the 
production of a fully functional gene product, while in the rhodamine selected 
strain, a point mutation results in the expression of an inactive variant of LmrR 
(14). Since the transcription of the lmrCD operon was shown to increase upon a 
challenge with Hoechst 33342, daunomycin, or cholate, and since the operon is 
constitutively expressed in the isolated MDR strains due to a defect in LmrR, it 
appears that LmrR is a negative transcriptional regulator of the lmrCD genes that 
is modulated by drugs (42). Recently, the structure of the apo and drug-bound 
LmrR was solved showing a typical DNA-binding domain that is connected to a 
unique sensory domain (43). The latter forms a hydrophobic cavity at the LmrR 
homodimer interface and binds Hoechst 33342 or daunomycin.
LmrCD mediates Hoechst 33342-resistance by secretion of the compound from 
the cell. For instance, L. lactis ΔlmrCD cells accumulate increased levels of Hoechst 
33342 as compared to the parental cells, while overexpression of LmrCD results 
in decreased levels of cell-associated Hoechst 33342 (4;14). Moreover, in inside-
out membrane vesicles, LmrCD was shown to expel the fluorescent compound 
from the phospholipid bilayer, and this process was shown to be ATP-dependent 
involving both NBDs of the LmrCD heterodimer (44). Following similar evidence, 
LmrCD was shown to be an important determinant of bile acid resistance (45). 
Both the in vitro and in vivo data support the notion that LmrCD is a major 
multidrug resistance transporter in L. lactis that provides resistance to a range of 
structurally unrelated compounds by means of an extrusion mechanism.
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The lactococcal MDR proteins and the model substrate Hoechst 33342
A strong LmrP-mediated transport of Hoechst 33342 is observed in membrane 
vesicles. This activity has been used to characterize the effect of inhibitory 
molecules like verapamil, quinine, and vinblastin, as well as several antibiotics on 
the transport activity of LmrP (23;27). In cysteine-scanning experiments the effect 
of  amino acid replacement on the transport activity of LmrP was evaluated using 
the in vitro assay, and these consistently show that Hoechst 33342 is a substrate 
for LmrP (24). However, overexpression of LmrP in L. lactis does not result in an 
increased cellular resistance to Hoechst 33342. Similarly, in L. lactis ΔlmrCD cells 
that are hypersensitive to Hoechst 33342, overexpression of LmrP does not result 
in an increased resistance to Hoechst 33342. 
Expression of LmrA in L. lactis wild-type cells, or in cells that harbour a deletion 
of lmrA, or of lmrA and lmrCD, does not result in an increased resistance to 
Hoechst 33342 (46). Rather, when expressed in L. lactis ΔlmrA ΔlmrCD, LmrA 
even appeared to facilitate rather than reduce the influx of Hoechst 33342 into 
cells. Expression of a truncated form of LmrA that lacks the ATP-binding domain, 
but that still contains the membrane embedded permease domain, causes an 
increased sensitivity of L. lactis to several toxic compounds including Hoechst 
33342, ethidium bromide, daunomycin, and the antibiotics tetracycline and 
erythromycin (33). Unfortunately, in those studies the effect of expression of the 
full-length transporter on the drug resistance in L. lactis was not reported, but 
likely also results in increased drug sensitivity as shown by the expression studies 
employing L. lactis ΔlmrA ΔlmrCD cells.
The above examples lead to the suggestion that although some transporters are 
predicted to belong to the class of MDR systems on the basis of their amino acid 
sequence, their physiological function might be different from MDR. In MDR 
characterization, transport activity in isolated membrane vesicles is often only 
monitored by following the fluorescence of Hoechst 33342. Evidently, LmrA 
mediates Hoechst 33342-transport in these membrane vesicles (32;37). However, 
we could show that the mutational inactivation of the ATPase activity of LmrA 
has little effect on this LmrA-mediated Hoechst 33342-transport activity (46), as 
recently confirmed by others (47). On the other hand, Hoechst 33342-transport 
is highly dependent on the transmembrane pH gradient, and this phenomenon 
seems to relate to the acidification of the lumen of the membrane vesicles. In this 
respect it should be noted that the Hoechst 33342 fluorescence in the presence 
of liposomes is strongly affected by the pH. Hoechst 33342 is essentially non-
fluorescent when present in an aqueous buffer, and becomes highly fluorescent 
when present in an apolar environment such as the interior of the phospholipid 
bilayer. The partitioning of Hoechst 33342 between the aqueous and lipid 
embedded phase seems pH-dependent. With a membrane-water partition 
coefficient of 5100 this compound has a high preference for the lipid bilayer (23). 
However, the pH of the aqueous phase affects the protonation state  and thus 
the charge of the nitrogen atoms in the piperazinyl and benzimidazole rings 
of Hoechst 33342 (48). The distribution of Hoechst 33342 between the aqueous 
phase and phospholipid bilayer is most likely dependent on the charge of the 
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compound. In aqueous solution, the fluorescence of Hoechst 33342 decreases with 
increasing pH, while in the presence of liposomes the Hoechst 33342 fluorescence 
increases with increasing pH (within the range of pH 5 to 8) (46). This has been 
taken as evidence that the fraction of lipid embedded Hoechst 33342 increases 
with increasing pH, likely because of the depronation of Hoechst 33342 which 
will favor partitioning into the hydrophobic lipid layer. This demonstrates that 
the Hoechst 33342 transport assay is affected by the pH of the suspending and 
luminal medium, and consequently it will be influenced by the pH gradient 
across the membrane. Secondly it should be noted that LmrA is usually 
overexpressed to a very high level, forming up to 30% of the total membrane 
protein (Figure 1.2) (32). A minor effect of this very abundant LmrA protein on the 
partitioning behaviour of Hoechst 33342 in the lipid bilayer may therefore result 
in pronounced changes in the Hoechst 33342 fluorescence that are interpreted 
as a transport activity. When membrane vesicles are used of the ΔlmrCD strain 
which contain LmrA at wild type levels, no Hoechst 33342-transport is observed. 
Taking together the observation that LmrA facilitates the influx of Hoechst 33342 
into intact cells and the observation that LmrA-mediated Hoechst 33342 transport 
in membrane vesicles is dependent on a pH gradient rather than on the ATPase 
activity of LmrA, it appears that Hoechst 33342 is not a genuine substrate for 
LmrA. With the notion that overexpression of LmrA or a gene knockout of lmrA 
has no clear effect on the resistance of L. lactis against a series of drugs, a true role 
of LmrA in cellular drug resistance therefore remains to be demonstrated.
In a bacteriocin producing species of L. lactis, a homologue of LmrA was 
identified that is encoded on a plasmid carrying the information for both the 
production and immunity for the bacteriocins LsbA and LsbB (49). This ABC-type 
transporter LmrB is responsible for the secretion of the two bacteriocins during 
their production and it also confers resistance to their bactericidal effects. It is of 
interest to note that this species of L. lactis does not harbour the lmrA gene on its 
chromosome. Moreover, LmrA can functionally substitute for LmrB and confer 
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Figure 1.2. High level overexpression of LmrA in 
Lactococcus lactis. Membrane vesicles prepared from 
L. lactis control cells and cells overexpressing LmrA 
from a plasmid were subjected to SDS-PAGE and 
Coomassie Brilliant Blue staining. The arrowhead 
indicates LmrA. Molecular masses of marker proteins 














Figure 1.3. The nisin biosynthetic gene cluster. Schematic representation of the 
nisABTCIPRKFEG gene cluster involved in nisin A synthesis and immunity. The genes 
are indicated by open arrows. Promoter regions are indicated by small solid arrows 
(nisin induced promoter regions indicated with an asterisk). IR, inverted repeat.
nisA nisB nisT nisC nisI nisP nisR nisK nisF nisEnisG
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Figure 1.4. Enzymatic modification of NisA. The 57 amino acid long peptide NisA 
forms the basis for the lantibiotic nisin A. The leader sequence formed by the 23 amino-
terminal amino acid residues directs the peptide emerging from the ribosome to the 
dehydratase NisB. This enzyme dehydrates serine and threonine residues outside 
the leader sequence, forming dehydroalanines (Dha) and dehydrobutyrines (Dhb), 
respectively. Lanthionine (Ala-S-Ala) and methyllanthionine (Abu-S-Ala) residues are 
formed by coupling of the free thiol-group of cysteines to the dehydrated residues, a 
reaction that is catalysed by the cyclase NisC. The amino acid residues that form the 
lantibiotic nisin A are numbered in italic. Dha, dehydroalanine; Dhb, dehydrobutyrine; 
Ala and Abu, respectively alanine and α-aminobutyric acid within (methyl)lanthionine 
residue.
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resistance to the bacteriocins in a LsbA and LsbB sensitive L. lactis strain. This 
suggests that LmrA is involved in peptide export rather than drug extrusion.
Peptide export in Lactococcus lactis
Many lactic acid bacteria produce small antimicrobial peptides termed bacteriocins 
and lantibiotics. The gene clusters that specify these antimicrobial peptides often 
also contain a gene encoding a putative transporter protein and many of these 
systems are homologous to MDR transporters. A special group of antimicrobial 
peptides are the lantibiotics, a term composed of the words lanthionine and 
antibiotic. Lantibiotics are ribosome-synthesized, posttranslational modified 
peptides that are biologically active against bacteria (50;51). The unifying 
characteristic of these peptides is the presence of lanthionine and methyllanthionine 
amino acid residues that are the product of an enzymatic dehydration of a serine 
or threonine residue and an enzymatic linkage to a cysteine to form a thioether 
bridge. These linkages within the peptide chain determine most of the structure 
of the lantibiotics and are crucial for their activity (52).
One of the most widely studied lantibiotics is nisin A which is used worldwide 
as food preservative (53). The 70 kb long transposon Tn5276, identified in one of 
the nisin A producing L. lactis strain, contains the genetic elements that encode 
the ability to produce this antimicrobial agent (54). In this mobile stretch of DNA 
the genes involved in nisin A synthesis and immunity, spanning approximately 13 
kb, are tightly clustered back to back in the order nisABTCIPRKFEG (Figure 1.3) 
(55-60). The first gene, nisA, encodes the 57 amino acid long peptide that forms 
the basis for the lantibiotic nisin A. Following the metabolic route of NisA, the 
leader sequence formed by the 23 amino-terminal amino acid residues directs 
the peptide emerging from the ribosome to the dehydratase NisB. This enzyme 
dehydrates serine and threonine residues outside the leader sequence, forming 
dehydroalanines and dehydrobutyrines, respectively (Figure 1.4). In the next step, 
the lanthionine and methyllanthionine residues are formed by coupling of the free 
thiol-group of cysteines to the dehydrated residues, a reaction that is catalysed by 
the cyclase NisC. The modified NisA molecule is translocated across the cellular 
membrane by the ABC-type transporter NisT. Subsequently the leader sequence 
is cleaved off by the peptidase NisP, liberating the biologically active lantibiotic 
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Figure 1.5. Metabolic route of NisA. 
NisA is directed to the dehydratase NisB. 
After dehydration by this enzyme and the 
formation of thioether linkages (lanthionine 
and methyllanthionine residues) by NisC, 
the modified NisA molecule is translocated 
across the cellular membrane (CM) by the 
ABC-type transporter NisT. Subsequently 
the leader sequence is cleaved off by the 
peptidase NisP, liberating the biologically 











nisin A (Figure 1.5). A positive feedback loop for the expression of the gene cluster 
is formed by the membrane embedded histidine kinase NisK which upon binding 
of nisin A activates the transcription regulator NisR. L. lactis cells are protected 
against the bactericidal effects of the nisin A they produce themselves by the 
immunity proteins NisI and NisFEG.
The three subsequent events of dehydration, cyclization, and translocation of 
the nisin A precursor likely occur at a membrane localized multimeric protein 
complex consisting of NisB, NisC and NisT. The dehydratase NisB and the cyclase 
NisC were shown to be associated with the membrane (55;61), while the nisin 
transporter, NisT, belongs to the class of ABC-type half-transporters (62).  By 
means of a yeast two-hybrid system and co-immunoprecipitation experiments, 
interactions were detected between NisC and NisB and between NisC and NisT 
(61). Although these three proteins likely form a complex at the membrane, a strict 
association is not essential for their activity. In the absence of NisB and NisC, the 
transporter NisT is able to secrete unmodified NisA and several peptides fused 
to the leader peptide of prenisin (63).  Likewise, NisB was shown to be active 
in L. lactis in the absence of NisT and/or NisC (64;65). Although the interaction 
between NisB, NisC and NisT is not essential for their activity per se it might be 
important for efficient production of nisin A. The production of nisin A precursor 
peptide is highly reduced by the absence of one of these three Nis proteins (66). 
The nisin A precursor peptide may be “passed along” from one enzyme to the 
next, and such channelling may allow for an efficient throughput and conversion. 
In a modified L. lactis strain harbouring a disrupted nisT gene, biologically active 
nisin A was detected in the cytoplasm as the result of proteolytic degradation 
of the fully modified nisin A precursor (62). The association of NisBCT into a 
complex may therefore also prevent accumulation of nisin A inside the cell. 
An interesting aspect of the nisin A biosynthesis enzymes is their apparent low 
substrate specificity. Neither the ring structures formed by the intramolecular 
thioether bridges, nor the dehydroalanine and dehydrobutyrine residues are 
essential for translocation of nisin A precursor peptide by NisT (63). The enzymes 
can even dehydrate, cyclise, and secrete a range of medically relevant peptides 
that are not related to lantibiotics when fused to the nisin A leader peptide 
(67). This flexibility of the enzymes may open possibilities to introduce specific 
thioether bridges in peptides of interest. Such biologically stable linkages may 
make these peptides more resistant to degradation or keep them in a favourable 
structural conformation. 
To direct the nisin A precursor peptide to the (putative) NisBCT complex in 
principle only one recognition site for the leader sequence on the complex is 
needed. Since dehydration is the first enzymatic step, NisB likely recognizes 
these precursors through an association with the leader sequence. However, 
NisC and NisT may also recognize the leader sequence. Detectable levels of 
prenisin are found in the suspending medium of cells expressing NisAT and 
NisC cyclises dehydrated prenisin in vitro (64;65). The effect of the absence of 
either of the three proteins on the production of prenisin has been analysed (66). 
Prenisin is no longer secreted by strains that lack the transporter NisT. However, 
in the absence of NisB, production is nearly complete abolished while significant 
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levels of prenisin are observed when only NisC is absent. These data support a 
model in which NisB mediates a key step between the ribosomal synthesis of the 
unmodified nisin A precursor peptide and the secretion of fully modified prenisin 
from the cell. Possibly a channelling process through the enzyme complex starts 
with the targeting of the nisin precursor to the NisB subunit.
 
Outline of this thesis
The aim of the studies presented in this thesis was to further define the function of 
the L. lactis multidrug transporters LmrA and LmrP in cellular drug resistance and to 
understand their mechanisms of action. In order to provide insights in the substrate 
specificity of the ABC transporter NisT, its function in relation to the activities of 
the NisB and NisC proteins involved in the maturation of the antimicrobial peptide 
nisin A was determined.
In Chapter 2 the effect of the expression of three different MDR proteins – the 
human ABCB1 (MDR1), L. lactis LmrA, and Oenococcus oeni OmrA - on cadmium 
resistance in E. coli is described. All three proteins confer cadmium resistance when 
expressed in the cadmium-hypersensitive E. coli CS1562 strain. Furthermore, in 
the presence of these transporters, less cadmium is found to be associated with 
the cells. The elevated resistance and reduced association of cadmium are likely 
the result of extrusion of this toxic metal ion by the MDR proteins. In support 
of this hypothesis, LmrA-mediated, ATP-dependent uptake of 109Cd2+ in inverted 
membrane vesicles of L. lactis is demonstrated.
Chapter 3 describes a detailed analysis of the activities of a set of LmrA ATPase- 
mutants in vitro as well as in vivo. To understand the role and cooperativity between 
the two NBDs of the LmrA dimer in the catalytic cycle, two ATPase-deficient 
mutants of LmrA were generated. Surprisingly, these ATPase-mutants were found 
to still mediate the transport of Hoechst 33342 in inside-out membrane vesicles 
of L. lactis. This ATP-dependent and LmrA-mediated Hoechst 33342-transport 
was shown to be dependent on the proton gradient across the membrane, and 
independent of ATP hydrolysis via the NBDs of LmrA.  In intact cells, LmrA was 
found to facilitate influx of the nucleic acid stain rather than secreting it from 
the cell as would be expected for a MDR transporter. Finally, in contrast to the 
heterodimeric ABC-type MDR transporter LmrCD, the expression of LmrA did 
not render L. lactis cells resistant to Hoechst 33342. A critical assessment of the 
Hoechst 33342-transport assay is presented, as this assay is commonly used in 
studies on MDR transporters.
In Chapter 4, a similar assessment of LmrP-mediated transport of Hoechst 33342 
and ethidium is made. The fluorescent compounds Hoechst 33342 and ethidium 
have been used extensively in the characterization of LmrP (8;23-27;68;69). 
LmrP secretes ethidium from intact cells and confers resistance to this toxic 
compound in growing cells. However, as described for LmrA (Chapter 3), LmrP 
did not rescue the Hoechst 33342 sensitive phenotype of L. lactis cells lacking the 
lmrCD genes, while in inside-out membrane vesicles a strong, LmrP-mediated 
transport of Hoechst 33342 can be detected. Combined, the studies presented in 
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Chapter 3 and 4 demonstrate that Hoechst 33342 is an unreliable diagnostic 
substrate to characterize putative MDR transporters.
Chapter 5 describes a cellular offence mechanism, rather than a defence 
mechanism. Herein, the contribution of the nisin A biosynthetic enzymes NisB 
and NisC and the transport protein NisT to the production of prenisin by L. lactis 
was determined. From the quantitative assessment, the dehydratase NisB has a 
major effect on the production of prenisin. It is hypothesized that these proteins 
function together in a complex and that channelling of the prepeptide within the 
membrane-associated nisin A biosynthetic protein complex allows for an efficient 
modification and secretion of the maturated nisin.





Heterologously expressed bacterial and human multidrug 
resistance proteins confer cadmium resistance 
to Escherichia coli
Maud Achard, H. Bart van den Berg van Saparoea, Arnold J. M. Driessen, 
and Jean-Paul Bourdineaud
Summary
The human MDR1 gene is induced by cadmium exposure although no resistance 
to this metal is observed in human cells overexpressing hMDR1. To assess 
the role of MDR proteins in cadmium resistance, human MDR1, Lactococcus 
lactis lmrA, and Oenococcus oeni omrA were expressed in an Escherichia coli tolC 
mutant strain which proved to be hypersensitive to cadmium. Both the human 
and bacterial MDR genes conferred cadmium resistance to E. coli up to 0.4 mM 
concentration. Protection was abolished by 100 µM verapamil. Quantification of 
intracellular cadmium concentration by atomic absorption spectrometry showed 
a reduced cadmium accumulation in cells expressing the MDR genes. Inside-out 
membrane vesicles of L. lactis overexpressing lmrA displayed an ATP-dependent 
109Cd2+-uptake that was stimulated by glutathione. An evolutionary model is 
discussed in which MDR proteins have evolved independently from an ancestor 
protein displaying both organic xenobiotic- and divalent metal-extrusion abilities.
Biochemistry (2005) 44, 5916 - 5922
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Introduction
Multidrug resistance (MDR) is one of the major causes of failure of chemotherapy 
employed for the treatment of cancer (70). Among others, MDR is caused by the 
overexpression of a 170 kDa membrane protein called MDR1 or P-glycoprotein 
(P-gp). MDR1 is a member of the ATP binding cassette (ABC) superfamily of 
transporters, whose functions include the ATP-dependent extrusion of amphiphilic 
compounds out of the cell (70). In addition to MDR1, other ABC transporters have 
been implicated in MDR in mammalian cells such as the multidrug resistance 
associated protein, MRP1(71;72).
Like cancer cells, many organisms have the ability to develop resistance to a 
variety of toxic compounds through ATP-dependent extrusion mechanisms. 
Indeed, MDR also occurs in lower eukaryotes and bacteria. For instance, MDR1-
like proteins have been identified in a variety of aquatic organisms (73) where 
they can account for the protection against a broad variety of toxic compounds 
such as xenobiotics and naturally occurring toxins, as well as endogenous toxic 
compounds. Such transporters can be relatively specific for a given substrate 
range or can handle a wide variety of structurally unrelated compounds. Among 
the xenobiotics, heavy metals pose a serious threat to the environment. Several 
ABC-transporters such as MRP1, Leishmania LtPgpA, and the yeast cadmium 
resistance factor 1 (YCF1) may take part in metal resistance. Indeed, these genuine 
xenobiotic pumps are also involved in heavy-metal detoxification: LtPgpA pumps 
out arsenite and antimony (74), YCF1 pumps out arsenite, and human MRP1 and 
YCF1 catalyze the extrusion of bis(glutathionato)cadmium conjugates (75;76). 
In our laboratory1, we focus on the problem of long-term pollution in aquatic 
species by heavy metals such as cadmium and mercury. In particular, we study 
resistance mechanisms against metal contamination displayed by a biological 
model, the Asiatic clam Corbicula fluminea. In this bivalve, a gene encodes a 
multixenobiotic resistance protein (MXR) that is homologous to the mammalian 
P-gp. The MXR protein level was considerably elevated in the tissues of bivalves 
living in a cadmium-contaminated environment (77). Similar observations have 
been made in the mussel Mytilus californianus exposed to arsenite and cadmium 
(78). Moreover, MRP1 is overexpressed in human heavy-metal-selected tumour 
cells (79), while MDR1 is induced by cadmium and arsenite ions although no 
resistance to cadmium ions has been observed in cells overexpressing P-gp (80). 
These different examples suggest that ABC transporters of the MDR group are 
induced in the presence of metal contaminants. This raises the question as to 
whether these proteins are directly involved in cellular extrusion of metals in 
addition to their role as xenobiotic extruders.
Herein we have analysed the role of MDR-like proteins in metal resistance. Three 
transporters were tested: the human MDR1 and two bacterial ABC-type multidrug 
extrusion systems, LmrA and OmrA. LmrA is an ABC transporter of Lactoccocus 
lactis (5) that is functionally and structurally related to the human MDR1 (31). It 
uses the free energy of ATP-hydrolysis to drive the export of toxic compounds 
1 Laboratoire d’Ecophysiologie et d’Ecotoxicologie des Systèmes Aquatiques (LEESA), 
Université Bordeaux, Arcachon, France
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from the inner leaflet of the cytoplasmic membrane (36). Homologues of LmrA 
have been detected in other lactic acid bacteria, like the Oenococcus oeni omrA 
gene (29). OmrA confers protection to bacteria grown on high salt medium. It also 
triggered bacterial resistance to sodium laurate, wine, and ethanol toxicity. 
To test their ability to provide resistance to toxic metals, the proteins were 
expressed in Escherichia coli. All three systems provided cadmium resistance to 
E. coli. Transport assays with inside-out membrane vesicles isolated from L. lactis 
suggest an LmrA-mediated cadmium extrusion activity.
Experimental procedures
Reagents. Cadmium chloride (CdCl2) was purchased from Merck; reduced 
glutathione, adenosine 5’-[β,γ-imino]triphosphate (AMP-PNP), nisin A, and 
verapamil were from Sigma. 109Cd2+ was purchased from Amersham (Pharmacia, 
Amersham).
Bacterial strains, growth conditions, and plasmid constructions. Bacterial strains used 
were E. coli CS1562 (F- λ- tolC6::Tn10 his leu proA argT his thi galK lacY trpE non 
mtl xyl ara rpsL sup+) (81), E. coli JM109 (e14-(McrA-) recA1 endA1 gyrA96 thi-1 
hsdR17 (rK- mK+) supE44 relA1Δ(lac-proAB) [F’ traD36 proAB lacIq ZΔM15]), E. coli 
W3110 (F- λ- thyA36), E. coli BL21(DE3) (B F- dcm ompT hsdS(rB- mB-) gal λ (DE3)), 
and L. lactis NZ9000 ΔlmrA (MG1363 derivative, pepN::nisRK) (49). E. coli was 
grown at 37 °C (or 28°C when transformed with pSF or pSF-MDR) in LB medium 
(5 g/L yeast extract, 10 g/L bactotryptone, 10 g/L NaCl) supplemented with the 
appropriate antibiotic (ampicillin, kanamycin, or chloramphenicol). L. lactis was 
grown at 30 °C in M17 medium (Difco) supplemented with 0.5% glucose and 
5 µg/mL chloramphenicol.
The human gene (hMDR1) and two bacterial homologues, lmrA and omrA, of 
L. lactis (5) and O. oeni (29), respectively, were expressed in E. coli strains JM109, 
W3110, and BL21, and in strain CS1562, which is hypersensitive to drugs (81) and 
cadmium (this work, Figure 2.1B) due to a deficiency in the TolC protein. 
Plasmids used are pSF and pSF-MDR containing an ampicillin resistance gene 
(82), pGK13 and pGKLmrA containing a chloramphenicol resistance gene(5), 
and pCR-XL-TOPO (Invitrogen) and pJPB66 (pCR-XL-TOPO which harbours the 
O. oeni omrA gene) containing a kanamycin resistance gene (29). For the isolation 
of inside-out membrane vesicles, L. lactis NZ9000 ΔlmrA was transformed with 
either pNZ8048 (control) or pNHLmrA (overexpressing lmrA).
Resistance assays on agar media. Overnight cultures with the appropriate antibiotic 
were adjusted to an OD660 of 2. Then, serial 10-fold dilutions were performed, and 
5 µl of each dilution was spotted on the agar medium with or without cadmium, 
verapamil, or cadmium and verapamil. The plates were incubated overnight at 
28 °C or 37 °C and photographed.
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Bacterial survival and metal quantification. Overnight cultures were diluted into fresh 
LB medium (1% v/v) containing the appropriate antibiotic and grown up to an 
OD660 of 0.1. Each culture was divided in three: a control, a culture containing 0.25, 
and a culture containing 0.4 mM CdCl2. Cultures were further incubated for 3 h at 
37 °C (or 28 °C for hMDR-transformed bacteria and corresponding control). 
Bacterial survival was determined as follows: after 3 h, 100 µl of each culture 
was taken, serial 10-fold dilutions were plated on LB solid medium, and 
colonies were counted after an overnight incubation. Survival ratios were 
calculated as the colony forming units (cfu) observed in presence of the metal 
to that observed without toxic compound. Cell-associated cadmium levels 
were determined as follows: after 3h of incubation, cells from 30 mL culture 
were collected by centrifugation (15 min, 6000g, 6 °C) and washed with a 
buffer containing 10 mM Tris·HCl, pH 7.4, and 0.15 mM NaCl. Pellets were 
destructed by nitric acid [3 mL of pure HNO3, 65% (v/v)] in a pressurised 
medium (borosilicate glass tubes) at 100 °C for 3 h. Samples were diluted with 
18 mL of ultrapure water (MilliQ plus), and cadmium concentrations were determined 
by atomic absorption spectrometry with Zeeman correction, using a graphite 
tube atomizer (AAS, Thermoptec M6Solaar). The detection limit was 0.1 µg Cd/L 
(3x standard deviation of the reagent blanks). Results were expressed in 
nanograms of Cd2+/106 bacteria. 
Isolation of inside-out membranes vesicles from L. lactis. Inside-out membrane vesicles 




























Figure 2.1. E. coli tolC mutant: a suitable strain to study xenobiotics and metal 
resistance conferred by expression of MDR transporters. (A) Effect of TolC on the 
ethidium bromide resistance introduced by expression of the hMDR1 transporter. 
E. coli CS1562 (tolC-) and JM109 (tolC+) were transformed with plasmids pSF (C) or 
pSF-MDR (hMDR1). An equivalent growth pattern was observed between control 
and hMDR1-expressing bacteria when the medium was devoid of ethidium bromide. 
(B) TolC is involved in cadmium resistance. Overnight cultures of E. coli CS1562 (tolC-) 
(open squares) and JM109 (tolC+) (filled circles) were diluted to an OD660 of 0.06 into 
LB medium containing various concentrations of cadmium. Cell growth was monitored 
as the absorbance at 660 nm after 12 h of incubation at 37 °C. Measurements were done 
in triplicate. Several other tolC+ strains [W3110 and BL21(DE3)] were tested with similar 
results for both panels A and B.
27
pNHLmrA. Cells were grown at 30 °C to an OD660 of about 0.7, whereupon lmrA 
expression was induced for 1 h by addition of 0.5 ng/mL nisin. Cells were cooled 
down on ice for 30 min and harvested by centrifugation (6000g for 8 min) at 4 °C. 
All subsequent steps were carried out at the same temperature. Cells were washed 
twice in 1 L of ice-cold 100 mM HEPES-KOH, pH 7.4. Pellets were resuspended in 
42 mL of the same buffer. N-Ethylmaleimide (NEM, Sigma), MgSO4, DNase I (Sigma), 
and lysozyme were added to a concentration of 1 mM, 10 mM, 0.1 mg/mL, and 
10 mg/mL, respectively. The cell suspension was incubated for 45 min at 
30 °C, cooled on ice and lysed by two successive passages through a French press 
(20,000 psi, Basic Z Model Cell Disrupter, Constant Cell Disruption Systems). 
The lysed cells were diluted to a volume of 70 mL with ice-cold HEPES-KOH, 
pH 7.4, containing 1 mM NEM. Unbroken cells and debris were removed 
by centrifugations (13,000g for 45 min followed by 25,000g for 30 min, 4 °C), 
whereupon the membranes were collected from the supernatant by high-speed 
centrifugation (125,000g for 1 h, 4 °C). Pellets were resuspended in 1.5 volumes of 
a buffer containing 50 mM HEPES-KOH, pH 7.4, 10% glycerol, and 1 mM NEM, 
frozen in small aliquots in liquid nitrogen, and stored at – 80 °C. Protein was 
assayed according to the method of Lowry (DC Protein Assay, Bio-Rad), using 
bovine serum albumin as a standard. 
Transport assays with 109Cd2+. Membrane vesicles were added to 1.5 mL of 50 mM 
HEPES-KOH, pH 7.4, 2 mM MgSO4, 8.5 mM NaCl, 5 mM phosphocreatine, 
0.1 mg/mL creatine kinase and 50 µM of 109Cd2+ (9.08 µCi/µmol specific activity) 
in a 5 mL plastic tube to a final concentration of 0.5 mg of protein/mL. After 1 min 
incubation at 30 °C, transport was initiated by the addition of ATP to 2 mM. When 
indicated, 650 µM reduced glutathione and/or 2 mM of AMP-PNP instead of ATP 
were (was) included in the reaction mixture. The transport was monitored over 
14 min, and at each time-point, 200 µL of the reaction mixture was passed over 
cellulose nitrate filters (0.2 µM, pore size, BA 83 Schleicher and Schuell). Filters 
were washed twice with 2 mL of ice-cold 0.1 M LiCl and assayed for radioactivity 
using a Liquid Scintillation analyser Tri-carb 2000 CA. Uptake rates were 
determined by means of a linear regression model. In the statistical analysis, a 
probability of P < 0.05 was considered significant. 
Results
hMDR1, LmrA and OmrA proteins protect bacteria against metal stress. The difference 
in in vivo metal ion susceptibility between E. coli cells harboring the hMDR1- 
or lmrA- or omrA-containing plasmids and bacterial cells harboring a control 
plasmid was first studied on solid media. hMDR1, lmrA and omrA expression 
in a tolC- background resulted in an increased resistance to cadmium chloride 
which was manifested by the colony formation at the highest dilution in the 
presence of 0.4 mM CdCl2 relative to control. Verapamil is a well-known inhibitor 
of MDR-type transporters. It has been shown that verapamil alone exerted no 
influence on bacterial growth at 100 µM concentration (83).  In the presence of 
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verapamil all resistance was abolished (Figure 2.2) suggesting a MDR-dependent 
resistance mechanism. This resistance phenotype against Cd2+ conferred by these 
ABC transporters could only be observed in a tolC- background. In a tolC+ strain, 
which resists higher levels of Cd2+ concentrations than a tolC mutant (Figure 2.1B), 
expression of the ABC transporters did not afford an additional Cd2+-resistance 
(Figure 2.2).
hMDR1, lmrA and omrA expression results in a lowered metal concentration in bacteria. 
Atomic absorption spectrometry was used to quantify the cadmium level 
associated with Cd-exposed E. coli tolC- cells that were transformed with either 
hMDR1-, lmrA-, omrA-containing plasmids or a control plasmid. When the culture 
medium contained 0.25 or 0.4 mM CdCl2, a marked decrease in cell-associated 
Cd2+ was observed with cells expressing hMDR1, lmrA or omrA, respectively. This 
reduction in cell-associated cadmium correlated with the 4.4-, 1.3-, and 5-fold 
increases in survival observed in the cells expressing hMDR1, lmrA, and omrA, 
respectively (Figures 2.3B,D,F). Some differences in cadmium accumulation were 
observed among the control cells (bacteria transformed with empty vectors, 
Figure 2.3). However, these differences likely reflect differences in growth 
temperature (in the case of pSF transformed bacteria) or plasmid copy number 
(high for pCR-XL-TOPO and low for pGK13). These data suggest that MDR1, 
LmrA and OmrA provide cadmium resistance to cells through metal pumping.
LmrA mediated cadmium transport. The increased resistance of cells to cadmium 
upon expression of MDR transporters is most likely due to an increased cellular 
extrusion of the cadmium. To establish a direct biochemical demonstration of the 
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Figure 2.2. Heterologously expressed ABC MDR transporters in E. coli confer 
protection against cadmium toxicity. The E. coli CS1562 (tolC-) and JM109 (tolC+) strains 
were transformed with omrA-, hMDR1-, and lmrA-harboring plasmids and the relevant 
control plasmids. (A) pGK13 (control) or pGKLmrA (LmrA). (B) pCR-XL-TOPO (control) 
or pJPB66 (OmrA). (C) pSF (control) or pSF-MDR (hMDR1). An equivalent growth 
pattern was observed between control bacteria and transporter-expressing bacteria 
when the medium was devoid of CdCl2, while verapamil (100 μM) alone exerted no 
influence on bacterial growth. Several other tolC+ strains [W3110 and BL21(DE3)] were 
tested and gave similar results.
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experiments were conducted with inside-out vesicles derived from L. lactis cells 
expressing LmrA. The cadmium concentration used in these experiments was set 
to 50 µM to facilitate the detection of the transport activity. This concentration 
is in the range of xenobiotic concentrations used in LmrA mechanistic studies 
(32). Control membrane vesicles were prepared from L. lactis NZ9000 ΔlmrA cells 
harbouring the control plasmid pNZ8048. Before the addition of ATP, non-specific 
cadmium adsorption was observed with the membrane vesicles. This behaviour 
is characteristic of divalent metals/membranes interaction, since we could also 



































































































































































Figure 2.3. Heterologously expressed ABC MDR transporters in the E. coli tolC 
mutant reduce the cell-associated level of cadmium. E. coli CS1562 (tolC mutant) was 
transformed with control plasmids and lmrA-, omrA-, and hMDR1-containing plasmids. 
After 3 h of incubation with the indicated amount of cadmium, the bacterial cultures 
were either serially diluted and plated or used for metal quantification. Colonies were 
counted, and the survival ratios were calculated as the colony-forming units observed at 
a given concentration of cadmium to that observed without added toxic compound (A, 
C, E). Cell-associated cadmium concentrations were determined by atomic absorption 
spectrometry, and results were expressed in ng of Cd2+/106 bacteria (B, D, F). The number 
of bacteria per digested pellet was determined by cell numeration. (A, B) Bacteria 
were transformed with either pGK13 or pGKLmrA. (C, D) Bacteria were transformed 
with either pCR-XL-TOPO or pJPB66 (containing the omrA gene). (E, F) Bacteria were 
transformed with either pSF or pSF-MDR. White bars stand for survival ratio or Cd2+ 
associated with control bacteria and black ones for survival ratio or Cd2+ associated with 
bacteria expressing one of the ABC transporters.
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observe Cd2+ binding on dead or living E. coli cells within seconds using a 
cadmium specific electrode (data not shown). 
109Cd2+-transport was initiated by the addition of ATP. LmrA-containing 
inside-out vesicles accumulated more cadmium than the control membranes 
(Figure 2.4A). This difference was calculated to be 30 ± 7 pmol Cd/min/mg protein 
(P < 0.05). To test if cadmium accumulation is dependent on the hydrolysis of 
ATP, the same experiment was performed with the non-hydrolysable ATP 
analogue, AMP-PNP. Again, the difference of 109Cd2+-uptake kinetics by LmrA-
containing vesicles with ATP compared to AMP-PNP was 30 ± 10 pmol Cd/min/
mg protein (P < 0.05). Moreover, no significant difference of Cd2+ uptake kinetics 
was observed between the LmrA containing vesicles in the presence of AMP-
PNP as compared to the control membranes with ATP. Taken together, these data 
suggest that LmrA mediates a low transport activity of Cd2+. The transport assays 
were carried out in the absence of glutathione, cysteine, or other molecules that 
may form a thiolate complex with Cd2+. Nevertheless, the assay contains ATP to 

































































Figure 2.4. LmrA-mediated ATP-dependent 109Cd2+ uptake in inside-out membrane 
vesicles. (A) The uptake of 109Cd2+ by inside-out vesicles derived from cells that 
overexpressed LmrA (squares) or that were devoid of LmrA (diamonds) was measured 
in the presence of ATP (filled square/diamond, solid line) or AMP-PNP (open square, 
dotted line). Values shown are the means with the indicated standard deviation 
(n = 3). 109Cd2+ was added at time -1 min, and reactions were started at time 0 by the 
addition of ATP or AMP-PNP. At time 0, the cadmium level was set to 0 to avoid 
background related to a nonspecific binding of cadmium to the membrane vesicles. 
(B) LmrA-catalyzed uptake of 109Cd2+ is stimulated by glutathione. The uptake of 109Cd2+ 
by inside-out vesicles derived from cells that overexpressed LmrA (filled and open 
squares) or control vesicles that were devoid of LmrA (filled and open diamonds) was 
measured in the presence of ATP in the presence (open symbols, thick line) or absence 
(filled symbols, thin line) of GSH. Values shown are means ± standard deviation (n = 3). 
109Cd2+ and GSH were added 1 min before starting the reaction by the addition of ATP. 
At time 0, the cadmium level was set to 0 to avoid background related to a nonspecific 
binding of cadmium to the membrane vesicles. The transport activity was defined as the 
amount of cadmium taken up during the first 2 min.
Chapter 2
31
transporters such as CFTR or hMDR1 have been shown to pump Mg-ATP (84;85). 
YCF1-catalysed cadmium extrusion is dependent on glutathione (GSH) and 
more precisely on the bis(glutathionato)-cadmium complex (75). Therefore, we 
addressed the possible influence of GSH on LmrA-mediated cadmium transport. 
109Cd2+ transport by LmrA containing inside-out vesicles was measured in the 
presence of ATP with or without 625 µM GSH and compared with control vesicles 
(Figure 2.4B). In the absence and presence of glutathione, the difference in transport 
activity between the LmrA and control membranes was 28 ± 7 and 124 ± 42 pmol 
Cd/min/mg protein, respectively (P < 0.05). This demonstrates that glutathione 
stimulates the LmrA-mediated cadmium transport activity by more than 4-fold. 
Discussion
Here we report on the ability of the heterologous expression of human MDR1 
and the bacterial lmrA and omrA genes to confer resistance in E. coli to cadmium. 
This study reveals a novel function of these proteins and provides a mechanistic 
explanation for the observation that rat mdr1 overexpression protects kidney 
cells against cadmium-mediated apoptosis (86). Surprisingly, overexpression of 
human P-gp in renal carcinoma cells does not result in an increased resistance to 
cadmium chloride (80). However, in these cells the activity of P-gp might have 
been masked by the activity of MRP proteins. Indeed, the nematode Caenorhabditis 
elegans becomes hypersensitive to heavy metals when both the MRP homologue 
and a member of the P-pg gene family are deleted (87).
We noted that the MDR protein mediated cadmium resistance was only evident in 
an E. coli strain lacking the outer membrane protein TolC. Loss of TolC is known 
to increase sensitivity to detergents and drugs, but it was unknown that a tolC 
mutation also results in an increased Cd2+-sensitivity. It has been suggested that 
residual metal resistance in a strain disrupted in both zntA, a P-type zinc ATPase, 
and zitB, a zinc/H+ antiporter of the major facilitor superfamily, is caused by 
additional factors or systems (88). Our studies suggest that one of these factors 
is TolC (and possibly associated inner membrane transporters such as AcrAB) 
since the MIC for Cd2+ was shifted from 1.1 to 0.35 mM in tolC+ and tolC- strains, 
respectively. Alternatively, the pleiotropic effects displayed by the tolC mutant 
could explain its increased sensitivity. Resistance to Cd2+ and to ethidium bromide 
conferred by MDR transporters was only observed in a tolC- genetic background 
(Figure 2.1A). This loss of a detectable MDR function in the tolC+ strains suggests 
that TolC impedes or masks the ability of these heterologously expressed MDR 
proteins to resist Cd. The latter may be due to the presence of functional and 
efficient endogenous cadmium scavenging systems in the TolC-containing strain. 
The here observed cadmium resistance associated with the three exogenous ABC 
protein expressions is unlikely the result of an interaction between these proteins 
and endogenous E. coli metal transporters such as the P-type ATPase ZntA. First, 
the observed bacterial resistance is abolished by verapamil, while verapamil is 
not a known  inhibitor of P-type ATPase (89). Furthermore, verapamil inhibition 
of ZntA would lead to a lack of growth at high Cd2+ concentrations [MIC 0.03 mM 
Cadmium resistance conferred by MDR proteins
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(90)] whereas growth in the presence of verapamil was observed at 0.4 mM 
CdCl2. In addition, at the concentration used, verapamil exerted no effect on the 
colony formation of the control E. coli strains on solid media demonstrating that 
the observed reversal of metal resistance is not due to inhibition of endogenous 
E. coli system but rather to the inhibition of LmrA, OmrA and hMDR1. Second, 
the LmrA activity is independent from accessory proteins (32), and murine 
and human MDR1 genes have previously been expressed functionally in E. coli 
without requirement of an endogenous system or factor (91;92).
Bacterial resistance to cadmium effected by LmrA, OmrA, and hMDR1 is also 
unlikely to be due to a physicochemical modification of the inner membrane 
which may in turn decrease the efficiency of the divalent metal ion uptake 
system ZupT (93). First, such an influence on ZupT activity would have a 
strong impact on bacterial systems requiring an optimal supply in Zn2+ and 
Cu2+ and thus it would affect cell activity or growth. We found no difference 
between the growth curves of bacteria expressing or devoid of heterologously 
expressed MDR-like transporters (data not shown). Second, it has already 
been shown that the expression of the murine MDR1 gene in E. coli is not 
accompanied by a dissipation of the proton motive force as lactose transport 
by LacY remained fully functional (92). Also, hMDR1 does not affect the levels 
of the proton motive force when expressed in mammalian cells (94). Moreover, 
the cellular ATP levels, as measured by a luminescent assay, were not affected 
in the transformed bacteria (data not shown) which shows that the energy 
status of the cell is not significantly influenced. Third, contrary to previous 
adopted strategies to express the human and murine MDR1 genes in E. coli 
(91;92), we did not use a strong E. coli promoter to drive the expression of the 
lmrA-, omrA-, and hMDR1 genes in order to avoid membrane perturbation by 
high-level protein expression. Finally, the sodium dodecyl sulphate-sensitivity 
of MDR-expressing bacteria was similar to that of control cells, indicating no 
major alterations of the cell envelope and membrane (data not shown).
Quantification of the cadmium level associated with cadmium-exposed 
tolC-  bacteria (Figure 2.3) showed that cells expressing one of the three 
transporters contained 2 to 8 times less cadmium than control cells. This 
strongly suggests that the ABC proteins extrude Cd-glutathione complexes 
and, in the absence of glutathione, Cd-ATP complexes. Direct evidence for 
cadmium transport was obtained with membrane vesicles derived from 
L. lactis, despite an important LmrA nonspecific Cd2+ binding. This high 
background might be due to the presence of the CadA-like P-type ATPase 
YuiA. In the absence of glutathione, LmrA-containing membranes showed a 
cadmium uptake rate of 28 pmol/min/(mg of protein) above that of control 
membranes. This transport rate is in the same order as previously shown for 
LmrA-catalysed transport of daunomycin into inside-out E. coli membrane 
vesicles [7.8 pmol/min/(mg of protein)] (5). When glutathione was added to 
the medium, a more than 4-fold increase in the rate of cadmium transport was 
observed up to 124 pmol/min/(mg of protein). Although much higher rates of 
cadmium transport have been reported for the yeast YCF1 (75) in the presence 
of glutathione [3.3 nmol/mg/(mg of protein)], it is difficult to directly compare 
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these rates as they have been determined in vastly different experimental systems. 
Unlike YCF1, cadmium detoxification is likely not the primary function of LmrA. 
Among the superfamily of ABC transporters several systems seem to have evolved 
to function as efficient metal ion detoxification devices, such as MRP1, LtPgpA, 
and YCF1, while others have retained this activity with only a lower efficiency.
A weak ATP-dependent LmrA-mediated Cd2+-transport activity occurred without 
added glutathione. Under those conditions, Cd2+ may be complexed with ATP 
(95) which was present in large excess. Murine and Drosophila P-gp homologues 
have been shown to serve as ATP-conducting channels in the plasma membrane 
(84;96). The cystic fibrosis transmembrane conductance regulator (CFTR), a 
chloride channel that belongs to the ABC superfamily, has also been demonstrated 
to conduct ATP movements (85). Finally, the ZntA ATPase accumulates Cd2+ in 
inside-out membrane vesicles 5-fold more efficiently in the presence of cysteine 
than in its absence (89). Cd2+, Hg2+, and Zn2+ form complexes with thiolates with 
affinities that are several orders of magnitude greater than complexes with ATP 
(89). This may explain the increased LmrA-mediated Cd2+-transport activity 
in the presence of glutathione. A high, nonspecific Cd2+ binding and transport 
activity of E. coli membrane vesicles precluded an accurate analysis of OmrA- and 
hMDR1-mediated 109Cd2+-transport. However, given the structural and functional 
relatedness of OmrA and hMDR1 with LmrA, and the observation that these 
systems render E. coli cells more resistant to Cd2+ with a concomitant decrease 
in intracellular cadmium concentrations, it is likely that OmrA and hMDR1 also 
extrude Cd2+. These systems have more in common. First, both LmrA and OmrA 
were shown to protect bacteria against sodium laurate toxicity and ethanol and 
wine shocks (29). Second, both CFTR and MDR proteins share ATP- and chloride-
channel activity (84;85;97). Third, CFTR is able to release glutathione into airway 
surface fluid (98), and displays functional similarity with the ABC proteins MRP1, 
MRP2 and YCF1 (71;72;75). Fourth, overexpression of CFTR leads to a multidrug 
resistance phenotype (99). And vice-versa, induction by antitumoral drugs 
of hMDR1 and hMRP1 complements CFTR function (100). These results raise 
the possibility that ABC transporters may be interchanged, as outlined by the 
complementary patterns of expression of the CFTR and hMDR1 genes observed 
in vivo (101). The common functional features in ABC transporters are likely 
to be explained by an early evolutionary event. ABC genes may have evolved 
separately and acquired a more specialized activity, while maintaining their 
general function with low efficiency. For instance, hMDR1, LmrA, and OmrA 
proteins are specialised in xenobiotic scavenging but still are able to confer some 
resistance against metals. In the future, it would be valuable to determine the 
selectivity of such proteins among heavy metals.





Proton motive force-dependent Hoechst 33342-transport 
by the ABC transporter LmrA of Lactococcus lactis
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Piotr S. Mazurkiewicz, and Arnold J.M. Driessen
Summary
The fluorescent compound Hoechst 33342 is a substrate for many multidrug 
resistance (MDR) transporters and is widely used to characterize their transport 
activity. We have constructed mutants of the adenosine triphosphate (ATP) 
binding cassette (ABC)-type MDR transporter LmrA of Lactococcus lactis that 
are defective in ATP hydrolysis. These mutants and wild-type LmrA showed an 
atypical behavior in the Hoechst 33342-transport assay. In membrane vesicles, 
Hoechst 33342-transport was shown to be independent of the ATPase activity of 
LmrA, and it was not inhibited by orthovanadate but sensitive to uncouplers that 
collapse the proton gradient and to N,N’-dicyclohexylcarbodiimide, an inhibitor 
of the F0F1-ATPase. In contrast, transport of Hoechst 33342 by the homologous, 
heterodimeric MDR transporter LmrCD showed a normal ATP dependence and 
was insensitive to uncouplers of the proton gradient. With intact cells, expression 
of LmrA resulted in an increased rate of Hoechst 33342-influx while LmrCD caused 
a decrease in the rate of Hoechst 33342-influx. Cellular toxicity assays using a 
triple knockout strain, i.e., L. lactis ΔlmrA ΔlmrCD, demonstrate that expression 
of LmrCD protects cells against the growth inhibitory effects of Hoechst 33342, 
while in the presence of LmrA, cells are more susceptible to Hoechst 33342. Our 
data demonstrate that the LmrA-mediated Hoechst 33342-transport in membrane 
vesicles is influenced by the transmembrane pH gradient due to a pH-dependent 
partitioning of Hoechst 33342 into the membrane.
Biochemistry (2005) 44, 16931 - 16938
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Introduction
The bisbenzimide dye Hoechst 33342 is a cell membrane-permeant DNA stain that 
exhibits a bright blue fluorescence upon binding to DNA. In Hoechst 33342-stained 
murine lymphocyte cells, it was observed that the fluorescence intensity is not 
always related to DNA content (102). This led to the suggestion that membranes 
may exhibit different permeabilities for Hoechst 33342. Involvement of drug 
resistance proteins followed from experiments with colchicine-resistant Chinese 
hamster ovary cell lines (102). Cell lines with an increased resistance to colchicine 
concomitantly showed a decreased uptake of the dye. At a later stage, Hoechst 
33342 was identified as a substrate for P-glycoprotein (P-gp) (103). 
Hoechst 33342 is not only fluorescent when bound to DNA but also exhibits an 
increased fluorescence when it partitions into the hydrophobic environment 
of the lipid membrane. Since Hoechst 33342 is essentially nonfluorescent in an 
aqueous environment, (net) transport of the compound from the membrane to the 
aqueous phase will result in a decrease in fluorescence. This has been the basis of 
Hoechst 33342-transport assays performed with reconstituted proteoliposomes 
and membrane vesicles derived from cells. Transport of Hoechst 33342 can be 
continuously monitored by the changes in fluorescence. 
The Hoechst 33342-transport assay was first used to show transport activity by 
reconstituted P-gp (103) and with plasma membrane vesicles derived from highly 
multidrug resistant cells that express high levels of P-gp (104-106). The assay 
has been widely used for the analysis of bacterial multidrug transporters, like 
BmrA from Bacillus subtilis (107), HorA from Lactobacillus brevis (108), MdfA from 
Escherichia coli (109), NorA from Staphylococcus aureus (110), and LmrP, LmrA and 
LmrCD from Lactococcus lactis (4;26;32). Likewise, Hoechst 33342 can also be used 
for binding studies (8). 
To study the self-association of the LmrA dimer and the presumed cooperativity 
between the nucleotide binding domains, LmrA-mutants defective in ATPase 
activity have been constructed. As expected, these mutations resulted in an 
inactivation of ATPase activity. Remarkably, the ATPase mutants of LmrA showed 
Hoechst 33342-transport. Here we show that LmrA mediates transmembrane 
passage of Hoechst 33342 in a pH-dependent manner.
Experimental procedures
Bacterial strains, plasmids, and growth conditions. Lactococcus lactis NZ9000 (ΔlmrA), 
an lmrA deletion strain (49), and NZ9000 (ΔlmrA ΔlmrCD) (44) were used as a 
host for pNZ8048-derived plasmids that permit expression of wild-type and 
mutant His-tagged LmrA and Strep-tagged LmrCD proteins under control of the 
nisin system (NICE) (Table 1) (111). Cells were grown in M17 medium (Difco) 
supplemented with 0.5% (w/v) glucose and 5 µg/mL chloramphenicol.
DNA manipulation. General procedures for cloning and DNA manipulation 
were performed essentially as described by Sambrook et al. (112). For 
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site-directed mutagenesis to create the nucleotide binding site-mutants G490A 
and E512Q of LmrA, the following primers were used: 5’-ggagtcaaaatttctggtgcac
aaagacaacg-3’ (G490A-FWD), 5’-cgttgtctttgtgcaccagaaattttgactcc-3’ (G490A-REV), 
5’-ctaatgcttgatcaagcaacagc-3’ (E512Q-FWD), 5’-gctgttgcttgatcaagcattag-3’ (E512Q-
REV), 5’-gattttgcttacgatgattctgaacaaatattgc-3’ [“upstream” primer (EcoRV)] and 
5’-ggttttctaattttggttcaaagaaagcttgagc-3’ [“downstream” primer (XbaI)]. The PCR 
overlap extension method (113) was used to introduce the G490A (codon “gca” 
instead of “gga” on the DNA level) and E512Q (codon “caa” instead of “gaa” on 
the DNA level) in the lmrA gene on the expression plasmid pNHLmrA yielding 
pHLA490A and pHLA512Q, respectively (Table 3.1).
Preparation of inside-out membrane vesicles. Inside-out membrane vesicles were 
prepared from L. lactis NZ9000 ΔlmrA cells harboring pNZ8048-based expression 
or control vectors. Cells were grown at 30 °C to an OD660 of 0.6 - 0.8, whereupon 
0.5 ng/mL of Nisin A was added. Growth was continued for a further 90 min. Cells 
were harvested by centrifugation, washed with 100 mM Hepes-KOH (pH 7.0), and 
resuspended in the same buffer. Inside-out membrane vesicles were prepared by 
French pressure cell treatment as described previously (32). Membrane vesicles 
suspended in 100 mM Hepes-KOH (pH 7.0) containing 10% (v/v) glycerol were 
stored at -80 °C until they were used.
DCCD treatment of membrane vesicles. To inactivate the F0F1-ATPase, 
membranes (10 mg/mL total protein) were incubated for 30 min with 10 mM 
N,N’-dicyclohexylcarbodiimide (DCCD) on ice. Membrane vesicles were collected 
by centrifugation, resuspended in 50 mM Hepes-KOH (pH 7.0) containing 
10% (v/v) glycerol, and stored at -80 °C.
Purification of His6-LmrA. Membranes (10 - 20 mg/mL total protein) bearing 
overexpressed histidine-tagged wild-type or mutant LmrA were solubilized in 
50 mM Hepes-KOH (pH 8.0), containing 0.3 M NaCl, 10% (v/v) glycerol and 
1% (w/v) n-dodecyl-β-D-maltoside (DDM). The suspension was mixed and 
incubated on ice for 30 min. Insoluble material was removed by centrifugation 
at 280,000g (20 min at 4 °C). Solubilized membrane proteins were mixed with 
Table 3.1: L. lactis plasmids
plasmid relevant characteristics ref.
Control vector 
pNZ8048
expression vector carrying the inducible PnisA, Cml
r 111
pNHLmrA pNZ8048 harboring the lmrA gene with upstream 
regions encoding an N-terminal six-histidine tag and an 
enterokinase cleavage site
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pHLA490A pNHLmrA encoding G490A ATPase mutant of LmrA this study
pHLA512Q pNHLmrA encoding E512Q ATPase mutant of LmrA this study
pNSGA pNZ8048 harboring the LmrCD gene with a downstream 




Ni2+-NTA agarose (Qiagen, ~25 µL of resin/mg of protein) which was pre-
equilibrated in buffer A [50 mM Hepes-KOH (pH 8.0), 0.3 M NaCl, 10% (v/v) 
glycerol, and 0.05% (w/v) DDM] containing 20 mM imidazole. The suspension 
was incubated for 1 h at 4 °C, transferred to a Bio-spin column (Bio-Rad), washed 
with 20 column volumes of buffer A containing 20 mM imidazole and eluted with 
buffer A (pH 7.0) containing 250 mM imidazole (all at 4 °C). The purified protein 
was used immediately for reconstitution.
Reconstitution of LmrA into liposomes. E. coli total lipid extract (Avanti Polar Lipids) 
was washed with an acetone/ether mixture (114), dried, and resuspended in 50 mM 
Hepes-KOH (pH 7.2) at a concentration of 20 mg/mL. The suspension was frozen 
in liquid nitrogen, slowly thawed at room temperature, and sonicated on ice using 
a tip sonicator at an intensity of 4 µm (peak to peak) for four cycles of sonication 
for 15 s and resting for 45 s. Aliquots of 2 mL were frozen in liquid nitrogen and 
slowly thawed at room temperature. This freeze-thaw step was repeated once, and 
aliquots of the liposome suspension were frozen in liquid nitrogen and stored at 
-80 °C. To obtain unilamellar liposomes with a relatively homogeneous size, 
the frozen liposome suspension was slowly thawed at room temperature and 
extruded 11 times through a 400 nm polycarbonate filter. After dilution to 4 mg of 
lipid/mL, liposomes were saturated with DDM and solubilization was monitored 
at OD450 as described by Paternostre et al. (115). Purified LmrA was mixed with 
DDM-saturated liposomes (1 µmol of DDM/mg of lipid) at a 1/20 ratio (w/w) and 
incubated for 30 min at room temperature under gentle agitation. The detergent 
was removed by two successive extractions with polystyrene beads (Bio-Beads 
SM-2, Bio-Rad, extensively washed with methanol, ethanol and water), first at 
a wet weight of 80 mg/mL of liposome suspension for 2 h at room temperature 
and then at a wet weight of 160 mg/mL of liposome suspension overnight at 
4 °C, under gentle agitation. The proteoliposomes were harvested by centrifugation 
(280,000g for 30 min at 4 °C), resuspended in 50 mM Hepes-KOH (pH 7.4) at a 
final concentration of 1 mg/mL, frozen in liquid nitrogen, and stored at -80 °C.
ATPase assay. The ATPase activity of reconstituted LmrA was determined using 
the colorimetric assay of Lanzetta et al. (116). Proteoliposomes were incubated 
at 30 °C in a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NH4Cl, 5 mM 
MgSO4, 15 mM MgCl2, and 1 mM ATP. At regular time intervals, samples of 30 µL 
were transferred to a 96-well microplate and 150 µL of malachite green molybdate 
reagent was added. After 5 min, 34% citric acid was added. Absorbance at 600 nm 
was measured after incubation for 50 min at room temperature and compared 
with that of a phosphorus standard.
Hoechst 33342-transport assays. The transport activity of LmrA and LmrCD was 
assayed by means of the drug Hoechst 33342 [2’-(4-ethoxyphenyl)-5-(4-methyl-1-
piperazinyl)-2,5’-bi-1H-benzimidazole, Molecular Probes] (4;32). 
Membrane vesicles: Inside-out membrane vesicles (0.5 mg of protein/mL) were 
suspended in 50 mM Hepes-KOH (pH 7.4) containing 2 mM MgSO4, 8.5 mM NaCl, 
5 mM phosphocreatine, and 0.1 mg/mL creatine kinase. After incubation for 1 min at 
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30 °C, 0.5 µM of Hoechst 33342 was added. Once the fluorescence signal was stable, 
2 mM of Mg2+-ATP was added and the Hoechst 33342 fluorescence was recorded 
over time.
Cells: L. lactis NZ9000 ΔlmrA cells harboring pNZ8048-based expression or control 
vectors were grown at 30 °C to an OD660 of 0.6-0.8, whereupon 0.5 ng/mL of nisin A 
was added. Growth was continued for a further 90 min. The cells were harvested 
and resuspended in 50 mM potassium phosphate (pH 7.0) containing 5 mM MgSO4. 
Dinitrophenol was added to 0.5 mM, and the cells were incubated for 30 min at 
30 °C. The cells were washed four times with 50 mM potassium phosphate 
(pH 7.0) containing 5 mM MgSO4, resuspended in the same buffer to an OD660 of 5, 
and kept on ice. For the actual experiment, the cells were diluted to an OD660 of 0.5 
in the same buffer at 30 °C. Hoechst 33342 was added to a concentration of 0.5 µM.
All measurements were performed with a PerkinElmer Life Sciences model 50B 
fluorometer with a magnetic stirred holder at 30 °C using emission and excitation 
wavelengths of 355 and 457 nm, respectively.
pH dependence of Hoechst 33342 fluorescence. Extruded liposomes (20 µL) in 50 mM 
Hepes-KOH (pH 7.2) at a concentration of 20 mg/mL were diluted in 2 mL of a 
buffer with an appropriate pH (50 mM Bis-Tris for pH 5.2, 6.0 and 6.5, and 50 mM 
Hepes-KOH for pH 7.0, 7.5 and 7.8), and then 1 µM nigericin and 1 µM Hoechst 
33342 were added.  For comparison, Hoechst 33342 fluorescence measurements 
were performed in the absence of liposomes. All data were acquired with a 
PerkinElmer Life Sciences model 50B fluorometer with a magnetic stirred holder at 
20 °C using emission and excitation wavelengths of 355 and 457 nm, respectively.
Hoechst 33342-resistance assay. To biologically monitor the activity of the 
MDR transporters, the growth rates of L. lactis NZ9000 ΔlmrA ΔlmrCD cells 
overexpressing LmrA, LmrCD, or the empty vector control in the presence of 
various concentrations of Hoechst 33342 were recorded. Overnight cultures were 
diluted 20 times into fresh medium and grown for 1 h. Expression was induced 
by addition of 0.1 ng/mL nisin A, and cells were grown for an additional hour. 
The induced cells were diluted to an OD660 of 0.05, and 150 µL aliquots were 
transferred to a 96-well microplate containing 50 µL of various concentrations 
of Hoechst 33342 in growth medium containing 0.1 ng/mL Nisin A. Silicon oil 
(50 µL) was placed on top of the samples to prevent evaporation. Cells were 
grown at 30 °C, and the cell density was monitored by measuring the OD660 every 
6 min for 10 h in a microplate reader (Molecular Devices, Thermomax). 
Results
Construction, expression and ATPase activity of LmrA mutants. To study the self-
association of the LmrA dimer and the presumed cooperativity between the 
nucleotide binding domains (NBD), two conserved amino acids that are critical 
for ATP hydrolysis were replaced by site-directed mutagenesis. This concerned 
substitution of the glycine at position 490 in the ABC signature motif with an 
LmrA-mediated Hoechst 33342-transport
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alanine, and replacement of the glutamic acid at position 512, the putative catalytic 
base in the ATPase reaction, with glutamine. These residues have been shown to 
be critical in other ABC transporters, and their mutagenesis normally results in an 
abolishment of both the ATPase and transport activity (117-119). The individual 
mutants (G490A and E512Q LmrA) were overexpressed with an N-terminal 
His-tag, purified to homogeneity, and reconstituted into proteoliposomes 
composed of E. coli lipids. The ATPase activity of LmrA and the two mutants 
was determined by monitoring the release of inorganic phosphate. The ATPase 
activity of both mutants was less than 3% of that observed for wild-type LmrA 
(Figure 3.1), demonstrating that the mutations in the conserved NBD motifs 
inactivate the LmrA ATPase activity.
Hoechst 33342-transport activity of LmrA ATPase mutants. To determine if the 
inactivation of the ATPase activity of LmrA also interferes with the ATP-dependent 
expulsion of drugs, the transport of Hoechst 33342 was examined. Hoechst 33342 
is a substrate for LmrA (31;32;37) and many other MDR transporters (107;110). 
Transport of this compound in inside-out membrane vesicles can be readily 
monitored by its fluorescence properties. In aqueous solution, Hoechst 33342 is 
essentially nonfluorescent, whereas partitioning into the membrane results in a 
significant increase in the fluorescence (103). Addition of Hoechst 33342 to L. lactis 
membrane vesicles indeed results in a marked increase in fluorescence (Figure 3.2). 
Upon addition of ATP, membrane vesicles harboring elevated levels of wild-type 
LmrA showed a high Hoechst 33342-transport activity as evidenced by a rapid 
fluorescence quenching (Figure 3.2A). In contrast, ΔlmrA membranes show only a 
very small level of fluorescence quenching. Surprisingly, membranes bearing the 
inactive G490A and E512Q ATPase mutants of LmrA showed a remarkably high 
level of ATP-dependent quenching of Hoechst 33342 fluorescence (Figure 3.2A). 
Whereas the transport activity of the G490A LmrA mutant was indistinguishable 




































































Figure 3.1. ATPase activity of 
reconstituted LmrA. The basal 
ATPase activity of LmrA (1), 
G490A (2) and E512Q (3) mutant 
LmrA was determined by monitoring 
the release of inorganic phosphate 
over time. The ATPase activity of 
LmrA was also recorded in the 
presence of 0.1 mM orthovanadate 
(4) or 10 mM DCCD (5). 
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Figure 3.2. Hoechst 33342-transport in inside-out membrane vesicles prepared from 
control-, LmrA-, and LmrCD-expressing cells. Hoechst 33342 was added (H) to inside-
out membrane vesicles, and transport was initiated by the addition of 2 mM Mg2+-ATP 
(ATP). (A) Inside-out membrane vesicles prepared from cells expressing LmrA (4), 
G490A LmrA (5), and E512Q LmrA (3), or control cells (2). Experiments were performed 
in the presence of 1 µM valinomycin. As indicated, at the end of the experiment, 2 µM 
nigericin was added. When nigericin was included in the assay before transport was 
initiated by the addition of ATP, only a low residual Hoechst 33342-transport activity 
was observed (1). For clarity, only the trace for inside-out membrane vesicles prepared 
from cells expressing E512Q mutant LmrA is shown. (B) Inside-out membrane vesicles 
prepared from cells expressing LmrA (2) or from control cells (1). As indicated, 25 mM 
methylammonium chloride was added. (C) Inside-out membrane vesicles prepared 
from LmrCD-expressing (2-5) or control (1) cells. Transport was assayed under standard 
conditions (1 and 5), and in the presence of 1 µM valinomycin (4), 1 µM nigericin (3), 
or 0.1 mM orthovanadate (2). (D) Inside-out membrane vesicles prepared from cells 
expressing wild-type LmrCD (3), double ATPase mutants of LmrC and LmrD, D495N 
and E587Q, respectively (2) and control cells (1).
Effect of ATPase inhibitors on the Hoechst 33342-transport activity of LmrA. 
Orthovanadate (VO4
3-) is an inhibitor of several ATPase enzymes, including 
P-gp (120) and other ABC transporters (121;122). The ATPase activity of LmrA 
is also inhibited by orthovanadate (Figure 3.1). At 0.1 mM orthovanadate, less 
than 3% of the ATPase activity remained. Next, the effect of orthovanadate on 
LmrA-mediated Hoechst 33342-transport
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LmrA-mediated Hoechst 33342-transport was assayed in membrane vesicles. 
At a concentration of orthovanadate that nearly completely abolished the 
ATPase activity of LmrA, essentially no effect was observed on the transport of 
Hoechst 33342 when ATP was added to the membrane vesicles (data not shown).
Effect of ionophores on the Hoechst 33342-transport activity of LmrA. In the inside-
out membrane system, ATP drives not only the LmrA-dependent transport of 
drugs but also proton influx by the H+-translocating F0F1-ATPase, resulting in the 
generating a proton motive force (pmf), inside acidic and positive. Since LmrA 
is an ATP-dependent transporter, its activity is not expected to be influenced by 
dissipation of the pmf by ionophores. Nigericin is an ionophore that mediates 
the electroneutral exchange of K+ for H+, thereby collapsing the transmembrane 
pH gradient in these membrane vesicles. Addition of this ionophore completely 
reversed the LmrA-dependent Hoechst 33342-transport activity (Figure 3.2A). 
When nigericin was included in the assay before transport was initiated by 
the addition of ATP, only a low residual Hoechst 33342-transport activity was 
observed (Figure 3.2A). Addition of the ionophore valinomycin, which mediates 
electrogenic K+ movements, thereby collapsing the transmembrane electrical 
potential, had no effect. Transport of Hoechst 33342 by the two LmrA ATPase 
mutants was also completely inhibited by nigericin. An alternative explanation for 
the nigericin sensitivity of the Hoechst 33342-transport activity of LmrA is that this 
ionophore is a substrate of the transporter. It may compete with Hoechst 33342 for 
binding and transport and thereby block the transport. This hypothesis, however, 
then assumes that LmrA discriminates between nigericin and valinomycin, 
another peptide ionophore that has no effect on Hoechst 33342-transport. For that 
reason we also used an alternative means to dissipate the ΔpH, employing the 
weak base methylammonium. Addition of 25 mM methylammonium completely 
reversed the LmrA-dependent Hoechst 33342-transport activity (Figure 3.2B). 
Taken together, these data suggest that LmrA-dependent Hoechst 33342-transport 








































Figure 3.3. Effect of DCCD 
on LmrA-mediated Hoechst 
33342-transport in membrane 
vesicles. Hoechst 33342 was 
added (H) to inside-out membrane 
vesicles prepared from control 
cells (2 and 3) or LmrA-expressing 
cells (1 and 4) that were treated 
with DCCD (1 and 2) or mock-
treated (3 and 4). The system 
was energized by the addition of 
2 mM Mg2+-ATP (ATP).
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Hoechst 33342-transport activity of LmrCD. We have recently described another 
MDR transporter of L. lactis termed LmrC and LmrD (4). These are ABC half-
transporters that constitute a functional heterodimeric ABC-type MDR transporter. 
In membrane vesicles, LmrCD shows a high ATP-dependent transport activity 
of Hoechst 33342 (4) (Figure 3.2C). In contrast to the LmrA-dependent activity, 
transport of Hoechst 33342 by LmrCD was only marginally affected by the 
ionophore nigericin and strongly inhibited by orthovanadate (Figure 3.2C). 
Likewise, we generated ATPase mutants of LmrC and LmrD, D495N and E587Q, 
respectively (44). When the double mutant LmrCD proteins were expressed, no 
Hoechst 33342-transport activity was observed (Figure 3.2D). This shows that 
LmrCD functions as a typical ATP-dependent MDR transporter, whereas the 
Hoechst 33342-transport activity observed with LmrA is apparently dependent 
on the pH gradient.
Effect of F0F1-ATPase inhibition on the LmrA-dependent Hoechst 33342-transport in 
membrane vesicles. Since proton motive force generation in membrane vesicles 
in the presence of ATP requires the activity of the F0F1-ATPase, we next tested 
the effect of N,N’-dicyclohexylcarbodiimide (DCCD), an effective inhibitor of the 
H+ translocation activity of the F0 domain (123). The ATPase activity of purified 
LmrA was not affected by 10 mM DCCD (Figure 3.1). However, treatment of the 
membrane vesicles with 10 mM DCCD completely abolished the ATP-dependent 
Hoechst 33342-transport activity of LmrA (Figure 3.3). Taken together, these data 
strongly suggest that LmrA-mediated transport of Hoechst 33342 is not dependent 
on the LmrA ATPase activity, but that it is mediated through the transmembrane 
pH gradient which in the membrane vesicles is generated by the F0F1-ATPase.
pH-dependent fluorescence of Hoechst 33342 in lipid vesicles. Acidification of the 
lumen of the membrane vesicles by the activity of F0F1-ATPase may influence the 
Hoechst 33342 fluorescence in the transport assay. To determine the influence of 
the pH on the fluorescence of Hoechst 33342, we have analyzed Hoechst 33342 
fluorescence in buffers of different pH values, both in the absence and in the 
presence of liposomes. Hoechst 33342 has a complex, pH-dependent spectrum, 
and when the dye is dissolved in a buffer, the fluorescence quantum yield is much 
higher at pH 5.0 than at pH 8.0 (Figure 3.4, triangles) (124). When liposomes are 
added to the Hoechst 33342 solution, the fluorescence increases by at least 2 orders 
of magnitude. However, now an inverted pH-dependence of the fluorescence 
is observed (Figure 3.4, circles). The pH-dependence of the dye fluorescence in 
aqueous solution suggests that the compound undergoes protonation and/or 
deprotonation of the nitrogen atoms in the piperazinyl and benzimidazole rings. 
Although our experiments do not directly measure partitioning, the increase of 
Hoechst 33342 fluorescence with an increase in pH in the presence of membranes 
is most likely caused by a more efficient partitioning of deprotonated and less 
charged Hoechst 33342 into the lipid membrane.
Transport of Hoechst 33342 in intact cells. The Hoechst 33342-transport assay in 
membrane vesicles essentially monitors repartitioning of Hoechst 33342 from 
LmrA-mediated Hoechst 33342-transport
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the membrane to the aqueous phase. This assay does not reveal the direction of 
transport per se; i.e., the Hoechst 33342 may either be transported into the lumen 
of the vesicles or be expelled into the suspending medium. In cells, Hoechst 33342 
becomes highly fluorescent when it intercalates with the DNA. This feature can 
be used to monitor Hoechst 33342-transport in intact cells as excretion should 
result in a shift of the equilibrium from the DNA to the free, soluble state of 
Hoechst 33342. In energy-depleted cells of L. lactis bearing overexpressed levels 
of LmrA, a rapid influx of Hoechst 33342 was observed (Figure 3.5) that was 
barely distinguishable from the influx of Hoechst 33342 into control cells. When 
cells were energized with glucose, we reproducibly observed that the Hoechst 
33342-influx into cells overexpressing LmrA occurred with a faster rate than in 































































.) Figure 3.4. pH-dependence of 
the Hoechst 33342 fluorescence. 
The fluorescence of free 
Hoechst 33342 (1 µM) in buffer 
(triangles, scale on the right 
axis) and in the presence of 
0.2 mg/mL liposomes and 
1 µM nigericin (circles, scale 
on the left axis). a.u. means 
arbitrary units. The data 
points represent the average 
of 30 s readings recorded after 
stabilization of the fluorescence 
signal of Hoechst 33342.







































Figure 3.5. Influx of Hoechst 33342 into 
cells overexpressing LmrA. Influx of 
Hoechst 33342 into washed, energy-
deprived cells expressing LmrA (1) or 
control cells (2) or cells re-energized 
with 25 mM glucose for 3 min (3 and 
4 respectively) was assayed in time. 
Hoechst 33342 (H) was added to a final 
concentration of 0.5 µM.
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33342 from the cells. Rather, its presence causes a slight but reproducible increase 
in the rate of influx of Hoechst 33342 into the cell. Since we have previously shown 
that under these conditions LmrCD mediates the export of Hoechst 33342 from 
cells (4), it appears that LmrA exhibits an aberrant behavior of allowing faster 
influx of Hoechst 33342 into the cells rather than expelling this compound.
Hoechst 33342-resistance of cells overexpressing LmrA or LmrCD. Hoechst 
33342-transport in intact cells was further studied in a cytotoxicity assay. For 
this assay, we have used a strain that lacks both LmrA and LmrCD, i.e., L. lactis 
NZ9000 ΔlmrA ΔlmrCD. This strain is like the individual ΔlmrCD strain that 
is hypersensitive to Hoechst 33342 and other drugs (14). Unlike the parental 
strain, L. lactis NZ9000 ΔlmrA ΔlmrCD is readily killed by low concentrations of 
Hoechst 33342. LmrA or LmrCD was expressed, and the Hoechst 33342-resistance 
of the cells was compared with that of control cells that were transformed with 
the empty vector. Expression of LmrA and LmrCD was confirmed by western 
blotting (data not shown). Figure 3.6 shows the growth rate as a function of the 
Hoechst 33342 concentration. The growth rates of cells expressing LmrCD are 
similar to those of the parental L. lactis NZ9000 cells harboring the empty vector, 
showing that expression of LmrCD in the (triple) deletion mutant completely 
rescues the hypersensitive phenotype of the cells towards Hoechst 33342. No 
protection was observed when LmrA was expressed. Rather, we reproducibly 
found cells to be more sensitive to the drug in the presence of LmrA. Moreover, the 
individual L. lactis NZ9000 ΔlmrA strain (49) exhibited a Hoechst 33342-resistance 
similar to that of the parental strain (data not shown). Taken together, these data 
demonstrate that unlike LmrCD, LmrA does not protect cells against the cytotoxic 
effects of Hoechst 33342.
Figure 3.6. LmrA does not provide cellular resistance to Hoechst 33342. L. lactis NZ9000 
ΔlmrA ΔlmrCD cells expressing LmrA (1) or LmrCD (3) or control cells harboring the 
empty vector (2) or the parental strain L. lactis NZ9000 harboring the empty vector (4) 
were grown in the presence of different concentrations of Hoechst 33342. The growth 
rate (µ) in the exponential growth phase was determined and plotted as a function of the 
Hoechst 33342 concentration. The data points indicate the average of three experiments. 

























Hoechst 33342 is an organic cation that is used to stain chromosomal DNA in live 
cells. It has also been used extensively to characterize the multidrug transporters 
in mammalian cells (103-106) and bacteria (4;26;32;107-110). Hoechst 33342 
is strongly fluorescent in the hydrophobic environment of the membrane, or 
when intercalated with DNA. However, it is virtually nonfluorescent in aqueous 
solution. Because of this property, Hoechst 33342 is a very useful compound in 
studying the transport activity of MDR transporters which extrude substrates 
from the cellular membrane into the external medium. We have compared the 
Hoechst 33342-transport activity of two bacterial ABC-type MDR transporters, 
i.e., LmrA of L. lactis which is both structurally and functionally a homolog 
of P-gp (5;31) and LmrCD of L. lactis, a recently identified heterodimeric 
ABC transporter that is highly active in drug excretion (4). Both systems are ABC 
transporters, and their activity is therefore expected to be dependent on hydrolysis 
of ATP. Both have been shown to transport Hoechst 33342 in a membrane 
vesicle system in an ATP-dependent manner. However, here we report that the 
Hoechst 33342-transport associated with LmrA in membrane vesicles does not 
require the ATPase activity of LmrA itself. Rather, it involves ATP hydrolysis 
by the F0F1-ATPase which generates a transmembrane pH gradient which in 
turn affects the membrane partitioning and/or the fluorescence properties 
of Hoechst 33342 that enters the membrane vesicles via LmrA. Hoechst 33342 
transport is, however, LmrA-dependent as it is not observed with control 
membrane vesicles. Moreover, an extensive study to obtain structural information 
about LmrA using a cysteine-scanning approach (37) shows that transmembrane 
segment 6 (TMS 6) of LmrA is particularly sensitive to mutations that interfere 
with Hoechst 33342 transport. Verapamil, a calcium-channel blocker, is also 
known as an inhibitor of transport of Hoechst 33342-transport by LmrA (31;32). 
In four of the mutants, the extent of inhibition of Hoechst 33342-transport by 
verapamil is also reduced, indicating that these residues are involved in both 
Hoechst 33342-transport and binding of verapamil. Finally, a study using a set 
of substrate photoaffinity ligands to identify the substrate-binding domain of 
LmrA confirms that TMS 6 is involved in substrate binding (38). Taken together 
these data indicate that Hoechst 33342 moves via the substrate binding domain 
of LmrA.
Several lines of evidence indicate that ATP hydrolysis by LmrA is not needed for 
LmrA-mediated Hoechst 33342-transport in membrane vesicles. First, mutagenesis 
of the conserved and functionally critical residues of the nucleotide binding 
domain of LmrA that abolishes its ATPase activity has no or little effect on Hoechst 
33342-transport in membrane vesicles. Second, orthovanadate, a potent inhibitor of 
the LmrA ATPase activity, has no effect on Hoechst 33342-transport in membranes. 
In a previous study (32) orthovanadate-sensitive Hoechst 33342-transport by 
LmrA was seen in proteoliposomes. However, the observed transport activity in 
proteoliposomes was extremely low compared to that in membrane vesicles. We 
have not been able to detect any significant difference in LmrA proteoliposomes 
with the Hoechst 33342-transport assay when comparing addition of ATP with that 
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of the nonhydrolyzable ATP analogue AMP-PNP (unpublished results). Third, 
LmrA-mediated Hoechst 33342-transport in membrane vesicles is completely 
inhibited by nigericin, an ionophore that acts as a H+/K+ antiporter, and by the weak 
base methylammonium. Both of these compounds collapse the transmembrane 
pH gradient in membrane vesicles. In contrast, Hoechst 33342-transport was not 
inhibited by another peptide ionophore valinomycin, suggesting that it is mostly, 
if not exclusively, dependent on the transmembrane pH gradient. The alternative 
explanation that nigericin is a substrate of LmrA and thus competes with Hoechst 
33342 for binding and transport by LmrA can not be ruled out, but this possibility 
seems unlikely as the same inhibitory effect is observed with methylammonium. 
Fourth, LmrA-mediated Hoechst 33342-transport is blocked by DCCD, whereas 
its ATPase activity is unaffected. DCCD is an efficient inhibitor of the F0F1-ATPase. 
The latter enzyme is solely responsible for the generation of a proton motive 
force in membrane vesicles of L. lactis. For comparison, similar experiments were 
conducted with membrane vesicles bearing elevated levels of the ABC-type MDR 
transporter LmrCD. Like LmrA, LmrCD mediates Hoechst 33342-transport in 
membrane vesicles. However, this transport reaction is strictly dependent on 
ATP hydrolysis by LmrCD as it is inhibited by nucleotide binding site mutations 
that block the ATPase activity. Transport is strongly inhibited by orthovanadate, 
but barely affected by nigericin. Taken together, these data strongly suggest that 
ΔpH-dependent Hoechst 33342-transport is a reaction that is specific for LmrA as 
Hoechst 33342-transport via the analogous LmrCD system is not influenced by 
the proton motive force.
It is generally believed that the Hoechst 33342-transport assay in membrane 
vesicles records the MDR transporter-dependent repartitioning of Hoechst 33342 
from the membrane phase into the aqueous solution. It is important to stress that 
these experiments do not reveal whether Hoechst 33342 is released inside of the 
lumen of the inside-out vesicles or into the external solution, although transport 
into the vesicles would be the expected physiological direction of transport. To 
determine the physiological direction of transport, experiments were carried out 
with intact cells. In this case, the Hoechst 33342 fluorescence mostly originates 
from the intercalation of Hoechst 33342 with DNA inside the cell. MDR transport 
activity in intact cells that is associated with drug extrusion will prevent entry of 
Hoechst 33342 into the cell. Indeed, this is the case with glucose-energized cells 
bearing elevated levels of LmrCD (4). In contrast, glucose-energized cells bearing 
elevated levels of LmrA were unable to prevent the entry of Hoechst 33342. This 
experiment demonstrates that LmrA does not mediate Hoechst 33342-extrusion; 
rather, LmrA highly reproducibly permits a slightly higher rate of influx of 
Hoechst 33342 into the cells as compared to the control. Also in the cytotoxicity 
tests, LmrA provided no protection against Hoechst 33342 and even makes cells 
more susceptible to Hoechst 33342. In contrast, expression of LmrCD rendered 
cells less sensitive to Hoechst 33342. Taken together, these data indicate that LmrA 
does not seem to function as a true multiple-drug transporter for Hoechst 33342. 
This appears to be different with other substrates. For instance, N-ethylmaleimide 
(NEM) labeling of a cysteine mutant of the glycine at position 386 in the Walker A 
region of the NBD of LmrA completely inhibited the LmrA-dependent fluorescent 
LmrA-mediated Hoechst 33342-transport
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phospholipid transbilayer movement in proteoliposomes (36). It is interesting to 
note that Hoechst 33342-transport in inside-out membrane vesicles bearing the 
same mutant of LmrA is not sensitive to NEM (G.J. Poelarends, unpublished 
data). It is, however, unclear how different substrates, i.e., Hoechst 33342 and 
fluorescent phospholipids, can be transported by different mechanisms by LmrA. 
As discussed above, our data strongly suggest that LmrA mediates cellular entry 
of Hoechst 33342. One major caveat of this kind of analysis is that the levels of 
LmrA upon overexpression can be as high as 30% of the total membrane protein 
(32). When the expression levels of LmrA are reduced, the Hoechst 33342-transport 
activity in vesicles can no longer be detected. At this stage, we cannot exclude 
the possibility that the Hoechst 33342-transport activity of LmrA is due to the 
large amounts of this membrane protein, but it should be stressed that all drug 
extrusion tests reported to date were performed under overexpressing conditions 
and that LmrA mutants have been described that exhibit a reduced Hoechst 
33342-transport activity (37). One may argue that LmrA forms a kind of channel 
in the membrane that allows facilitated influx of Hoechst 33342. Our experiments 
with the pH dependence of the Hoechst 33342 fluorescence in the presence of 
liposomes indicate that the transport activity in membrane vesicles is due to a 
pH-dependent partitioning of the Hoechst 33342 between the membrane and water 
phase or, alternatively, a pH dependence of the fluorescence of the membrane-
inserted Hoechst 33342. We consider the pH-dependent partitioning model, 
however, more likely. In solution, Hoechst 33342 exhibits a low fluorescence that 
was even further reduced with an increase in pH. In the presence of liposomes, 
a marked increase in fluorescence is observed but the pH dependence of the 
fluorescence now shows a reversed pH profile, i.e., the fluorescence increases 
with pH. This phenomenon is likely due to a more efficient partitioning of the 
deprotonated and less charged Hoechst 33342 into lipids. In membrane vesicles, 
the generation of a transmembrane pH gradient by the F0F1-ATPase results in an 
acidic pH inside. This low pH will favor a repartioning of Hoechst 33342 from 
the membrane phase into the acidic aqueous phase of the lumen of the vesicles, 
thus causing a lowering of the dye fluorescence. Since this activity is dependent 
on LmrA, it seems that LmrA accelerates the movement of Hoechst 33342 from 
the membrane phase to the aqueous phase. Importantly, with intact cells, LmrA 
is unable to excrete Hoechst 33342 from the cells, and its presence even increases 
the cytotoxicity of Hoechst 33342 in L. lactis cells. This strongly suggests that 
LmrA facilitates the transmembrane movement of Hoechst 33342. It is unclear if 
this activity relates to the peculiar H+/drug symport reaction that was suggested 
recently for the separately expressed transmembrane domain of LmrA (LmrA-
MD) (33), as our study involved only the full-length LmrA. In contrast to the 
growth studies reported by Venter et al. (33), who used a wild-type L. lactis 
strain, our study employs a triple knockout strain which lacks LmrA, LmrC and 
LmrD. Therefore, the results of the growth inhibition studies cannot be directly 
compared as the triple deletion strain is much more susceptible to Hoechst 33342. 
It is difficult to envisage how the proton-linked activity of LmrA would contribute 
to its proposed physiological function as a drug efflux system.
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This study raises questions about the physiological significance of LmrA as a 
multiple-drug transporter. Moreover, a knockout of the lmrA gene in L. lactis has 
no effect on the Hoechst 33342 (this chapter) and ethidium (4) sensitivity of the 
cells, while inactivation of the lmrCD genes makes cells highly susceptible to these 
compounds. Therefore, it will be important to study the exact role of LmrA in the 





Effect of the calcium channel blocker verapamil on 
drug-extrusion and resistance mediated by the 
multidrug resistance protein LmrP of Lactococcus lactis
H. Bart van den Berg van Saparoea, Lydia de Bos, and Arnold J.M. Driessen
Summary
The calcium channel blocker verapamil is known to inhibit the transport of the 
fluorescent model substrates Hoechst 33342 and ethidium by the lactococcal 
multidrug resistance protein LmrP. Here we show that verapamil reverses the 
LmrP-mediated resistance of Lactococcus lactis ΔlmrCD cells to the antibiotic 
erythromycin and the drug ethidium bromide. Interestingly, expression of lmrP 
in this strain results in a growth inhibition that can be reversed by verapamil. This 
phenomenon is more pronounced with cells expressing the energy-uncoupled 
mutant D68C-C270A LmrP, which is unable to couple proton translocation to 
substrate excretion. These data suggest that inhibitory compounds present in the 
growth medium enter the cell via LmrP. LmrP mediates the verpamil-sensitive 
transport of Hoechst 33342 in inverted membrane vesicles of L. lactis, but it 
provides no protection against Hoechst 33342 in growing cells. These data further 
demonstrate that Hoechst 33342-transport is an unreliable diagnostic tool to study 
multidrug resistance transporters in vivo. 
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Introduction
LmrP is a multidrug resistance (MDR) transporter of the lactic acid bacterium 
Lactococcus lactis that belongs to the Major Facilitator Superfamily. The  lmrP gene 
was identified in a screen for elevated resistance to ethidium bromide using a 
chromosomal DNA library of L. lactis that was expressed in an Escherichia coli 
strain. Further analysis showed that LmrP confers resistance to ethidium bromide, 
daunomycin, and TPP+ (7). In E. coli strain DH5α, LmrP was shown to increase the 
resistance to a range of antibiotics such as lincosamide, streptogramin, tetracycline 
and 14- and 15-membered macrolides (27). Mechanistic studies on LmrP mostly 
rely on the fluorescent model substrates ethidium and Hoechst 33342. Indeed, in 
the natural host L. lactis, LmrP has been shown to provide resistance to ethidium 
bromide (25), but for Hoechst 33342 no such studies have been reported.
MDR transporters are of particular (medical) interest due to their role in 
diminishing the effectiveness of chemotherapeutic agents. One way to counteract 
this phenomenon is to re-sensitize the cells targeted by these chemotherapeutic 
agents by inhibiting the MDR proteins. For instance the calcium channel inhibitor 
verapamil that also inhibits MDR transporters has been shown to improve 
the efficacy of cancer treatment (125). Verapamil inhibits the LmrP-mediated 
transport of the fluorescent model substrate Hoechst 33342 by membrane vesicles 
of L. lactis (23) and it blocks the LmrP-mediated ethidium efflux from L. lactis cells 
(14). Its effect on LmrP-mediated resistance against toxic compounds has not been 
reported. Here, we have determined the effect of verapamil on the LmrP-mediated 
resistance against erythromycin, ethidium and Hoechst 33342 using an L. lactis 
strain that lacks the major multidrug transporter LmrCD which is responsible 
for ethidium bromide and Hoechst 33342 efflux from cells. In these ΔlmrCD cells, 
LrmP conferred resistance to erythromycin and ethidium bromide, but not against 
Hoechst 33342 even though this compound can be used to study the activity of 
LmrP in inverted membrane vesicles.  Paradoxically, the expression of LmrP 
reduced the growth rate of the cells in the absence of the antibiotic or drug. This 
growth rate inhibition was reversed by verapamil and enhanced by the expression 
of the energy-uncoupled mutant D68C-C270A LmrP. Remarkably, verapamil also 
increased the sensitivity of the cells for Hoechst 33342 and caused an increased 
uptake of Hoechst 33342. However, this phenomenon was independent of LmrP. 
These data suggest that Hoechst 33342 is not a genuine substrate for LmrP in vivo 
and indicate that another verapamil-sensitive transporter is responsible for the 
endogenous Hoechst 33342-resistance of the L. lactis ΔlmrCD strain.
Experimental procedures
Bacterial strains, growth conditions, and plasmids. L. lactis strain NZ9000 ΔlmrCD (14) 
was grown in liquid medium at 30 °C. GM17 medium was prepared by addition 
of 0.5% (wt/vol) of glucose to M17 broth (Difco). Chemically defined medium 
(CDM) was prepared as described by Li et al. (126) to which 1% (wt/vol) glucose 
was added as carbon source. Chloramphenicol (5 µg/mL) was used for plasmid 
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Table 4.1: Expression plasmids used in Lactococcus lactis  NZ9000 ΔlmrCD
plasmid relevant characteristics ref.
Control vector pNZ8048 expression vector carrying the inducible PnisA, Cml
r 26
pHLP5 pNZ8048 harboring the lmrP gene with downstream 
regions encoding a C-terminal six-histidine tag and 
a factor Xa cleavage site
26
pHLP5 C270A pHLP5 encoding C270A mutant of LmrP 24
pHLP5 D68C-C270A pHLP5 encoding D68C-C270A mutant of LmrP 24
selection. Nisin A (Sigma) was used at a concentration of 5 ng/mL for induction
of expression unless stated otherwise. Plasmids used in this study are listed in 
Table 4.1.
Determination of specific growth rate. Specific growth rates were determined by growth 
in 96-well microtitre plates under semi-anaerobic conditions. Cells inoculated into 
fresh medium from overnight cultures were grown to mid-exponential phase. In 
a sterile low-protein-binding 96-well microplates (Greiner), 100 µL aliquots of 
10  times diluted cell culture were added to 100 µL of medium containing the 
additional compounds (erythromycin, ethidium bromide, Hoechst 33342 
and/or verapamil [Sigma]) and Nisin A at a concentration to yield the proper final 
concentration. Silicone oil (50 µL) was pipetted on top of the sample to prevent 
evaporation. The cells were grown at 30 °C while the cell density was monitored 
by measuring optical density at 660 nm (OD660) every 3 minutes for 14 hours in a 
multiscan photometer (Titretek Multiscan MCC/340 MKII). The natural log of the 
relative OD660 [ln(OD660, t=n/OD660, t=0), where t is time, OD660, t=n is the OD660 at time 
point n, and OD660, t=0 is the OD660 at time zero] was plotted against time, and the 
slope of the curve (the specific growth rate, µ) during the exponential growth 
phase was determined (127).
Ethidium and Hoechst 33342-influx into intact cells. Cells were grown to mid-
exponential phase and grown for another hour in the presence of nisin A. Cells 
were harvested, washed with ice-cold buffer (50 mM potassium phosphate, 
pH 7.0, containing 5 mM MgSO4) and resuspended in 1/20 volume of the same 
buffer. The cell suspension was diluted with buffer at 30 °C to a final volume of 
2 mL with an OD660 of 0.5 (for ethidium influx) or an OD660 of 0.1 (for Hoechst 
33342-influx). Glucose was added to a final concentration of 25 mM and where 
appropriate verapamil was added. After 3 minutes ethidium bromide or Hoechst 
33342 was added to a final concentration of 10 µM or 2 µM respectively. The 
fluorescence was monitored in a PerkinElmer Life Sciences model 50B fluorometer 
with a magnetic stirred holder at 30 °C using emission and excitation wavelengths 
of 500 and 580 nm respectively for ethidium fluorescence and 355 and 457 nm 
respectively for Hoechst 33342 fluorescence.
Hoechst 33342-transport in inverted membrane vesicles. Inverted membrane vesicles 
were prepared essentially as described previously (46). Cells were grown to an OD660 
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of 0.6-0.8, whereupon nisin A was added. Growth was continued for a further 90 min, 
cells were harvested, washed with 100 mM Hepes-KOH (pH 7.0), and resuspended 
in the same buffer. Cells were disrupted by French pressure cell treatment. Inverted 
membrane vesicles suspended in 100 mM Hepes-KOH (pH 7.0) containing 10% 
(v/v) glycerol were stored at -80 °C until they were used. Inverted membrane 
vesicles were diluted approximately 100 times to final concentration of 0.5 mg 
of protein/mL in 50 mM Hepes-KOH (pH 7.4) containing 2 mM MgSO4, 8.5 mM 
NaCl, 5 mM phosphocreatine, 0.1 mg/mL creatine kinase, and where appropriate 
100 µM verapamil. After incubation for 1 min at 30 °C, Hoechst 33342 was added 
to 0.5 µM. Once the signal was stable, Mg2+-ATP was added to 2 mM and the 
Hoechst 33342 fluorescence was recorded over time as described for Hoechst 
33342-influx into intact cells as described above.
Results
Verapamil inhibits LmrP-mediated erythromycin-resistance. Expression of lmrP 
increases the resistance of E. coli DH5α cells to the macrolide antibiotic 
erythromycin (27). Whether LmrP can confer erythromycin-resistance to its 
natural host L. lactis has not been reported. To determine the effect of LmrP on the 
sensitivity of L. lactis NZ9000 ΔlmrCD to erythromycin, the specific growth rate 
was determined in GM17 medium containing the antibiotic. This strain lacks the 
major drug transporter LmrCD, but contains a genomic copy of lmrP. Expression 
of lmrP was forced using the nisin controlled gene expression system and the 
pHLP5 plasmid. As shown in Figure 4.1, expression of lmrP confers resistance to 





























Figure 4.1. Verapamil reverses LmrP-mediated resistance to erythromycin. The 
specific growth rate µ of L. lactis NZ9000 ΔlmrCD cells expressing plasmid encoded 
lrmP (squares) and of control cells harbouring the pNZ8048 control plasmid (circles) 
is plotted against the concentration of erythromycin in the growth medium GM17 
without (solid lines) or with 50 µM verapamil (dashed lines). N=3, standard deviation 
is indicated with error bars.
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that decreases the specific growth rate by 50% (IC50) was five-fold higher for 
the strain overexpressing lmrP (~0.34 µg/mL) than that for the control strain 
(~0.06 µg/mL). 
The calcium channel blocker verapamil has been shown to inhibit LmrP-mediated 
Hoechst 33342-transport in membrane vesicles with a half-maximal inhibition (IC50) 
at 2.3 µM (23). Likewise, it inhibits LmrP-mediated efflux of ethidium from cells 
(25). The presence of 50 µM verapamil in the growth medium (GM17) reduced the 
erythromycin-resistance of the LmrP-overexpressing strain to levels similar to that 
of the control strain (Figure 4.1). Interestingly, at erythromycin concentrations up to 
30 ng/mL, in the absence of verapamil, the specific growth rate of cells overexpressing 
LmrP was significantly lower than that of the control cells, while in the presence of 
50 µM verapamil the specific growth rates of the two strains were similar. This 
indicates an LmrP-mediated, verapamil sensitive growth inhibition which is 
independent of the presence of added drugs. Since verapamil inhibits substrate 
transport by LmrP, the growth inhibiting effect is most likely related to the 
transport activity of LmrP.
LmrP-mediated, verapamil-sensitive growth inhibition. Since the observed growth 
inhibition upon overexpression of lmrP is most likely related to its transport 
activity, we also analysed the specific growth rate of L. lactis cells expressing the 
energy-uncoupled D68C-C270A LmrP mutant (25) (Figure 4.2A). In the absence 
of the inducing agent nisin A, cells harbouring the different expression plasmids 
exhibited similar specific growth rates. A nisin A induction-dependent growth rate 
inhibition was observed for the cells harbouring the wild-type and D68C-C270A 
LmrP expression vectors. Cells expressing the wild-type LmrP or the cysteine-
less mutant C270A LmrP (parental to the D68C-C270A mutant) still exhibited a 
substantial growth at a nisin concentration of 5 ng/mL (approximately 50 and 
30% of that in the absence of nisin A, respectively). Expression of the energy-
uncoupled LmrP mutant, however, almost completely inhibited growth of the 
cells (reduced by approximately 97%) under those conditions.
The effect of verapamil on the growth inhibitory effect of LmrP expression was 
studied further with L. lactis ΔlmrCD cells grown in GM17 medium in the presence 
of different concentrations of verapamil (Figure 4.2C). The specific growth rate 
of the control cells was not affected by verapamil at the concentrations tested 
(up to 150 µM), whereas verapamil increased the specific growth rate of cells 
expressing wild-type LmrP or C270A LmrP to the levels of the control strain. This 
demonstrates that verapamil causes a complete reversal of the growth inhibiting 
effect mediated by LmrP. In contrast, the strong inhibiting effect mediated by 
expression of D68C-C270A LmrP could only be partially reversed, exhibiting a 
specific growth rate of 0.3 h-1 in the presence of 150 µM verapamil (60% of that of 
the control strain).
The phenomenon of growth inhibition was also studied with cells grown in 
chemically defined medium (CDM). Expression of LmrP resulted in a growth 
rate reduction, but only at the highest nisin A concentration tested (5 ng/mL) 
(Figure 4.2B), while no effect was seen with the control cells. The reduction in 
specific growth rate in CDM mediated by expression of LmrP was completely 
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reversed by verapamil at concentrations of 25 µM and higher (Figure 4.2D). 
Expression of the uncoupled mutant D68C-C270A LmrP did not affect the growth 
rate in CDM, which allowed us to study the effect of this mutant on the drug 
resistance of cells.
Resistance and transport of ethidium bromide. The nucleic acid stain ethidium has been 
extensively used to characterize the transport activity of the lactococcal multidrug 
resistance protein LmrP. The effect of wild-type LmrP, C270A LmrP and D68C-































































Figure 4.2. Expression of LmrP inhibits growth of L. lactis NZ9000 ΔlmrCD. The 
specific growth rate µ of the L. lactis cells harbouring the lmrP (squares), C270A lmrP 
(diamonds) or D68C-C270A lmrP (triangles) expression plasmid or the control plasmid 
(circles) is plotted against the concentration of the expression inducer nisin A with cells 
grown in GM17 (A) or in chemically defined medium (C). The effect of verapamil on 
the specific growth rate of the same strains in GM17 medium (B) or chemically defined 
medium (D). The specific growth rate µ of L. lactis cells harbouring the different plasmids 
is plotted against the concentration of verapamil in growth medium containing 5 ng/mL 
nisin A. N=3; standard deviation is indicated with error bars.
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Figure 4.3. Verapamil reverses the LmrP-mediated resistance to ethidium bromide. 
The specific growth rate (µ) of L. lactis NZ9000 ΔlmrCD cells harbouring the pNZ8048 
control plasmid (A, circles), or plasmids encoding lmrP (A, squares), C270A lmrP 
(B, diamonds) or D68C-C270A lmrP (B, triangles) is plotted against the ethidium bromide 
concentration. Cells were grown in chemically defined medium without (solid lines) 
or with 100 µM verapamil (dashed lines). N=3, standard deviation is indicated by the 
error bars. Ethidium influx into L. lactis cells harbouring the pNZ8048 control plasmid 
(C, control), or plasmids encoding lmrP (C, LmrP), C270A lmrP (D, C270A LmrP) or 
D68C-C270A lmrP (D, D68C-C270A LmrP). Ethidium bromide was added (arrow) to 
cells suspended in glucose containing buffer without (solid lines) or with (+V, dashed 
lines) 100 µM verapamil or to buffer without cells (no cells, dotted lines). The ethidium 
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We determined the effect of ethidium bromide on the growth rate of L. lactis 
ΔlmrCD cells overexpressing LmrP and grown in CDM with 5 ng/mL of the inducer 
nisin A. Ethidium bromide at 2.5 µM reduced the specific growth rate of the control 
strain by approximately 50%, while complete growth inhibition required 15 µM of 
ethidium bromide (Figure 4.3A). Cells expressing wild-type LmrP exhibited the 
characteristic reduced growth rate in the absence of ethidium, while growth was 
half-maximal in the presence of 20 µM of ethidium bromide. This demonstrates 
that LmrP mediates resistance to this toxic nucleic acid stain. In the presence of 
100 µM of verapamil, the control strain was found to be more susceptible to 
ethidium bromide suggesting that the endogenous ethidium bromide-resistance 
mechanisms are sensitive to verapamil. Likewise, the presence of 100 µM of 
verapamil rendered LmrP-overexpressing cells more sensitive to ethidium 
bromide (Figure 4.3A). Cells expressing the energy-uncoupled D68C-C270A LmrP 
were even more sensitive to ethidium bromide (Figure 4.3B), but surprisingly, the 
sensitivity was not affected by 100 µM of verapamil. Apparently, this mutant is no 
longer sensitive to verapamil, or has partially lost its sensitivity.
The influx of ethidium into cells can be monitored by an increase in fluorescence 
quantum yield of ethidium bromide upon the binding to nucleic acids. 
The fluorescence development upon addition of 10 µM ethidium to LmrP-
overexpressing and control cells indicated a LmrP-mediated extrusion of ethidium 
from cells (Figure 4.3C). The LmrP-dependent extrusion activity was blocked by 
verapamil. With the D68C-C270A LmrP-expressing cells (Figure 4.3D), a rapid 
influx of ethidium into the cells was observed while this phenomenon was only 
partially inhibited by verapamil.
Resistance and transport of Hoechst 33342. The nucleic acid stain Hoechst 33342 has 
been used extensively in the characterization of LmrP. Due to its highly enhanced 
fluorescence in the hydrophobic environment of lipid membranes this compound 
has been used extensively as a model substrate in transport studies employing 
isolated membranes vesicles. We determined the effect of Hoechst 33342 on the 
growth rate of L. lactis ΔlmrCD cells expressing LmrP grown in CDM containing 
5 ng/mL of the inducer nisin A (Figure 4.4A and B). However, no beneficial effect 
of LmrP expression on the growth of L. lactis in the presence of Hoechst 33342 
could be observed. Remarkably, verapamil increased the sensitivity of both the 
control and LmrP-over-expressing strain to Hoechst 33342 suggesting that there 
must be an endogenous, verapamil-sensitive transport mechanism independent 
of LmrP. Interestingly, at the lower concentrations of Hoechst 33342, the growth 
rate was increased. The latter phenomenon was less apparent with cells expressing 
the cysteine-less mutant C270A LmrP, and was absent in the cells that expressed 
the uncoupled mutant D68C-C270A LmrP. Expression of the latter mutant also 
made cells more susceptible to Hoechst 33342, and in analogy to the ethidium 
bromide-sensitivity, this phenomenon was not reversed by the presence of 
150 µM verapamil. 
Like ethidium bromide-transport, Hoechst 33342 influx into cells can be monitored 
by the fluorescence increase due to binding to the nucleic acids. Both control and 
LmrP-overexpressing cells accumulated more Hoechst 33342 in the presence of 
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Figure 4.4. LmrP does not confer resistance to Hoechst 33342. The specific growth rate 
µ of L. lactis NZ9000 ΔlmrCD cells harbouring the pNZ8048 control plasmid (A, circles), 
or plasmids encoding lmrP (A, squares), C270A lmrP (B, diamonds) or D68C-C270A lmrP 
(B, triangles) is plotted against the concentration of Hoechst 33342. Cells were grown 
in chemically defined medium without (solid lines) or with 150 µM verapamil (dashed 
lines). N=3, standard deviation is indicated by the error bars. Hoechst 33342 influx into 
L. lactis NZ9000 ΔlmrCD cells harbouring the pNZ8048 control plasmid (C, control), or 
plasmids encoding lmrP (C, LmrP), C270A lmrP (D, C270A LmrP) or D68C-C270A lmrP 
(D, D68C-C270A LmrP). Hoechst 33342 was added (arrow) to cells suspended in glucose 
containing buffer without (solid lines) or with (+V, dashed lines) 100 µM verapamil 
or to buffer without cells (no cells, dotted lines). The Hoechst 33342 fluorescence was 
followed in time.
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significantly reduce the influx of Hoechst 33342 (Figure 4.4C). Cells expressing 
the energy-uncoupled mutant D68C-C270A LmrP rapidly accumulated Hoechst 
33342 in the first two minutes, whereupon the fluorescence level stabilized 
(Figure 4.4D). In the presence of verapamil, D68C-C270A LmrP-expressing cells 
accumulated higher levels of Hoechst 33342. These data demonstrate that there 
is no obvious correlation between the accumulation of Hoechst 33342 and the 
cellular resistance levels. Moreover, LmrP does not render cells more resistant to 
Hoechst 33342.
Hoechst 33342-transport in inverted membrane vesicles. The fluorescence properties 
of Hoechst 33342, fluorescent in the hydrophobic environment of the cellular 
membrane and essentially non-fluorescent in an aqueous environment, have been 
used extensively to study the transport activity of MDR transporters in isolated 
cellular membranes (23;24;110;128;129). Hoechst 33342 was added to inverted 
membrane vesicles isolated from cells expressing wild-type LmrP, C270A LmrP or 
D68C-C270A LmrP and from control cells. After the Hoechst 33342 fluorescence 
signal had stabilized, ATP was added to generate a proton motive force via the 
F0F1-ATPase. This caused a rapid quenching of the Hoechst 33342 fluorescence 
in membranes containing LmrP. This phenomenon was reversed by 100 µM of 
verapamil (Figure 4.5A). Similar results were obtained with the C270A LmrP-
containing membranes (Figure 4.5B). In contrast, only low levels of quenching 
of the fluorescence were observed with inverted membrane vesicles containing 
the uncoupled D68C-C270A LmrP mutant or with control membrane vesicles. 
Likewise, no apparent effect of verapamil was observed. These data suggest that 
in contrast to intact cells, LmrP mediates the verapamil-sensitive transport of 
Hoechst 33342 in inverted membrane vesicles. 
Figure 4.5. LmrP-mediated Hoechst 33342-transport in membrane vesicles. Hoechst 
33342-transport in inverted membrane vesicles derived from L. lactis NZ9000 ΔlmrCD 
cells harbouring the pNZ8048 control plasmid (A, control), or plasmids encoding lmrP 
(A, LmrP), C270A lmrP (B, C270A LmrP) or D68C-C270A lmrP (B, D68C-C270A LmrP). 
Hoechst 33342 was added (H) to the membrane vesicle suspension in the absence or 
presence (+V) of 150 µM verapamil. Transport was initiated by the addition of 2 mM 
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Compounds that reverse the effect of MDR transporters may be useful in combating 
the increasing problem of multidrug-resistant pathogens and resistance of cancer 
cells to antibiotics and chemotherapeutic drugs, respectively. In this study we 
determined the effect of the chemosensitizing agent verapamil on the activity of 
the wild-type and an uncoupled mutant of LmrP under various growth conditions 
and in transport assays. For this purpose, lmrP was overexpressed in a host strain 
that lacks the ABC-type MDR transporter LmrCD which is a major determinant 
of drug resistance in L. lactis. First, verapamil was shown to reverse the LmrP-
mediated resistance to erythromycin and ethidium bromide. Interestingly, in 
the absence of an added drug or antibiotic, LmrP-expressing cells exhibited a 
reduced growth rate relative to the control strain. Also, this phenomenon was 
reversed by verapamil suggesting that a transport activity of LmrP is the cause of 
the growth rate reduction rather than synthesis of the protein per se. Moreover, 
the phenomenon was observed both with cells grown in complex medium 
as well as with chemically defined medium. Possible activities of LmrP that 
may limit the growth rate would be secretion of essential cellular metabolites, 
proton translocation into the cell (compromising the proton motive force) or 
facilitated influx of (cytotoxic) extracellular compounds. Although the latter 
may not immediately be apparent for an MDR protein, LmrP has been shown to 
facilitate the influx of ethidium and propidium into non-energized cells (8), while 
energy-uncoupled mutants of LmrP facilitate influx of ethidium under energized 
conditions. Likewise, in the complex M17 medium the growth inhibitory effect 
was even larger with the expression of the uncoupled D68C-C270A LmrP mutant, 
and this phenomenon was also reversed by verapamil. Possibly, LmrP facilitates 
the influx of certain cytotoxic compounds present in the growth medium under 
energized conditions. Attempts to identify this compound by a breakdown of 
the medium components, however, did not yield conclusive results, but possible 
candidates are vitamins and riboflavin that can be toxic at higher concentration.
The effect of verapamil on the different D68C-C270A LmrP-mediated phenomena 
(i.e. growth rate reduction, drug sensitivity and drug influx) appeared not 
consistent. Differences in the physiological conditions of the assays may affect 
the LmrP mutant, but it seems more likely that this mutant has a poor affinity for 
verapamil as suggested by the dose-response curve shown in Figure 4.2C. Since 
the mutant exhibits an energy uncoupled drug influx at a high rate, incomplete 
inhibition by verapamil may render these cells still highly susceptible to the drugs 
in growth experiments. 
The nucleic acid stains ethidium and Hoechst 33342 are extensively used to 
characterize MDR transport activity. Our data supports the notion that ethidium 
is an authentic substrate for LmrP as the resistance and cellular extrusion are 
both LmrP-dependent. Both processes are also sensitive to verapamil, indicating 
a good correlation between transport and cellular resistance. In contrast, with 
Hoechst 33342 such a correlation was not observed. Although Hoechst 33342 
appears to be a substrate for LmrP in isolated membrane vesicles, no such 
transport was observed in intact cells, nor could an LmrP-dependent cellular 
resistance against Hoechst 33342 be demonstrated. While the transport activity in 
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membrane vesicles could be reversed by verapamil, no such an LmrP-dependent 
effect could be observed with the transport activity and cellular resistance. On 
the other hand, the uncoupled LmrP mutant allowed the rapid influx of Hoechst 
33342 into the cells and rendered cells more susceptible to Hoechst 33342 growth 
inhibition. These data strongly indicate that Hoechst 33342 is not a genuine 
substrate for LmrP. How can this apparent discrepancy be explained? Recently, 
we noticed that Hoechst 33342 is also not a genuine substrate for the ABC-
type MDR transporter LmrA (46). LmrA did not provide resistance to Hoechst 
33342 in intact cells nor could a transport activity be demonstrated under those 
conditions. In contrast, an LmrA-dependent Hoechst 33342-transport activity 
could be detected only in membrane vesicles, but this activity is independent of 
the ATPase activity of LmrA and finally could be attributed to a LmrA- and pH-
dependent partitioning of Hoechst 33342 into the lumen of the vesicle. A major 
pitfall of the Hoechst 33342-transport assay with membrane vesicles is that the 
fluorescent assay does not record the direction of transport, but only monitors 
partitioning of Hoechst 33342 between the membrane and aqueous phase. While 
the membrane-associated Hoechst 33342 is fluorescent, the aqueous form is 
quenched. With energized inverted membrane vesicles, the luminal pH is acidic 
and this affects the pH-dependent partitioning behaviour such that the protonated 
form of Hoechst 33342 will accumulate in the lumen of the vesicles. In contrast, in 
intact cells Hoechst 33342-transport is monitored through the high quantum yield 
fluorescence of the drug intercalated with the DNA with only a small contribution 
to the total fluorescence of the membrane-partitioned Hoechst 33342. Apparently, 
both LmrA and LmrP are unable to alter the DNA partitioning of Hoechst 33342, 
and no appreciable levels of resistance are obtained against this toxic compound. 
In contrast, our previous studies with cells expressing the heterodimeric ABC 
transporter LmrCD showed that Hoechst 333342 is a substrate for this transporter 
resulting in a highly increased resistance which correlates with a strong energy-
dependent extrusion of Hoechst 33342 from the cells (4;14;44;46). These data 
further demonstrate that Hoechst 33342 cannot be used as a reliable substrate 
to monitor the transport activity of MDR transporters, and necessitates a critical 
assessment of the reports on MDR transporters that solely rely on the use of this 
drug for transport characterisation.
The increased susceptibility of the control cells to Hoechst 33342 in the presence 
of verapamil indicates the presence of an endogenous Hoechst 33342-resistance 
mechanism. These cells still contain genomic copies of lmrP and lmrA, but because 
of the lack of an elevated Hoechst 33342 resistance upon overexpression of LmrP 
(this study) or LmrA (46), it is unlikely that these transporters are responsible for 
the endogenous resistance. Since the strain used lacks LmrCD, these data suggest 
that a sofar unidentified MDR transporter might be involved in this verapamil-
sensitive Hoechst 33342 resistance of L. lactis. It will be a major challenge to 
identify this system in order to understand the intricate mechanisms that are used 




Distinct contributions of the nisin biosynthesis enzymes 
NisB and NisC and the transporter NisT to prenisin 
production by Lactococcus lactis
H. Bart van den Berg van Saparoea*, Patrick J. Bakkes*, Gert N. Moll, 
and Arnold J.M. Driessen
Summary
Several Lactococcus lactis strains produce the lantibiotic nisin. The dedicated 
enzymes NisB and NisC and the transporter NisT modify and secrete the 
ribosomally synthesized nisin precursor peptide. NisB can function in the absence 
of the cyclase NisC, yielding the dehydrated prenisin that lacks the thioether rings. 
A kinetic analysis of nisin A production by L. lactis NZ9700 demonstrated that the 
prenisin was released from the cell into the medium before the processing of the 
leader sequence occurs. Upon the deletion of nisC, the production of prenisin is 
reduced by 70%, while in the absence of nisB, the production of prenisin was nearly 
completely abolished. In cells lacking nisT, no secretion was observed while the 
expression of nisABC in these cells resulted in considerable growth rate inhibition 
caused by the intracellular accumulation of active nisin A. Overall, these data 
indicate that the efficiency of prenisin transport by NisT is markedly enhanced by 
NisB, suggesting a channeling mechanism of prenisin transfer between the nisin 
modification enzymes and the transporter.
Applied and Environmental Microbiology (2008) 74, 5541 - 5548
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Introduction
In 1928, Rogers and Whittier reported “the formation of a definite substance 
inhibiting growth” during lactic acid fermentation (130). Two decades later the 
growth inhibitory substance was identified and named nisin, for Lancefield 
group N Inhibitory Substance (131). The elucidation of the molecular structure 
of the 3.4-kDa nisin peptide (132) revealed the presence of one lanthionine 
residue and four β-methyllanthionine residues making up five intramolecular 
ring structures. Antibiotic peptides containing lanthionine residues are now 
collectively known as lantibiotics (133;134). Nisin is used in the food industry 
as preservative. Its antimicrobial action is directed predominantly against gram-
positive food borne pathogens like Listeria species. This activity is based on two 
features, i.e., nisin binds to the pyrophosphate moiety of lipid II and removes 
lipid II from its functional location, thereby inhibiting cell wall synthesis, and it 
induces the formation of lipid II-nisin hybrid pores in the cytoplasmic membrane 
(135). Nisin biosynthesis and immunity require 11 genes (55-60) organized in a 
cluster nisABTCIPRKFEG. nisA encodes the nisin A precursor peptide containing 
an N-terminal leader sequence of 23 amino acids. NisB dehydrates serine and 
threonine residues in the nisin precursor peptide, yielding 2,3-didehydroalanine 
and 2,3-didehydrobutyrine, respectively. Next, the cyclase NisC couples the 
free thiol-group of the cysteines to the dehydroresidues in a region-specific 
manner. The modified nisin A precursor containing five lanthionine rings is 
secreted from the cell by the ABC-type transporter NisT. Finally, on the outside 
of the cell, the leader sequence is removed by the protease NisP and biologically 
active nisin A is released (60). NisI and NisFEG are involved in immunity to 
the lantibiotic nisin A produced by the cells (136). The histidine kinase NisK 
senses extracellular nisin A, and upon autophosphorylation, the phosphate 
group is transferred to the transcriptional activator NisR (137). Activated NisR 
promotes the transcription of the nis gene cluster (with the exception of nisRK). 
The regulatory system NisRK induces expression in a dose-dependent manner; 
therefore, the expression of the gene cluster leads to an autoinduction cycle (137). 
The ability of extracellular nisin A to induce the expression of the nis genes in a 
dose-dependent manner has been employed in the successful and widely used 
nisin-controlled gene expression (NICE) system (138). The most commonly used 
host of the NICE system is the Lactococcus lactis strain NZ9000. This strain does 
not contain the nisin gene cluster; only the nisRK genes are integrated into the 
genome. and the gene or genes of interest are typically expressed from a plasmid. 
The nisB, nisT, and nisC genes are jointly transcribed as part of an operon (139). The 
products of these three genes, NisB, NisT, and NisC, were suggested previously 
to be part of a membrane-associated multimeric complex in the nisin-producing 
L. lactis strain KS100 (61). A gene disruption study in the related L. lactis strain 
NZ9700 demonstrated that nisB and nisT are essential for nisin A production 
and that nisC is essential for maturation (140). However, since the disruption 
of these genes breaks the cycle of autoinduction, nisin A-induced genes are no 
longer expressed and the effects observed may indirectly affect biosynthesis. In a 
previous study using the NICE system and the host L. lactis NZ9000, expression 
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of nisABT and nisAT resulted in the production of dehydrated prenisin and 
unmodified prenisin, respectively (63). This outcome demonstrated that the NisB 
and NisT activities are independent of complex formation per se, but the study 
did not investigate the efficiency of prenisin production. An extensive range 
of prenisin mutant forms with mutations in the first two ring structures on the 
amino-terminal side, as well as a range of medically relevant peptides fused to the 
nisin leader peptide, can be produced by L. lactis cells expressing nisBTC (67;141). 
These peptides contain dehydroresidues and thioether bridges, suggesting that 
the nisin biosynthesis enzymes and transporter are capable of producing and 
secreting a broad variety of modified peptides (142). Here, we now report the 
effect of each of the NisB, NisC, and NisT proteins on the relative production 
efficiency of the nisin precursor peptide. The data indicate that NisT efficiently 
excretes both fully modified and dehydrated prenisin and that the unmodified 
peptide is secreted poorly. These data suggest the channeling of prenisin from 
NisB to NisT to ensure efficient production.
Experimental procedures
Bacterial strains, plasmids and growth conditions. The expression strain 
L. lactis NZ9000 (111), the nisin-producing strain L. lactis NZ9700 (58) and the 
nonproducing strain L. lactis NZ9800 (58) were grown at 30 °C in chemically 
defined medium (CDM) (126) with 1% (wt/vol) glucose as carbon source. When 
appropriate, chloramphenicol and erythromycin (both at 4 µg/ml) were used for 
plasmid selection. Plasmids used in this study are listed in Table 5.1. In plasmid 
pNZnisA-E3, the codons ACACGA, encoding amino acids T46 and A47 of NisA, 
were replaced by site-directed mutagenesis with the codons TGATCA, introducing 
a stop, to yield plasmid pNZnisAtrunc-E3. Plasmids pIL3hpTC, pIL3hpBC and 
pIL3hpBT were created by PCR amplification of plasmid pIL3BTC from the start 
codon of nisT until the start codon of nisB, from the start codon of nisC until 
the start codon of nisT, and from the stop codon of nisT until the stop codon 
of nisC, respectively. PCR amplification was done with 5’-end-phosphorylated 
PCR primers and Phusion DNA polymerase (Finnzymes, Finland). Linear PCR 
products were ligated using T4 DNA ligase (Roche). Plasmid pIL3T was created 
in the same way as pIL3TC using pIL3BT as a template.
In vivo protein labeling. Fresh CDM was inoculated with samples from stock cultures 
frozen at -80 °C, and the cells were grown overnight. Each culture was then 
11-fold diluted in fresh CDM and incubated for approximately 2 h until it reached 
an optical density at 660 nm (OD660) of 0.3 to 0.6. Nisin A (Sigma) was added to obtain 
a concentration of 10 ng/mL, unless stated otherwise, and the culture was then 
incubated for half an hour. After cooling the cultures on ice, cells were harvested by 
centrifugation and washed with ice-cold CDM lacking methionine and containing 
10 ng of nisin A/mL, unless stated otherwise. After centrifugation, cells were 
resuspended in the same medium to an OD660 of 0.5 and kept on ice. The cell 
suspension was incubated in a water bath at 30 °C. After 5 to 10 min of preincubation, 
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Table 5.1: Expression plasmids used in Lactococcus lactis  NZ9000
plasmid relevant characteristics ref.
pNZnisA-E3 nisA expression vector carrying the inducible PnisA, Ery
r 63
pNZnisAtrunc-E3 pNZnisA-E3 derivative harboring a mutated nisA gene 
encoding NisA amino acids -23 to 22 [NisA(Δ23-34)]
this study
pNGnisT nisT expression vector carrying the inducible PnisA, Cml
r 63
pIL3BTC# nisBTC expression vector, PnisA, Cml
r 142
pIL3hpTC# nisBTC expression vector; pIL3BTC derivative this study
pIL3hpBC# nisBC expression vector; pIL3BTC derivative this study
pIL3hpBT# nisBT expression vector; pIL3BTC derivative this study
pIL3hpT# nisT expression vector; pIL3BTC derivative this study
# hp, hairpin; inverted repeat located upstream of the nisB gene.
a 1/250 volume of Redivue Pro-mix l-[35S] in vitro cell-labeling mix (GE Healthcare) 
was added (final concentration of ~40 µM, with 1.48 MBq of [35S]methionine/mL). In 
the prolonged prenisin production studies, the suspension was supplemented with 
unlabelled methionine at a concentration of 0.1 mM. Samples were taken at regular 
time intervals, and reaction mixtures were chased with 20 mM of unlabeled 
methionine. Cells and medium were separated by centrifugation. Cell pellets 
were lysed using 5 mg of lysozyme (Sigma)/mL in the presence of a small amount 
of DNase I (Sigma) in 100 mM HEPES-KOH, pH 7.0. Protein was precipitated 
from medium fractions by the addition of ¼ volume of 1 g/mL trichloroacetic 
acid (TCA; Sigma) and then incubated for 30 min on ice and subsequently 
subjected to centrifugation. Protein pellets were washed with acetone (-20 °C) and 
resuspended in 1 M Tris-HCl, pH 8.45. Medium and cell protein samples were 
analyzed by Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(Tricine-SDS-PAGE; 16% total acrylamide, of which 5% was bisacrylamide) (143) 
using a Mini-PROTEAN II electrophoresis system (Bio-Rad). Gels were dried on a 
Model 583 gel dryer (Bio-Rad) and imaged using a Cyclone Plus phosphorimager 
(PerkinElmer), and protein band intensities were quantitated. Nisin precursor 
NisA harbors 3 methionines: M23, M17, and M21. The relative intensities of the 
prenisin bands were corrected for the absence of the first methionine in 60% of the 
prenisin secreted by nisBTC expressing cells as determined by mass spectrometry. 
A similar production experiment was performed using unlabeled methionine. At 
the time points indicated (see Figure 5.3A), samples were taken and processed 
as described above. Intracellular prenisin was subsequently detected by 
immunoblotting using antibodies directed against the nisin leader sequence (63).
Specific growth rate determination. Specific growth rates were determined based 
on growth in 96-well microtiter plates under semianaerobic conditions. Cells 
inoculated into fresh medium from overnight cultures were grown to mid-
exponential phase. The cultures were diluted 20-fold in fresh medium, and 
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nisin was added. Aliquots of 200 µL of the cell suspension were transferred into 
sterile low-protein-binding 96-well microplates (Greiner). Silicone oil (50 µL) was 
pipetted onto the top of the sample to prevent evaporation. Cells were grown at 
30 °C in the absence or presence of various inducing amounts of nisin, and the 
cell density was monitored by measuring the OD660 every 3 minutes for 14 hours 
with a multiscan photometer (Titretek Multiscan MCC/340 MKII). The natural log 
of the relative OD660 [ln(OD660, t=n/OD660, t=0), where t is time, OD660, t=n is the OD660 
at time point n, and OD660, t=0 is the OD660 at time zero] was plotted against the 
time, and the slope of the curve (the maximum specific growth rate, µ) during the 
exponential growth phase was determined (127).
MALDI-TOF mass spectrometry. Fresh CDM was inoculated with aliquots from 
-80 °C frozen stock cultures and grown overnight. Cultures were then diluted 
11-fold in fresh CDM and incubated for 2 h until an OD660 of 0.3 to 0.6 was reached. 
Nisin (Sigma) was added to a concentration of 10 ng/mL, and the cultures were 
incubated for 4 h. Cells and medium were separated by centrifugation. Protein 
was precipitated from medium fractions by addition of ¼ volume of 1-g/mL 
TCA (Sigma), overnight incubation on ice, and centrifugation. The protein 
pellet was washed with acetone (-20 °C) and resuspended in demineralised 
water. Trifluoroacetic acid (TFA) was added to the protein samples to a final 
concentration of 0.1% (vol/vol). Samples for matrix-assisted laser desorption-time 
of flight (MALDI-TOF) mass spectrometry were obtained by purification with a 
ZipTipC18 pipette tip (Millipore). ZipTips were activated and equilibrated with 
50% (vol/vol) acetonitrile, followed by demineralised water. A TFA-acidified 
protein sample was then applied to the ZipTip, which was subsequently washed 
with a 0.2% (vol/vol) TFA solution. Bound proteins were eluted using a 50% (vol/
vol) acetonitrile solution containing 0.1% (vol/vol) TFA. Eluted proteins were 
vacuum dried and stored at -20 °C. Prior to mass spectrometry analysis, the 
dried eluents were dissolved in 50% (vol/vol) acetonitrile containing 0.1% TFA 
and mixed with α-cyano-4-hydroxycinnamic acid matrix solution (Sigma) in a 1:1 
ratio (final volume, 10 µL). Samples (1.2 µL) were then spotted onto the MALDI 
target and allowed to dry. Mass spectra were recorded with a Voyager-DE PRO 
MALDI-TOF mass spectrometer (Applied Biosystems). Spectra were recorded in 
linear mode. In order to maintain high level of sensitivity, an external calibration 
was performed.
Nisin bioactivity assay. Protein from medium fractions was prepared essentially as 
described for mass spectrometry analysis. TCA-precipitated protein was washed 
thoroughly with  ice-cold (-20 °C) acetone and then dried using a SpeedVac 
(30 min at 45 °C) and subsequently dissolved in 25 µL of 100 mM HEPES-KOH 
(pH 7) buffer. Aliquots were diluted twofold with the same buffer with or without 
20 of trypsin/mL. A high concentration of trypsin was used to ensure the complete 
removal of the nisin leader sequence. Samples were incubated for 30 min at 37 °C and 
subsequently cooled down on ice. The specific growth rate of the indicator strain 
L. lactis LL108 (pORI280) was determined in 100-µL culture volume in the presence 
of 4 µL of the protein samples.
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Stability of secreted prenisin-derived peptides. The stability of prenisin-derived peptides 
was evaluated by long-term incubation of the purified peptides in spent medium. 
The L. lactis NZ9000 strains harboring nisAT, nisABT, and nisABTC were used 
to produce unmodified, dehydrated, and fully modified prenisin, respectively. 
Cells were grown on minimal medium (67) containing 0.5% (wt/vol) glucose and 
induced with 10 ng of nisin A (Sigma)/mL for 24 h. After centrifugation, the cell-
free medium containing the peptide was subsequently diluted 1:1 with 100 mM 
lactic acid,  filtered through a 0.2-µm-pore-size filter (Whatman), and subjected 
to SP-Sepharose chromatography. Bound peptide was eluted with 50 mM lactic 
acid containing 1 M NaCl. Centriprep YM-3 (Millipore) centrifugal devices were 
used to remove the salt and to concentrate the peptides. Peptides were stored in 
100 mM HEPES-KOH, pH 7, containing 10% (vol/vol) glycerol. For the peptide 
stability assay, spent medium was prepared from a culture of L. lactis NZ9000 
cells grown overnight at 30 °C in CDM containing 1% (wt/vol) glucose. Cells were 
removed by centrifugation and subsequent filtration through a 0.2-µm-pore-size 
filter. Purified peptide and commercial nisin A (Sigma) at a concentration of ~0.3 
mg/mL were incubated in the presence of 100 mM HEPES-KOH, pH 7, or spent 
medium at 30 °C. After 0 and 4 h, samples were removed and analyzed by Tricine-
SDS-16% PAGE. Proteins were stained with Coomassie Brilliant Blue. Blue-
prestained protein standards (Invitrogen) were used as molecular size markers.
Results
Nisin A production by L. lactis strain NZ9700. The nisin-producing strain L. lactis 
NZ9700 harbors a single chromosomal copy of the nisin-sucrose transposon 
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Figure 5.1. Prenisin secreted by L. lactis NZ9700 is slowly processed into mature 
nisin. L. lactis NZ9700 cells were pulse-labeled with [35S]methionine. Samples were 
taken at the indicated time points after the addition of [35S]methionine. Cells were lysed, 
and medium components were precipitated with TCA. A fraction containing 10% of 
the lysed cells (A) and the complete precipitated medium fraction (B) were loaded onto 
a Tricine-SDS-16% polyacrylamide gel. Molecular sizes (MW) of marker proteins are 
indicated in between the panels; prenisin and mature nisin are indicated by black and 
white arrowheads, respectively. *, samples from a similarly labeled L. lactis NZ9800 
culture.
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Tn5276 containing the complete nisin biosynthesis gene cluster, including 
the leader peptidase gene nisP and the immunity genes nisI and nisFEG (58). To 
study the kinetics of production of nisin, L. lactis NZ9700 cells were pulse-labeled 
with [35S]methionine, together with trace amounts of nisin A to ensure proper 
induction of the nisin gene cluster. The fate of radiolabeled prenisin over 
time was monitored through the separation of cells from the medium fraction 
by centrifugation. Efficient protein labeling occurred within the first minute 
(Figure 5.1A). Interestingly, prenisin was already detected in the medium fractions 
as the most prominent labeled protein 1 min after the addition of [35S]methionine 
(Figure 5.1B). In time, the intensity of the prenisin band decreased while a 
protein band with higher-level mobility increased in intensity. A protein with 
similarly high-level mobility was associated with the cells (Figure 5.1A). Based 
on comparison with the mobilities of the marker proteins, the molecular mass of 
approximately 3.5 kDa corresponded to the mature nisin A (3,354 Da). In contrast, 
the prenisin and nisin A were not observed in either the lysate or medium fraction 
from cells of L. lactis NZ9800, an L. lactis NZ9700 derivative that does not produce 
nisin (Figure 5.1) (58). Moreover, in the absence of NisP, only the fully modified 
prenisin was observed in the medium fraction (see Figure 5.2A). The data 
demonstrate that the prenisin is released from the cell into the medium before the 
processing of the leader sequence occurs. Thus, prenisin export and release are 
not coupled to leader cleavage, which is a slow process as compared to secretion. 
Specific contributions of NisB, NisC, and NisT to prenisin production. A recent study 
has shown that L. lactis NZ9000 cells expressing nisABTC from a plasmid secrete 
fully modified prenisin (63). In the absence of NisC or of both NisB and NisC, 
dehydrated prenisin without the thioether rings or unmodified prenisin can 
be detected in the medium, respectively, as evidenced by mass spectrometry. 
However, the efficiency of the secretion of unmodified or partially modified 
prenisin has not been studied. Here, the specific contribution of the enzymes 
NisB, NisC, and NisT to the efficiency of prenisin production was determined. 
Since secretion is not strictly coupled to the removal of the leader sequence, the 
expression strain NZ9000, which lacks the leader peptidase NisP, is a suitable 
host to study prenisin production. For this investigation, nisA was expressed 
from pNZnisA-E3 and nisBTC was expressed from pIL3BTC, which includes the 
inverted repeat present in Tn5276 between nisA and nisB (63;142). This inverted 
repeat limits the expression of the nisBTC genes, affecting the stoichiometry of 
NisA prepeptide and NisB, NisC, and NisT (37). Derivatives of the pIL3BTC 
plasmid were constructed by deleting nisB, nisT, nisC, or both nisB and nisC while 
leaving the inverted repeat intact. Cells containing pNZnisA-E3 and one of the 
five pIL3hp plasmids (Table 5.1) were grown in the presence of [35S]methionine. 
Prenisin production was induced by the addition of nisin A to a concentration of 
10 ng/mL. At this concentration, the maximum induction level is achieved (data 
not shown) (111). Labeled protein of both the cell and medium fractions was 
analyzed during 4 h of incubation (Figure 5.2). The relative amounts of prenisin 
in the various medium fractions were determined using dilutions of the medium 
fraction of nisABTC-expressing cells as a standard (Table 5.2). Interestingly, in 















































Figure 5.2. Prenisin 
production by L. lactis 
NZ9000 cells expressing 
different combinations 
of the nisB, nisT, and 
nisC genes together with 
nisA. Cells expressing the 
indicated nisin genes in 
medium containing 0.1 mM 
unlabelled methionine were 
labeled with [35S]methionine, 
and, at the indicated time 
points, cell (left) and medium 
(right) fractions were isolated 
as described in the legend to 
Figure 5.1. Molecular sizes 
(MW) of marker proteins 
are indicated on the right. 
Prenisin is indicated by 
black arrowheads, and 
an intracellular prenisin 
degradation product is 




the absence of the transporter NisT, some dehydrated (and presumably cyclized) 
prenisin was detected in the medium but production was reduced by more than 
99% relative to that in cells expressing the full system NisBTC (compare Figure 
5.2C with A and also see Table 5.2). Concomitantly, a peptide similar in size to fully 
modified prenisin (6 kDa) accumulated inside the nisABC-expressing cells (Figure 
5.2C). Western blot analysis using antibodies directed against the nisin leader 
sequence confirmed the identity of this peptide, showing a slightly higher level 
of accumulation of prenisin in nisABC-expressing cells than in cells expressing 
nisABTC (Figure 5.3A, compare lanes 10 to 12 with lanes 4 to 6). Consistent 
with previous data, this finding indicates that nisin production is dependent on 
NisT. It should be noted, however, that the antibody does not recognize mature 
nisin A or the NisA degradation products. On the other hand, in the absence 
of the modification enzymes NisB and NisC but in the presence of NisT, the 
levels of production of unmodified prenisin were also very low (Figure 5.2E 
and Table 5.2), albeit reproducibly slightly higher (2%) than those in the absence 
of NisT (Figure 5.2C and Table 5.2). Likewise, cells expressing both NisT and 
NisC produced similarly small amounts of prenisin (Figure 5.2B). In contrast, 
the expression of NisB together with the transporter NisT yielded dehydrated 
prenisin at a level of 30% relative to that of fully modified prenisin produced 
when the full system is present. Note that in both the cell and medium fractions 
from the strain expressing NisBC (Figure 5.2C) or NisB alone in the presence 
of NisT (Figure 5.2D), proteins with a mobilities similar to that of nisin A upon 
gel electrophoresis were observed (compare Figure 5.2C and D with Figure 5.1). 
The observed levels of the various secreted prenisin forms were not due to 
differences in extracellular stability. Purified nisin A, fully modified prenisin, 
dehydrated prenisin, and unmodified prenisin were found to be completely stable 
when incubated for up to 4 h in filter-sterilized spent medium from a culture 
fo the L. lactis NZ9000 strain (Figure 5.3) or in buffer (data not shown). These 
data indicate that during the course of the production experiment, the secreted 
peptides were intrinsically stable and not lost by proteolytic degradation.
Identities of prenisin forms produced by L. lactis cells in the absence and presence of NisB, 
NisC, and NisT. Next, we established whether NisB and NisC expressed from the 
pILhp plasmids were fully functional. To confirm the dehydration of the produced 
prenisin, TCA-precipitated medium samples were analyzed by MALDI-TOF 
mass spectrometry (Table 5.2). For the sample of L. lactis NZ9000 cells expressing 
nisABTC, peaks at a mass-over-charge ratio (m/z) corresponding to prenisin forms 
containing or lacking the initiating methionine were observed, consistent with 
previous observations (63). Interestingly, for both species, peaks were present at 
masses 126 and 144 Da lower than the mass of the unmodified prenisin peptide. 
These mass losses correspond, respectively, to seven and eight times the mass 
of water (18 Da), indicating efficient dehydration of the prenisin. In a previous 
study, a commercial nisin A sample has been shown to contain a form of nisin A 
with an unmodified Ser33 residue ([Ser33]nisin), potentially due to incomplete 
dehydration (144). However, in the same study other (chemical) modifications 
were reported that resulted in the same molecular mass as that
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0.02 - ND (5,963) 5,832.1 (5,832)
a D, dehydrated serine (three) and threonine (five) residues; T, thioether bridges (five). 
The dehydration of one residue results in mass loss of 18 Da, while thioether bridge 
formation does not result in mass change.  
b Amount of the peptide in the medium after 4 h of incubation, expressed as the ratio 
of the amount of the indicated peptide to the amount in the medium fraction of 
nisABTC-expressing cells.
c TCA-precipitated peptide was treated with trypsin to liberate nisin A, and the 
inhibition of L. lactis LL108 (pORI280) growth was assessed with a bioassay. 
+, present; -, absent.
d Result for the peptide with seven dehydrated residues.
e ND, not detected.
of [Ser33]nisin, namely, the addition of  water to Dha5, resulting in [2-hydroxy-
Ala5]nisin, which can be further converted to [Ile4-amide,pyruvyl-Leu6]des-
Dha5-nisin. The detected peaks at masses of 5,838.8 and 5,705.7 Da (Table 5.2) 
therefore likely correspond to [Ser33]prenisin, [2-hydroxy-Ala5]prenisin, and 
[Ile4-amide,pyruvyl-Leu6]des-Dha5-prenisin. 
Only in the case of NisBTC was the complete prenisin, including the initiating 
methionine, observed, while under the other conditions tested, only prenisin 
without the initiating methionine was observed (Table 5.2). In all medium samples 
from cells expressing nisB (Table 5.2) molecules with masses of approximately 
5,706 and 5,688 Da, corresponding to prenisin containing seven and eight 
dehydrated residues, respectively, were detected. In nisin A, Ser29 is never 
dehydrated, which has been attributed to steric hindrance by the formation of the 
neighboring thioether ring E. In case of nisA and nisBT coexpression, thioether 
rings are not formed since NisC is absent and, therefore, Ser29 may be available 
for dehydration. Nevertheless, prenisin with nine dehydrated residues could not 
be detected, suggesting that one of the residues escapes dehydration. In a parallel 
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experiment with cells expressing a truncated form of NisA lacking amino acids 23 
to 34 [NisA(Δ23-34)], similar dehydration efficiency was observed. Molecules with 
masses 72 and 90 Da lower than that of the unmodified truncated prenisin peptide 
(with and without initiating methionine, 4,695 Da and 4,563 Da, respectively) were 
detected when the gene encoding NisA(Δ23-34) was coexpressed with nisBTC or 
nisBT (data not shown). The 90-Da mass reduction corresponds to the expected 
dehydration of Thr2, Ser3, Ser5, Thr8, and Thr13. The 72-Da reduction in mass 
may result from incomplete dehydration or complete dehydration followed by 
the addition of water to Dha5.
To assess the correct dehydration and cyclization of prenisin, a growth inhibition 
assay was used. A medium fraction of nisABTC-expressing cells treated with 
trypsin to remove the leader peptide inhibited the growth of L. lactis LL108 
(pOri280) (141), indicating the presence of active nisin A and thus confirming the 
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Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Figure 5.3. Intracellular accumulation of prenisin and stability of secreted prenisin 
and derived peptides. (A) Intracellular prenisin accumulation in L. lactis NZ9000 cells 
lacking nisABTC or expressing different combinations of the nisB, nisT, and nisC genes 
together with nisA as indicated. Samples were taken prior to induction (0 h) and after 
2 and 4 h of induction. Equal amounts of lysed cells were analyzed by Tricine–SDS–
16% PAGE, followed by immunoblotting using antibodies directed against the leader 
sequence (lanes 4 to 21). Samples of about 2 µg each of purified unmodified prenisin 
(pn; lane 1), dehydrated prenisin (lane 2), nisin A (lane 3), and fully modified prenisin 
(lane 22) were loaded as controls. Note that the antibody does not recognize the mature 
nisin A. (B) Purified peptide at a concentration of ~0.3 mg/mL was incubated at 30°C 
in filter-sterilized spent medium from an L. lactis NZ9000 culture. At the time points 
indicated, samples were taken and analyzed by Tricine–SDS–16% PAGE and Coomassie 
brilliant blue staining. MW, molecular size markers.
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proper cyclization (Table 5.2). As expected, in the absence of NisB or NisC no 
active nisin A was obtained (Table 5.2).
Mature nisin A accumulates inside the cell in the absence of NisT. In the nisin producer 
strain L. lactis N8, a deletion in the nisT gene leads to the accumulation of mature nisin 
in the cytoplasm of the cells (62). Apparently, fully modified prenisin is produced but 
remains in the cytoplasm due to the absence of the transporter. The accumulation of 
mature nisin likely results from the conversion of prenisin into nisin by intracellular 
proteases. The expression of nisABC significantly reduced the specific growth rate 
of the host strain by approximately 30% at the highest induction level (10 ng of 
nisin A/mL), whereas no significant reduction of the growth rate was observed 
for the other strains that lacked one or both of the modification enzymes 
(Figure 5.4). Indeed, in the cellular fractions of nisABC-expressing cells, peptides 
similar in size to fully modified prenisin (6 kDa) (Figure 5.2C and 5.3A) and nisin 
(3.4 kDa) accumulated (Figure 5.2C). 
A truncated form of nisin lacking amino acids 23 to 34 has been shown previously 
to display reduced growth-inhibiting activity against a nisin-sensitive L. lactis 
Figure 5.4. In the absence of nisT, the expression of nisABC inhibits the growth of 
L. lactis NZ9000. L. lactis NZ9000 strains containing different combinations of nisA or 
truncated nisA [nisAtrunc, encoding NisA(Δ23–34)] and the nisB, nisT, and nisC genes 
(as indicated) under the control of the nisin-inducible promoter were grown in CDM 
containing nisin A at a concentration of 0 (white bars), 0.1 (lightest gray bars), 2 (medium 
gray bars), or 10 (darkest gray bars) ng/mL. The specific growth rate (µ) was determined 
from the increase of the OD660 in the exponential growth phase. Each bar indicates the 
average specific growth rate of three independent cultures. The standard deviations are 





















































































strain (141). The residual antimicrobial activity of this peptide was attributed to 
its retained ability to bind to lipid II while the pore-forming activity was lost. 
When the same truncated form of NisA was expressed together with NisBC, 
no significant reduction of the growth rate of the host strain was observed 
(Figure 5.4).
Discussion
Nisin A production depends on the concerted activities of the modifying and 
membrane-associated enzymes NisB and NisC, the transporter NisT, and the 
extracellular protease NisP. By means of the yeast two-hybrid system and 
coimmunoprecipitation experiments, NisB, NisT, and NisC have been shown 
previously to be interacting proteins (61). However, the functional significance 
of this interaction has remained elusive, as all three proteins have been shown 
to function in the absence of the other two (63-65). Here we have presented a 
quantitative assessment of the role of the individual Nis proteins in prenisin 
production. Plasmids carrying the nisB, nisC, and nisT genes separately or in 
combination were employed, and their expression was induced by the addition of 
nisin A. In the absence of any one of the three components of the nisin synthetase 
complex, a profound reduction in prenisin production was observed. In line with 
previous observations (62), NisT was essential for the secretion of the completely 
modified prenisin from the cell. Remarkably, in the absence of the dehydratase 
NisB, a very low level of unmodified prenisin (only 2% of the level observed for 
nisABTC-expressing cells) was found in the medium, irrespective of the presence 
(in nisATC-expressing cells) or absence (in nisAT-expressing cells) of NisC. Mass 
spectrometry showed that the small amounts of secreted prenisin correspond 
to the unmodified form. On the other hand, in cells expressing both nisB and 
nisT, a substantial level of dehydrated prenisin (about 30% of that in the control 
cells) was detected in the medium fraction. The loss of production was not due 
to proteolysis of the secreted peptides in the external medium, as the long-term 
incubation of the fully modified nisin A and prenisin, and the dehydrated or 
unmodified prenisin with spent medium did not reveal any major differences 
in stability. Rather, our results suggest that a compromised translocation is the 
main reason for the reduced production of dehydrated and unmodified prenisin. 
Consistent with this hypothesis is the observation that a prenisin-derived peptide 
(~ 3 kDa) accumulated in the nisABT-expressing cells (Figure 5.2D). The same fragment 
was observed in nisABC-expressing cells (Figure 5.2C) but could not be detected in 
nisAT- or nisATC-expressing cells (Figure 5.2A and B). The possibility that the deletion 
of nisB somehow affects the ribosomal synthesis of prenisn (NisA) was investigated 
by Western blot analysis of the cellular fractions with nisin leader antibodies 
(Figure 5.3A). Cells expressing nisABT, nisATC, or nisAT, however, accumulated 
comparable levels of prenisin following 4 h of production. Therefore, we hypothesize 
that the strongly reduced production of unmodified and dehydrated prenisin was 
due to reduced export activity and that the prenisin peptides, among others, were 
partially proteolyzed in the cell to release nisin A, which is growth inhibitory 
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(Figure 5.4). In line with this suggestion was the intracellular presence of small 
peptides in the nisABC strain, which were likely nisin A and further degradation 
products (Figure 5.2C; also see below).
In the absence of NisT, the production of prenisin in the medium was reduced 
more than 100-fold, with a concomitant accumulation of nisin A in the cells, which 
likely originates from the nonspecific removal of the leader sequence from the fully 
modified prenisin by cytoplasmic proteases (Figure 5.2C). Thioether rings have 
been shown previously to stabilize and protect (poly)peptides from proteolytic 
cleavage (60;67) and may allow for the fully modified prenisin and nisin A to 
accumulate inside the cell. In support of this possibility, cells expressing nisABC 
showed a significantly reduced growth rate under strong inducing conditions. 
Under identical conditions, the expression of a truncated form of prenisin lacking 
the 12 C-terminal amino acids (23 to 34) and unable to form pores (141) did not 
result in a reduction of the growth rate. Therefore, we conclude that in the absence 
of NisT, nisABC-expressing cells accumulate toxic levels of nisin A in the cytosol, 
leading to pore formation and the inhibition of cell wall synthesis. 
Siegers et al. (61) have shown that NisB, NisC, and NisT are contained in a 
membrane-bound nisin synthetase complex. The possible benefit of complex 
formation may be that prenisin modification and secretion are well-coupled 
processes. The extremely fast appearance of fully modified prenisin in the 
medium (Figure 5.1) is consistent with such a channeling mechanism. In the 
presence of NisB but in the absence of NisC, significant albeit reduced production 
was observed, whereas the absence of NisB resulted in an almost complete loss 
of production under all conditions tested. Therefore, we propose that NisB is a 
central component of the NisBTC complex that is essential for the transfer of the 
modified prenisin to NisT (Figure 5.5). An alternative explanation for our results 
is that NisT is highly specific for the fully modified prenisin only. However, 
we consider this hypothesis less likely as Rink et al. (142) reported the efficient 
production of a series of unmodified peptides in a NisT strain provided that these 
peptides contained the nisin leader sequence.
The results of the pulse-labeling experiments (Figure 5.1) with [35S]methionine 
and L. lactis strain NZ9700, which contains a single copy of the nisin-sucrose 
transposon Tn5276 (58), show that the secretion of fully modified prenisin and 
subsequent processing into nisin A are independent processes. Fully modified 
prenisin was already detected in the medium after 1 min of incubation, indicating 
that synthesis, modification, and secretion are relatively fast processes. The 
secreted fully modified prenisin was subsequently slowly processed into nisin 
A by NisP. Processing occurs either at the membrane surface or, alternatively, 
in the culture medium, as some NisP is released into the medium. Overall, the 
data demonstrate that the removal of the leader peptide is not coupled strictly 
to the export event and that unprocessed prenisin is first released into the 
medium (Figure 5.5). Importantly, secretion thus appears to be a faster event than 
processing. This view is further supported by findings that the disruption of the 
nisP gene allows the secretion of the unprocessed fully modified prenisin (63), 
which demonstrates that these processes are not mechanistically coupled. 
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Employing the enzymes NisB and NisC and the transporter NisT of the nisin 
biosynthesis complex for the biological production of peptides containing 
dehydroalanine and dehydrobutyrine residues and thioether bridges may open 
a window to a multitude of improvements on antimicrobial and therapeutic 
peptides known today. Recent studies have shown that these proteins are capable 
of modifying and transporting a range of peptides that are not related to the 
natural substrate prenisin (63;67;145). This finding further demonstrates that the 
substrate specificity of NisT is relatively broad and supports the notion that the 
lack of production in the absence of NisB (and NisC) is due to a poor targeting and 




















Figure 5.5. Proposed channeling mechanism of prenisin transfer between the nisin 
modification enzymes NisB and NisC and the transporter NisT. (A) Prenisin is targeted 
to the NisBTC complex, dehydrated by NisB, cyclized by NisC, and subsequently 
secreted by NisT. Outside the cell, the mature prenisin is processed by NisP into the 
active nisin. CM, cell membrane. (B) In the absence of NisB, the production of prenisin 
is almost completely abolished, suggesting a role of NisB in membrane targeting and 
channeling of unmodified prenisin in the cell. Without this targeting, the unmodified 
prenisin is proteolyzed in the cell.





H. Bart van den Berg van Saparoea and Arnold J.M. Driessen
The ability to secrete structurally unrelated hydrophobic compounds from the cell 
is part of a range of strategies that microorganisms employ to resist the negative 
effects of toxic molecules in their environment. Pathogenic microorganisms 
employ such mechanisms to develop resistance to (multiple) antibiotics and this 
has become a major problem in health care reducing the options to cure infections 
with alternative antibiotics. Development of multidrug resistance (MDR) is also 
a major cause of failure in the chemotherapeutic treatment of cancer, and this is 
based on MDR transporters that are related to and function in a similar manner 
as the bacterial proteins. Previous studies have shown that in a laboratory setting 
the lactic acid bacterium Lactococcus lactis readily develops resistance to toxic 
compounds such as ethidium, daunomycin, and rhodamine 6G (22). These are 
compounds that the organism normally does not face in its natural environment, 
but apparently exposure to such molecules recruits defense mechanisms that 
likely fulfill a role in the general resistance of L. lactis against adverse compounds. 
Although each adapted strain was selected individually for resistance against one 
of the toxic compounds, all three obtained strains exhibited the MDR phenotype, 
i.e., an increased resistance to a panel of structurally unrelated drugs. 
Before the genetic basis of the MDR phenotype in L. lactis was discovered, 
four genes encoding MDR transport proteins in the genome of L. lactis were 
characterized, i.e., these are  lmrP, lmrA, lmrC and lmrD (4;5;7). LmrA is an ABC 
half transporter that is thought to function as a homodimer. LmrC and LmrD are 
ABC half transporters that function as a heterodimer, while LmrP belongs to the 
major facilitator superfamily that acts as a drug/H+ antiporter. When expressed 
in Escherichia coli or in human lung fibroblast cells, LmrA confers resistance to 
a wide range of toxic compounds (5;28;31). However, when the lmrA gene is 
overexpressed or inactivated in its natural host L. lactis no specific phenotype in 
multidrug resistance is apparent (example for Hoechst 33342-resistance shown 
in Figure 6.1) (46). This suggests a role of LmrA other than MDR, or indicates 
that other MDR transporters are more prominent in this organism. In this respect, 
when exposed to heavy metals, several eukaryotic organisms or cells (Asiatic 
clam, mussel, and human tumor cells) increase the expression of ABC-type MDR 
proteins suggesting an involvement of this type of MDR proteins in heavy metal 
resistance. The studies presented in Chapter 2 demonstrate that the three MDR 
proteins tested confer resistance to cadmium to E. coli. Also the expression of 
LmrA in E. coli results in an increased resistance to cadmium (Chapter 2). Similar 
results were obtained with the LmrA-homologs OmrA of the lactic acid bacterium 
Oenococcus oeni that is responsible for the malolactic fermentation in wine making, 
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and MDR1 (ABCB1 or P-glycoprotein), a human MDR protein. The presence 
of verapamil, a known antagonist of MDR proteins, completely abolished the 
effect, indicating that the cadmium-resistance is directly related to the transport 
activity of these proteins. The increased resistance to cadmium appears to 
be based on secretion of this toxic compound from the cell as less cadmium is 
associated with cells expressing the various MDR transporters as compared to 
control cells. Cadmium transport by LmrA was more directly demonstrated by 
uptake experiments employing inside-out membrane vesicles. Although these 
experiments revealed a considerable uptake activity in control membrane vesicles 
that lack LmrA, suggesting the presence of endogenous mechanisms of cadmium 
excretion, also an LmrA-dependent cadmium uptake could be detected. This 
uptake activity was elevated 4-fold when glutathione was included in the assay. 
Under these conditions cadmium is likely transported by LmrA in the form of 
a glutathione-cadmium complex. Similarly, in the absence of glutathione LmrA 
may transport an ATP-cadmium complex rather than the free cadmium ion. In 
the assay, ATP was present in 40-fold excess over cadmium. Whether LmrA is 
a major determinant of the endogenous heavy metals resistance mechanism of 
L. lactis remains to be determined but seems questionable because of the high 
cadmium uptake activity observed in control membrane vesicles. These systems 























Figure 6.1. Cellular resistance of Lactococcus lactis to Hoechst 33342. L. lactis NZ9000 
ΔlmrA ΔlmrCD cells expressing LmrA (4), LmrCD (2), control cells harboring the empty 
vector (3), or the parental strain L. lactis NZ9000 harboring the empty vector (1) were 
grown in the presence of different concentrations of Hoechst 33342. The growth rate 
(µ) in the exponential growth phase was determined and plotted as a function of the 
Hoechst 33342 concentration. The data points indicate the average of three experiments. 
The error bars indicate the standard deviation.
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LmrA that was overexpressed in these studies. In this respect, it is unclear if the 
lmrA deletion strain exhibits an altered susceptibility to heavy metals. 
The ABC-type (half)transporter proteins LmrC and LmrD are encoded in a 
single operon in the genome of L. lactis and constitute a heterodimeric MDR 
protein (4). Disruption of the lmrC and lmrD genes increases the susceptibility of 
L. lactis to several toxic compounds and reduces the ability of cells to secrete 
these compounds (14). The notion that LmrCD plays a major role in the drug 
resistance phenotype of L. lactis was further supported by the observation that 
transcription of the lmrCD genes is upregulated in response to a challenge with 
Hoechst 33342, daunomycin (42), or cholate (45). Analysis of the transcription 
profile and regulation of all potential and characterized MDR transporter 
encoding genes in L. lactis might thus be a diagnostic tool to determine which 
of these genes is truly involved in drug resistance. Eventually, such studies may 
even provide leads towards the substrate spectrum of the respective transporter. 
How the expression of other putative MDR transporters in L. lactis is regulated 
is presently not known. Northern analysis demonstrates that the lmrP and lmrA 
genes are expressed in L. lactis strain MG1363, but not in the IL1403 strain (49). 
One further question in this respect is whether the expression of lmrP and/or 
lmrA changes when L. lactis cells are challenged with one of the known substrates 
of LmrP or LmrA, e.g. ethidium or Hoechst 33342. However, the expression of 
these genes is not altered upon a challenge with these two drugs (R. van Merkerk, 
unpublished results). 
Ethidium has been an important substrate in the characterization of LmrP. 
Consistently, a strong LmrP-dependent ethidium secretion activity has been 
observed. Likewise, when overexpressed, LmrP confers resistance to ethidium 
in both E. coli and L. lactis. However, whether LmrP is actually involved in the 
endogenous ethidium resistance of L. lactis has not yet been firmly established. 
Deletion of the lmrP gene has only a marginal effect on the ethidium resistance 
phenotype of L. lactis (7), which could relate to observations that lmrP is expressed 
only in the late exponential growth phase. Alternatively, other transporters might 
be more important for ethidium export such as for instance LmrCD whose gene 
deletion has a marked effect on the endogenous ethidium resistance. L. lactis cells 
overexpressing LmrP show a reduced growth rate (Chapter 4), a phenomenon 
that is abolished by the addition of verapamil. This suggests that the growth rate 
effect results from the transport activity of LmrP. Under overexpression conditions 
LmrP may secrete essential cellular metabolites, compromise the proton motive 
force due to proton translocation into the cell, or facilitate the influx of (cytotoxic) 
extracellular compounds. The growth rate inhibitory effect was even more 
pronounced in cells expressing the energy-uncoupled mutant of LmrP, D68C-
C270A LmrP. This protein has lost the ability to directionally transport substrates, 
and only facilitates the diffusion of substrates across the membrane independent 
of the proton motive force. Likewise, expression of D68C-C270A LmrP increases 
the susceptibility of cells to ethidium. This mutant also facilitates the influx of 
Hoechst 33342 into cells rendering cells hypersensitive to this compound. On 
the other hand, overexpression of wild-type LmrP does not increase the cellular 
resistance to Hoechst 33342, nor does it increase the efflux of Hoechst 33342 in 
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cells harbouring the disrupted lmrC and lmrD genes. This is a surprising result 
since a strong LmrP-dependent Hoechst 33342-transport activity is consistently 
observed in membrane vesicles, and indicates that Hoechst 33342 is not a genuine 
substrate of LmrP.
The above observations raised the question whether Hoechst 33342-transport 
in membrane vesicles is a reliable indicator for MDR transport activity. This 
question is augmented by the results of studies on LmrA (Chapter 3). As with 
LmrP, a strong LmrA-dependent Hoechst 33342-transport activity is observed 
in membrane vesicles. However, this transport is completely inhibited by 
dissipation of the proton gradient across the membrane or when the generation 
of this gradient is prevented. Remarkably, this transport is not dependent on the 
ATPase activity of LmrA. These data firmly demonstrate that LmrA-mediated 
Hoechst 33342-transport in membrane vesicles is not the genuine secretion activity 
of an ABC-type MDR protein. The dependence on the proton gradient suggests 
an involvement of proton concentration in Hoechst 33342-transport. Partitioning 
of Hoechst 33342 between lipid membranes and the suspending medium indeed 
depends strongly on the pH. In the presence of liposomes, a decrease in fluorescence 
of Hoechst 33342 is observed when the pH of the suspending medium is lowered 
from 8.0 to 5.25. Although these experiments did not directly measure partitioning, 
the observed pH-dependence of the Hoechst 33342 fluorescence is most likely 
caused by a less efficient partitioning of the protonated form of Hoechst 33342 
into the lipid membrane. When ATP is added to inside-out membrane vesicles, the 
F1F0-ATPase generates a transmembrane proton gradient, acidic pH inside. On the 
inside of the vesicle, the low pH will cause a shift in partitioning of Hoechst 33342 
towards the aqueous phase thus lowering its fluorescence. LmrA, present in high 
amounts (up to 30% of total protein), may facilitate the movement of Hoechst 
33342 between the two leaflets of the membrane and from the membrane to the 
aqueous phase (Figure 6.2). These observations suggest that Hoechst 33342 is also 
not a genuine substrate for LmrA. This notion was reinforced by the observation 
that both under energy-deprived as well as under energized conditions, LmrA 
facilitated influx of this DNA stain into the cells. Instead of conferring Hoechst 
33342-resistance to the hypersensitive L. lactis ΔlmrA ΔlmrCD cells, LmrA 
expression rendered cells more susceptible. Collectively, it seems that Hoechst 
33342-transport in membrane vesicles is not a reliable indicator of MDR transport 
unless there is clear evidence that the expression of the transporter under study 
causes an increased resistance of cells to this compound. An example for this is 
LmrCD-dependent Hoechst 33342-transport. This transport activity in membrane 
vesicles is only marginally susceptible to dissipation of the proton gradient 
and it is dependent on the ATPase activity of LmrCD. Furthermore, expression 
of lmrCD from a plasmid fully restores the Hoechst 33342-resistance of L. lactis 
ΔlmrA ΔlmrCD cells to the wild-type level. Those experiments did not depend on 
the massive overexpression of the LmrCD transporter. Rather, wild-type levels 
appear sufficient to provide the cells with an increased resistant to Hoechst 33342. 
Thus, these observations demonstrate that Hoechst 33342 is a genuine substrate 
of LmrCD, and further stress the difficulty to predict the reliability of Hoechst 




Figure 6.2. Model for the LmrA-dependent Hoechst 33342-transport activity in 
membrane vesicles. Hoechst 33342 added to inside-out membrane vesicles quickly 
partitions into the outer leaflet of the lipid bilayer resulting in a high fluorescence (grey 
Hoechst 33342 molecules). LmrA, present at high amounts (up to 30% of total protein) in 
the membrane vesicles, in an ATP-independent manner facilitates a flip-flop movement 
of Hoechst 33342 into the inner leaflet of the membrane or from the membrane to 
the aqueous phase. When ATP is added, the F1F0-ATPase generates a transmembrane 
proton gradient, acidic pH inside. On the inside of the membrane vesicle, the low pH 
will further protonate the Hoechst 33342 and thus favour a partitioning of the Hoechst 
33342 from the membrane into the aqueous phase (white Hoechst 33342 molecules) with 



































membrane vesicles. In general, the Hoechst 33342-transport assay should be 
interpreted with care when the apparent transport activity depends on the high 
level overexpression of the MDR transporter under study. 
The above studies question a role of LmrA in MDR in L. lactis, but because of the lack 
of a phenotype of the lmrA gene deletion in L. lactis, it has been difficult to address 
alternative functions of LmrA.  In this respect, in L. lactis LmrA has also been shown 
to confer resistance to the bacteriocins LsbA and LsbB (49). In addition, LmrA can 
functionally substitute for the homologous ABC-type transporter LmrB, which is 
responsible for the secretion and immunity against these bacteriocins. Therefore, 
future experiments should explore a possible role of LmrA in the resistance of 
L. lactis to antimicrobial peptides. 
The best studied antimicrobial peptide produced by lactic acid bacteria is the 
lantibiotic nisin A. Its structure is determined by the unusual and biochemically 
stable thioether bridges. These thioether bridges are introduced in the NisA 
peptide by the enzymes NisB and NisC after ribosomal synthesis. Although all 
proteins encoded in the nis gene cluster are dedicated to the synthesis of and 
immunity to nisin A, these enzymes can introduce thioether bridges in other 
peptides as well (63). NisT is an ABC-type transporter dedicated to nisin A 
production and appears to be equipped with a broad substrate specificity as it can 
translocate various modified peptides provided that they are fused to the nisin A 
leader sequence. This promiscuity of the enzymes and the transporter may open 
possibilities to introduce specific intramolecular thioether bridges in peptides of 
interest, and couple their production to secretion into the external medium. In 
Chapter 5, a quantitative assessment of the contribution of NisB, NisC, and NisT to 
the production of prenisin by L. lactis is presented. The dehydratase NisB catalyses 
the first step in the posttranslational modification, the dehydration of serine and 
threonine residues in the peptide. The cyclase NisC catalyses the second step in 
the posttranslational modification, the formation of thioether bridges by coupling 
the free thiol group of cysteines to dehydroresidues within the same peptide. 
The modified peptide is translocated across the cellular membrane by NisT. 
On the outside of the cell the peptide is cleaved by the protease NisP, releasing 
leader peptide and the lantibiotic nisin A. Nisin A precursor peptide (prenisin) 
is observed in the medium before this proteolysis takes place, indicating that 
translocation and leader cleavage are not coupled. 
Production of prenisin depends highly on the dehydratase NisB. The absence of 
this enzyme nearly completely abolishes the production of prenisin. NisT alone 
or NisT in combination with NisC does not result in an efficient production of 
the peptide. On the other hand, the absence of NisC has less of an effect (a 70% 
reduction) on the production of prenisin, indicating that NisB together with the 
transporter NisT supports a substantial production of the peptide. In the absence 
of NisT no secretion is observed, but expression of nisABC results in a considerable 
inhibition of the growth rate of the cells. The modified peptide produced by NisBC 
contains a leader peptide and should therefore not exhibit antimicrobial activity. 
However, proteolysis of the peptide that accumulates inside the cell releases active 
nisin A and this is likely the cause of the observed growth rate inhibition. Since 
NisB is important for effective prenisin production, we suggest a channelling 
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mechanism of prenisin through the NisBCT protein complex. In this model NisB 
is the central component. According to this hypothesis, the leader sequence would 
direct the NisA peptide to NisB in the NisBCT complex located at the membrane. 
Once bound to NisB the peptide would be efficiently transferred through the 
modification enzymes and finally to the transporter to effect its secretion to the 
outside of the cell.  It has to be noted that in the analysis described in Chapter 5, 
production of different peptides, although similar, is compared. Dependent on 
the presence or absence of NisB and NisC, unmodified, dehydrated or dehydrated 
and cyclised NisA is secreted by NisT. A similar study using peptides that are 
not modified by the enzymes NisB and NisC may therefore provide further 
insight in the proposed channelling mechanism through the NisBCT complex. 
Lantibiotic biosynthesis enzymes may be employed in the synthesis of novel 
modified peptides, e.g., new or improved antimicrobial or chemotherapeutic 
peptides. Therefore, a detailed knowledge of the molecular mechanism of the 






Samenvatting in het Nederlands (Summary in Dutch)
H. Bart van den Berg van Saparoea and Arnold J.M. Driessen
Het vermogen om een scala aan hydrofobe stoffen die niet verwant zijn qua 
(chemische) structuur uit te scheiden is onderdeel van een reeks van strategieën 
die door micro-organismen wordt gebruikt om de negatieve effecten van 
dergelijke toxische moleculen in hun omgeving te weerstaan. Ziekteverwekkende 
micro-organismen gebruiken dezelfde mechanismen om resistentie tegen 
meerdere antibiotica tegelijkertijd te ontwikkelen. Dit fenomeen beperkt de 
mogelijkheden om bij de behandeling van infecties naar alternatieve antibiotica 
over te stappen wanneer een bepaald antibioticum niet effectief blijkt te zijn en 
dit vormt een groot probleem voor de gezondheidszorg. Het ontwikkelen van 
deze multidrugresistentie (MDR) is eveneens een belangrijke oorzaak van het 
falen van chemotherapie ter bestrijding van kanker. Deze vorm van resistentie 
wordt veroorzaakt door MDR-transporteiwitten die verwant zijn aan en een 
soortgelijke werking hebben als de bacteriële MDR-transporteiwitten. Eerdere 
studies hebben aangetoond dat de melkzuurbacterie Lactococcus lactis onder 
laboratoriumomstandigheden eenvoudig resistentie ontwikkelt tegen giftige 
stoffen als ethidium, daunomycine, en rhodamine 6G (22). Dit organisme komt 
deze stoffen normaliter niet tegen in haar natuurlijke omgeving, maar blijkbaar 
wekt de blootstelling hieraan een beschermingsmechanisme op dat waarschijnlijk 
een rol speelt in de algemene resistentie van L. lactis tegen schadelijke stoffen. 
Hoewel iedere aangepaste stam afzonderlijk was geselecteerd op resistentie tegen 
één van de giftige stoffen, vertoonden alle drie verkregen stammen het MDR- 
fenotype. Dat wil zeggen, een verhoogde resistentie voor meerdere, qua structuur 
betreft onverwante, toxische stoffen. 
Voordat de genetische basis van het MDR-fenotype in L. lactis werd ontdekt, 
zijn er vier genen uit het genoom van L. lactis gekarakteriseerd die coderen voor 
MDR-transporteiwitten, te weten lmrP, lmrA, lmrC en lmrD (4;5;7). LmrA is een 
ABC-type half-transporteiwit dat geacht wordt te werken in de vorm van een 
homodimeer. LmrC en LmrD zijn eveneens ABC-type half-transporteiwitten, 
maar deze werken samen in de vorm van een heterodimeer. LmrP behoort tot 
de major facilitator superfamily en werkt als een drug/H+ antiporteiwit. Wanneer 
LmrA tot expressie wordt gebracht in de darmbacterie Escherichia coli of in 
humane long-fibroblast cellen, verleent het resistentie tegen een brede reeks 
toxische stoffen (5;28;31). Echter, wanneer hetzelfde lmrA gen in haar natuurlijke 
gastheer L. lactis tot overexpressie wordt gebracht, of wordt uitgeschakeld, dan 
wordt er geen specifiek fenotype in de multidrugresistentie waargenomen (een 
voorbeeld van Hoechst 33342-resistentie is weergegeven in Figuur 7.1) (46). Dit 
suggereert dat LmrA een andere rol heeft dan in MDR, of wijst erop dat andere 
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MDR-transporteiwitten hierin een meer uitgesproken rol spelen. 
Verschillende eukaryote organismen of cellen (Aziatische korfmossel, gewone 
mossel en menselijke tumor cellen) verhogen de expressie van ABC-type MDR-
transporteiwitten wanneer zij worden blootgesteld aan zware metalen. Dit suggereert 
dat dit type MDR-transporteiwitten mogelijk ook betrokken is bij resistentie tegen 
zware metalen. De in Hoofdstuk 2 beschreven studies laten zien dat de drie
 onderzochte MDR-transporteiwitten resistentie verschaffen aan E. coli voor 
cadmium. Ook de expressie van LmrA in E. coli resulteert in een verhoogde 
resistentie voor cadmium (Hoofdstuk 2). Vergelijkbare resultaten werden 
gevonden voor het aan LmrA homologe eiwit OmrA van de melkzuurbacterie 
Oenococcus oeni, die verantwoordelijk is voor de malolactische (appelzuur) 
fermentatie bij wijnproductie, en MDR1 (ABCB1 of P-glycoproteine), een 
menselijk MDR-transporteiwit. De aanwezigheid van verapamil, een bekende 
antagonist van MDR-transporteiwitten, doet dit effect volledig teniet, wat 
aangeeft dat de toename in cadmiumresistentie direct gerelateerd is aan de 
transportactiviteit van deze eiwitten. Deze toename in resistentie lijkt het gevolg 
te zijn van de secretie van cadmium uit de cel, omdat er minder cadmium 
geassocieerd is met cellen die de verschillende MDR-transporteiwitten tot 
expressie brengen dan met controle cellen. Het transport van cadmium door 
LmrA is op een directere manier aangetoond met opname-experimenten waarbij 
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Figuur 7.1. Resistentie van Lactococcus lactis voor Hoechst 33342. L. lactis NZ9000 
ΔlmrA ΔlmrCD die LmrA (4) of LmrCD (2) tot expressie brengen, controlecellen die 
het controleplasmide bevatten (3), of L. lactis NZ9000 die het controleplasmide bevat 
(1), zijn gegroeid in aanwezigheid van verschillende concentraties Hoechst 33342. 
De groeisnelheid (µ) in de exponentiële groeifase werd bepaald en uitgezet als functie 
van de Hoechst 33342 concentratie. De datapunten geven het gemiddelde van drie 


























gebruik is gemaakt van binnenstebuiten-gekeerde membraanblaasjes. Hoewel 
bij deze experimenten een aanzienlijke opnameactiviteit werd gezien in controle 
membraanblaasjes die geen LmrA bevatten, wat de aanwezigheid van endogene 
cadmiumsecretiemechanismen suggereert, werd er ook een LmrA-afhankelijke 
cadmiumopname waargenomen. Deze opnameactiviteit was vier maal hoger 
wanneer ook glutathion in de test aanwezig was. Onder deze omstandigheden 
wordt cadmium waarschijnlijk door LmrA getransporteerd in de vorm van een 
glutathion-cadmium complex. Het kan zijn dat LmrA op vergelijkbare wijze een 
ATP-cadmiumcomplex transporteert, in plaats van het vrije cadmiumion, wanneer 
er geen glutathion aanwezig is. In de test was er veertigmaal zoveel ATP aanwezig 
als cadmium. Of LmrA een belangrijke factor vormt in de intrinsieke resistentie 
van L. lactis voor zware metalen moet nog worden vastgesteld, maar dit lijkt 
discutabel gezien de hoge cadmiumopnameactiviteit die wordt waargenomen in 
controle-membraanblaasjes. De systemen die hiervoor verantwoordelijk zijn, zijn 
waarschijnlijk meer gespecialiseerd en efficiënter in het uitscheiden van zware 
metalen dan LmrA, dat in deze studies in hoge hoeveelheden aanwezig was. 
Het is onbekend of de gevoeligheid van L. lactis voor zware metalen verandert 
wanneer het lmrA-gen wordt uitgeschakeld.
De ABC-type (half)transporteiwitten LmrC en LmrD worden gecodeerd door 
een enkel operon in het genoom van L. lactis en vormen een heterodimerisch 
MDR-transporteiwit (4). Uitschakeling van de lmrC en lmrD-genen leidt tot een 
toename in de gevoeligheid voor verschillende toxische stoffen en vermindert het 
vermogen van cellen om deze stoffen uit te scheiden (14). Het idee dat LmrCD 
een belangrijke rol speelt in het drugresistentie fenotype van L. lactis wordt 
verder ondersteund door de waarneming dat transcriptie van de lmrCD-genen 
wordt verhoogd wanneer de cellen in aanraking komen met Hoechst 33342, 
daunomycine (42), of cholaat (45). Analyse van het transcriptieprofiel en de 
regulatie van alle potentiële en gekarakteriseerde MDR-transporteiwitcoderende 
genen in L. lactis zou daarom een diagnostisch middel kunnen zijn om te bepalen 
welke van deze genen daadwerkelijk betrokken zijn bij drugresistentie. Dit soort 
studies zou ook aanwijzingen kunnen opleveren over het substraatspectrum van 
het respectievelijke transporteiwit. Hoe de expressie van andere potentiële MDR-
transporteiwitten in L. lactis wordt gereguleerd is op dit moment niet bekend. 
Northern-analyse laat zien dat de lmrP en lmrA genen tot expressie komen in de 
L. lactis-stam MG1363, maar niet in de stam IL1403 (49). Een andere vraag, wat 
dit betreft, is of de expressie van lmrP en/of lmrA verandert, wanneer L. lactis 
cellen in contact komen met een van de bekende substraten van LmrP of LmrA, 
bijvoorbeeld ethidium of Hoechst 33342. De expressie van deze genen verandert 
echter niet bij contact met deze twee toxische stoffen (R. van Merkerk, niet 
gepubliceerde resultaten).
Ethidium is een belangrijk substraat geweest bij het karakteriseren van LmrP, 
waarbij consequent een sterke, LmrP-afhankelijke ethidiumsecretieactiviteit 
werd waargenomen. Eveneens verleent de expressie van LmrP resistentie tegen 
ethidium aan zowel E. coli als aan L. lactis. Aan de ander kant is nog niet met 
zekerheid vastgesteld of LmrP daadwerkelijk betrokken is bij de intrinsieke 
resistentie van L. lactis voor ethidium. Deletie van het lmrP-gen heeft slechts een 
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marginaal effect op het ethidiumresistentiefenotype van L. lactis (7), wat verband 
zou kunnen houden met de waarneming dat lmrP alleen in de laatexponentiële 
groeifase tot expressie komt. Het kan ook zijn dat andere transporteiwitten een 
belangrijkere rol spelen in ethidiumsecretie, bijvoorbeeld LmrCD. Deletie van 
de lmrCD-genen heeft een sterk effect op de intrinsieke resistentie van L. lactis 
voor ethidium. L. lactiscellen die LmrP tot overexpressie brengen, vertonen een 
verlaagde groeisnelheid (Hoofdstuk 4). Dit effect op de groeisnelheid wordt 
tenietgedaan door verapamil, wat suggereert dat het veroorzaakt wordt door 
de transportactiviteit van LmrP. Het is mogelijk dat, onder de conditie van 
overexpressie, LmrP essentiële, cellulaire metabolieten uitscheidt, de proton 
motive force (protonpotentiaal) verzwakt door protontranslocatie de cel in, of de 
influx van (cytotoxische) extracellulaire stoffen faciliteert. Het groeiremmende 
effect was sterker in cellen die een energie-ontkoppelde mutant van LmrP, D68C-
C270A LmrP, tot expressie brachten. Dit eiwit is niet meer in staat om substraat in 
een specifieke richting te transporteren, en faciliteert alleen nog maar de diffusie 
van substraat over het membraan, los (ontkoppeld) van de protonengradiënt. 
Expressie van D68C-C270A-LmrP leidt tot een toename in de gevoeligheid van 
cellen voor ethidium. Deze mutant faciliteert ook de influx van Hoechst 33342 
in cellen en maakt cellen overgevoelig voor deze stof. Aan de andere kant leidt 
overexpressie van wildtype-LmrP niet tot een toename van de resistentie van cellen 
voor Hoechst 33342. Het verhoogt ook niet de efflux van Hoechst 33342 uit cellen 
waarin de lmrC en lmrD- genen zijn uitgeschakeld. Dit resultaat is opmerkelijk, 
omdat in membraanblaasjes consequent een sterke, LmrP-afhankelijke Hoechst 
33342-transportactiviteit wordt waargenomen, en geeft aan dat Hoechst 33342 
geen echt substraat lijkt te zijn voor LmrP.
Gezien de hierboven beschreven waarnemingen is het de vraag of Hoechst 
33342-transport in membraanblaasjes een betrouwbare indicator is voor MDR-
transportactiviteit. Dit wordt versterkt door de resultaten van studies aan LmrA 
(Hoofdstuk 3). Net als met LmrP wordt er een sterke, LmrA-afhankelijke Hoechst 
33342-transportactiviteit waargenomen in membraanblaasjes. Dit transport 
wordt echter volledig tenietgedaan door dissipatie van de protongradiënt over 
het membraan of wanneer de opbouw van deze gradiënt wordt voorkomen. 
Opmerkelijk genoeg is het transport niet afhankelijk van de ATPase-activiteit 
van LmrA. Deze data laten duidelijk zien dat het LmrA-afhankelijke Hoechst 
33342-transport in membraanblaasjes geen echte secretieactiviteit is van een 
ABC-type MDR transporteiwit. Dat dit Hoechst 33342-transport afhankelijk 
is van de protongradiënt suggereert dat de protonconcentratie het proces 
beïnvloedt. De verdeling van Hoechst 33342 over het membraan en het 
omgevende medium hangt inderdaad sterk af van de pH. In aanwezigheid 
van liposomen wordt een afname in fluorescentie van Hoechst 33342 
waargenomen wanneer de pH van het omgevende medium daalt van 8.0 
naar 5.25. Hoewel deze experimenten niet op een directe manier de verdeling 
over membraan en waterfase meten, wordt de pH-afhankelijkheid van de 
Hoechst 33342-fluorescentie meest waarschijnlijk veroorzaakt door een lagere 
membraan/medium-verdeling van de geprotoneerde vorm van Hoechst 33342. 
Wanneer ATP wordt toegevoegd aan binnenstebuitengekeerde membraanblaasjes, 
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Figuur 7.2. Model voor de LmrA-afhankelijke Hoechst 33342-transportactiviteit 
in membraanblaasjes. Hoechst 33342 dat wordt toegevoegd aan binnenstebuiten-
gekeerde membraanblaasjes verdeelt zich snel over de waterfase en de buitenste laag 
van het membraan, wat resulteert in een hoge fluorescentie (grijze Hoechst 33342 
moleculen). LmrA, aanwezig in hoge hoeveelheden (tot 30% van het eiwittotaal) in 
de membraanblaasjes, faciliteert een flip-flop-beweging van Hoechst 33342 naar de 
binnenste laag van het membraan of van het membraan naar de waterfase binnenin 
het blaasje op een ATP-onafhankelijke wijze. Wanneer ATP wordt toegevoegd, 
genereert F1F0-ATPase een protongradiënt over het membraan (lage pH binnen). Aan 
de binnenkant van het blaasje zorgt de lage pH voor een verdere protonering van 
Hoechst 33342, waardoor de verdeling van Hoechst 33342 verschuift van het membraan 




































genereert het F1F0-ATPase een protongradiënt over het membraan (lage pH 
binnen). Aan de binnenkant van het blaasje zorgt de verlaging van de pH voor 
een verandering in de verdeling van Hoechst 33342, waarbij meer Hoechst 
33342 in de waterfase terechtkomt, wat gepaard gaat met een verlaging van 
fluorescentie. LmrA, dat in hoge hoeveelheden aanwezig is (tot 30% van het 
eiwittotaal), zou de beweging van Hoechst 33342 tussen de twee zijden van het 
membraan en van het membraan naar de waterfase kunnen vergemakkelijken 
(Figuur 7.2). De eerder genoemde waarnemingen suggereren dat Hoechst 
33342 ook geen echt substraat is van LmrA. Dit idee wordt versterkt door de 
waarneming dat bij intacte cellen, zowel onder niet-geënergeerde als onder 
geënergeerde condities, LmrA de influx van deze DNA-kleurstof faciliteert. 
In plaats van resistentie voor Hoechst 33342 te verschaffen aan overgevoelige 
L. lactis ΔlmrA ΔlmrCD-cellen, maakte de expressie van LmrA de cellen gevoeliger 
voor deze stof. Concluderend kan worden gesteld dat Hoechst 33342-transport 
in membraanblaasjes geen betrouwbare indicator is voor MDR-transport, tenzij 
er duidelijk bewijs is dat de expressie van het bestudeerde transporteiwit een 
verhoogde resistentie voor deze stof geeft aan cellen. Een voorbeeld hiervan 
is LmrCD-afhankelijk Hoechst 33342-transport. Deze transportactiviteit 
in membraanblaasjes is maar zeer licht gevoelig voor de dissipatie van de 
protongradiënt en is afhankelijk van de ATPase-activiteit van LmrCD. Bovendien 
herstelt expressie van lmrCD vanaf een plasmide de resistentie voor Hoechst 
33342 van L. lactis ΔlmrA ΔlmrCD-cellen volledig tot het wildtype niveau. Deze 
experimenten hingen niet af van hoge overexpressie van het LmrCD transporteiwit. 
Wildtype niveaus lijken voldoende om de cellen een verhoogde resistentie te 
geven voor Hoechst 33342. Deze waarnemingen laten zien dat Hoechst 33342 
een echt substraat is van LmrCD, en benadrukken verder dat het moeilijk is de 
betrouwbaarheid van Hoechst 33342 als substraat te voorspellen, wanneer alleen 
transportexperimenten met membraanblaasjes worden gebruikt. In het algemeen 
geldt dat Hoechst 33342-transportexperimenten met terughoudendheid zouden 
moeten worden geïnterpreteerd wanneer de schijnbare transportactiviteit afhangt 
van een hoog overexpressieniveau van het bestudeerde MDR-transporteiwit.
De bovenstaande studies brengen de rol van LmrA in MDR in L. lactis in twijfel, 
maar vanwege het ontbreken van een fenotype van de lmrA-gendeletie in 
L. lactis is het moeilijk een alternatieve functie van LmrA te onderzoeken. Het is 
aangetoond dat LmrA in L. lactis resistentie geeft voor de bacteriocines LsbA en 
LsbB (49). Bovendien kan LmrA het homologe ABC-type-transporteiwit LmrB, 
dat verantwoordelijk is voor de secretie en immuniteit voor deze bacteriocines, 
in functionele zin vervangen. Toekomstige experimenten zouden daarom een 
potentiële rol van LmrA in de resistentie van L. lactis voor antimicrobiële peptiden 
moeten onderzoeken.
Het best bestudeerde, door melkzuur bacteriën geproduceerde antimicrobiële 
peptide is het lantibioticum nisine A. Haar structuur wordt bepaald door de 
ongewone, biochemisch stabiele thioetherbruggen. Deze thioetherbruggen 
worden door de enzymen NisB en NisC aangebracht in het NisA peptide na 
synthese door het ribosoom. Hoewel alle door de nis-genencluster gecodeerde 
eiwitten gewijd zijn aan de synthese van en immuniteit voor nisine A, kunnen 
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deze enzymen ook thioetherbruggen aanbrengen in andere peptiden (63). NisT 
is een ABC-type transporteiwit dat gewijd is aan de productie van nisine A, 
maar het lijkt een brede substraatspecificiteit te hebben. Het kan verschillende 
gemodificeerde eiwitten transporteren, mits deze met de nisine A signaalsequentie 
gefuseerd zijn. Deze promiscuïteit van de enzymen en het transporteiwit zou de 
mogelijkheid kunnen openen om specifieke, intramoleculaire thioetherbruggen 
aan te brengen in willekeurige peptiden, en de productie hiervan te koppelen 
aan secretie in het externe medium. In Hoofdstuk 5 is een kwantitatieve bepaling 
gepresenteerd van de bijdrage van NisB, NisC, en NisT aan de productie van 
pre-nisine door L. lactis. Het dehydratase NisB katalyseert de eerste stap 
in het posttranslationele modificatieproces, de dehydratatie van serine- en 
threonineresiduen in het peptide. Het cyclase NisC katalyseert de tweede stap, de 
vorming van thioetherbruggen door de vrije thiolgroep van cysteines te koppelen 
aan dehydroresiduen binnen hetzelfde peptide. Het gemodificeerde peptide 
wordt over het membraan getransporteerd door NisT. Aan de buitenkant van de 
cel wordt het peptide gesplitst door het protease NisP, waarbij signaalpeptide en 
het lantibioticum nisine A vrijkomt. De voorloper van het nisine A peptide (pre-
nisine) wordt waargenomen in het medium voordat deze proteolyse plaatsvindt, 
wat aangeeft dat transport en afsplitsing van het signaalpeptide niet aan elkaar 
gekoppeld zijn.
De productie van pre-nisine is sterk afhankelijk van het dehydratase NisB. 
Wanneer dit enzym afwezig is, wordt vrijwel geen productie van pre-nisine 
waargenomen. NisT alleen, of NisT in combinatie met NisC, resulteert niet in een 
efficiënte productie van het peptide. Aan de andere kant resulteert het ontbreken 
van NisC in een kleiner effect (een 70% reductie) op de productie van prenisine, 
wat aangeeft dat NisB samen met het transporteiwit NisT een aanzienlijke 
productie van het peptide ondersteunt. Zonder NisT wordt geen secretie 
waargenomen, maar expressie van nisABC resulteert wel in een aanmerkelijke 
verlaging van de groeisnelheid van de cellen. Het gemodificeerde peptide dat 
geproduceerd wordt door NisBC bevat een signaalpeptide en zou daarom 
geen antimicrobiële activiteit moeten vertonen. Proteolyse van het peptide dat 
zich in de cel ophoopt maakt echter actief nisine A vrij, wat waarschijnlijk de 
verlaging in de groeisnelheid veroorzaakt. Aangezien NisB belangrijk is voor 
effectieve productie van pre-nisine, stellen we een geleidingsmechanisme voor 
waarbij pre-nisine door het NisBCT eiwitcomplex geleid wordt. In dit model is 
NisB de centrale component. Volgens deze hypothese zal de signaalsequentie 
het NisA peptide naar NisB in het NisBCT-complex, dat zich bij het membraan 
bevindt, sturen. Eenmaal aan NisB gebonden zal het peptide op efficiënte wijze 
doorgegeven worden via de modificerende enzymen naar het transporteiwit om 
zo uiteindelijk uitgescheiden te worden door de cel. Het moet gezegd worden dat 
in de in Hoofdstuk 5 beschreven analyse de productie van verschillende, hoewel 
gelijkende, peptiden wordt vergeleken. Afhankelijk van de aan- of afwezigheid 
van NisB en NisC wordt ongemodificeerd, gedehydrateerd, of gedehydrateerd en 
gecycliseerd NisA uitgescheiden door NisT. Eenzelfde studie, waarbij peptiden 
worden gebruikt die niet door de enzymen NisB en NisC worden gemodificeerd, 
zou daarom meer inzicht kunnen verschaffen in het geleidingsmechanisme door 
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het NisBCT-complex zoals hier wordt voorgesteld. Lantibioticum-biosynthese-
enzymen zouden kunnen worden ingezet voor de synthese van nieuwe 
gemodificeerde peptiden, bijvoorbeeld nieuwe of verbeterde antimicrobiële of 
chemotherapeutische peptiden. Bij het toekomstige rationeel ontwerp dat dit zal 
vergen is een uitgebreide kennis van het moleculaire mechanisme van het nisine-
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